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Abstract 
 
Exogenous Control of the Assembly of Transcriptional  
Complexes at Gene Promoters 
 
by 
 
Jonas Westergaard Hojfeldt 
 
Chair: Anna K. Mapp 
 
Establishment of gene expression patterns defines cellular function and 
the first critical step in this process is transcription. Exogenous agents that can 
alter transcription hold tremendous utility as chemical genetic probes and as 
therapeutics. In my dissertation research I have pursued strategies for controlling 
the transcription of genes with small drug-like molecules.  
The transcriptional status of genes is defined by coregulatory complexes 
recruited to gene promoters. To achieve control of this recruitment, small 
molecules that bind to these proteins must be discovered. By use of a high-
throughput biochemical screen, sekikaic acid was discovered as a potent ligand 
 xiv 
of the transcriptional coactivator protein CBP. Sekikaic acid binds to the KIX 
domain of CBP and its binding precludes the in vitro interaction of transcriptional 
activation domains from the human transcription factors MLL and CREB to two 
distinct sites on KIX.  
In order for a small molecule to recruit target proteins to individual genes, 
it must have the ability to localize to DNA. Nuclear receptors were identified as 
potential targets that could tether bifunctional molecules to their target genes.  
Conjugates of glucocorticoid receptor (GR) ligands and a ligand of the FK506 
binding protein (FKBP) were prepared, and it was demonstrated that the 
conjugates bind the receptor and recruit an FKBP fusion protein that influence 
the transcriptional control of target genes in concert with intrinsic GR activity. The 
ability to recruit nuclear receptor extrinsic functionality to target genes with 
receptor targeting bifunctional molecules has potential to greatly increase our 
level of control over the therapeutically relevant genes that can be targeted via 
nuclear receptors. 
The traditional paradigm of artificial transcription factor design is an 
attempt to mimic natural transcription factors by binding their direct interaction 
partners. The arsenal of ligands that bind these proteins is limiting, and instead 
untraditional recruitment targets have been identified: the enzymatic subunits of 
chromatin modifying complexes. High affinity ligands of these subunits have 
been discovered and it is demonstrated in this work that a histone deacetylase 
inhibitor can be incorporated into NR targeting bifunctional recruiters that retain 
the ability of each conjugate partner to bind its respective protein target. 
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Chapter 1 
 
Artificial transcriptional regulators - ligands and bifunctional recruiters* 
 
1.1 Abstract 
The human body is comprised of several hundred distinct cell types that develop 
from a single cell through regulated expression of individual genes in the 
common genome.1 The first critical step in this process is transcription and is 
governed by a large number of transcription factors. Small molecules that can 
alter transcription hold tremendous utility as chemical genetic probes and as 
therapeutics. This introductory chapter defines the principles of direct 
transcriptional regulation by small molecules and surveys previous discoveries of 
small ligands (drug-like molecules and short peptides) that bind transcriptional 
coregulatory proteins and have the potential or demonstrated capability to control 
assembly of coregulatory proteins at gene promoters.  
 
1.2 Introduction 
Transcription, the initial step in gene expression, brings to life an organism’s 
heritable code. The master regulators of this process, proteins termed 
transcription factors (TFs), generate immense cellular diversity from a common 
genetic template by activating or repressing specific gene targets.2 Given this 
critical role, it is not surprising that misregulated transcription strongly correlates 
with disease.3 Thus, one strategy for combating disease is to modulate 
transcription in a way that restores the cell’s healthy phenotype.4 The highly 
                                            
* This chapter is adapted from a published review article: Hojfeldt, J. W., Van Dyke, A. R. & 
Mapp, A. K. Chem. Soc. Rev., 2011, DOI: 10.1039/C1CS15050B - Reproduced by permission of 
The Royal Society of Chemistry (RSC). 
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regulated action of transcription factors can be modulated indirectly by small 
drug-like molecules targeting cellular signaling events.5 Predictable gene 
selective effects through these targets can be realized with a complete 
understanding of signaling networks and the transcription factors they effect, and 
are reliant on non-aberrant signal cascades in disease states. Neither of these 
criteria is a reality (e.g. non-canonical transcription factor targets of nuclear β-
catenin6,7 and constitutive activation of NF-κB in Hodgkin lymphoma8,9), thus 
direct targeting of transcription processes is an attractive goal. Transcriptional 
coregulatory complexes recruited to gene promoters define the transcriptional 
status of genes, and small molecules capable of recruiting these complexes to 
promoters or block their recruitment by endogenous transcription factors will 
directly affect the transcription of genes. To achieve control of recruitment of 
target proteins to gene promoters, small molecules that bind to these proteins 
(ligands of transcriptional coregulatory proteins) must be discovered and linked to 
functionality that can tether the recruiter at a target gene,10 or these same ligands 
may be used as negative recruiters by blocking interactions between target 
proteins and endogenous recruiters (transcription factors) (Figure 1.1).11  
1.3 Basic mechanisms of transcription initiation 
All protein-coding genes are transcribed by RNA polymerase II (Pol2), which is a 
multi-subunit enzyme. Pol2 must bind at a gene promoter, located near the 
beginning of a gene, together with a set of general transcription factors (TFIIA-
TFIIH) forming what is called the pre-initiation complex (PIC). At many genes the 
formation of the PIC is the limiting step in transcriptional activation, while certain 
steps such as promoter clearance (in which the bound polymerase proceeds 
from the promoter along the gene) can be limiting in other contexts.12,13 Thus, in 
most cases transcriptional activation faces the challenge of facilitating PIC 
formation at a promoter (Figure 1.2), while transcriptional repression results from 
the blockage of this assembly.  
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Figure 1.1 Ligands of coregulatory proteins can control their recruitment 
Ligands that bind transcriptional coregulatory proteins can be incorporated into 
bifunctional molecules that can recruit target complex to promoters, or, for 
ligands that perturb interaction with endogenous transcription factors, they can 
be used to inhibit recruitment. 
 
 
 
Figure 1.2 Transcriptional activators orchestrate PIC formation One class of 
eukaryotic transcription factors are transcriptional activators. These are 
bifunctional molecules, minimally composed of a DNA-binding domain (DBD) that 
provides gene-targeting specificity and a transcriptional activation domain (TAD) 
that contacts multiple surfaces within transcriptional coregulatory complexes. 
Through these contacts the TAD orchestrates recruitment of factors that remodel 
chromatin (catalyze nucleosome repositioning and changes in post-translation 
modification (PTM) patterns of histones) and factors that scaffold recruitment of 
the general transcription factors to form the preinitiation complex (PIC). 
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An intrinsic barrier to PIC formation is chromatin, the protein scaffold of genomic 
DNA. In chromatin, 146 DNA base pairs wrap around an octamer of histone 
proteins to form the smallest chromatin entity called a nucleosome.14 
Nucleosomes placed along a strand of DNA form a structure resembling beads 
on a string. Chromatin facilitates packaging of approximately two meters of DNA 
in each human cell and maintains a dynamically accessible genome by forming 
different higher-order structures in which nucleosomes are highly or loosely 
compacted. Condensed chromatin is associated with inactive genes; this is 
logical as the DNA in these structures is buried, hindering its interaction with 
protein factors. Even in open chromatin, also called euchromatin, single 
nucleosomes can pose a barrier.15 For example, a nucleosome located at a 
TATA box (a common sequence element in promoters) prevents binding of the 
TFIID subunit, TBP, and this alone prevents formation of the PIC.16 Therefore, 
one class of transcriptional cofactors that often needs to be recruited to genes to 
regulate PIC formation are comprised of ATP-dependent chromatin remodeling 
enzymes, which catalyze the repositioning of nucleosomes.17 Chromatin also 
serves a role beyond a simple packaging scaffold. Residues in the amino and 
carboxyl tails of the histone proteins are subject to an extensive combination of 
posttranslational modifications. This includes acetylation, methylation, 
phosphorylation, ubiquitylation, and SUMOylation.18 These modifications serve 
as marks allowing protein factors to distinguish a location in the genome 
independent of the underlying DNA sequence. Some of these marks are 
inherited during subsequent cell divisions and are therefore classified as 
epigenetic factors. The enzymes that place or remove these marks constitute an 
additional set of transcriptional regulators that are recruited to genes, and the 
study of these proteins and their associated regulation mechanisms are currently 
an intense research focus. 
 
1.4 Principles of inhibiting recruitment of coregulatory proteins to DNA 
It is the role of transcription factors to orchestrate the previously discussed 
processes at gene promoters: chromatin remodeling, cofactor recruitment, and 
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PIC assembly (Figure 1.2). TFs are minimally composed of a sequence selective 
DNA-binding domain (DBD) that specifies the locality of action and a 
transcriptional regulatory domain that recruits necessary coregulatory complexes 
through a series of protein-protein interactions. One obvious strategy to modulate 
transcription is through inhibition of these interactions.  
 
Small molecules binding directly to DNA are necessarily required to bind to a 
large surface area to gain sequence specificity and must in addition bind with 
high affinity to compete with sub-nanomolar affinities typical of DBD-DNA 
interactions.19 This criterion makes even designed DNA-binding molecules large 
structures that lack the attractive advantages of small molecules. Progress is 
being made in the field, as relatively short synthetic oligomers have been 
demonstrated to bind genomic DNA in living cells and block binding of 
transcription factors: pyrrole-imidazole polyamides20 and locked nucleic acids 
(LNAs)21 (Figure 1.3). However, the LNAs need to be transfected into cells, and 
the polyamides show general cytotoxicity at concentrations very close to 
efficacies doses, which may be an indication that their effect is indirect or is non-
specific. If strategies could be devised to give these structures improved 
properties in biological systems,22,23 programmable sequence-selective DNA 
ligands may emerge with many attractive applications. Inhibition of DNA binding 
can also be achieved through ligand binding to the transcription factor rather than 
DNA; for example, an inhibitor of homodimerization of the human transcription 
factor, STAT3, prevents STAT3 binding to DNA24 (Figure 1.3). 
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Figure 1.3 Inhibitors of DNA-TF and TF-coregulator interactions A. The 
shown pyrrole-imidazole polyamide inhibits glucocorticoid receptor binding to 
DNA; B. The structure of two connected locked nucleic acids is shown on left. 
The sequence of a mixed LNA-DNA oligomer that blocks progesterone receptor 
binding to DNA is shown to the right. LNA-monomers are in capital letters; C. 
Inhibitor of STAT3 homodimerization; D. Sequence of an α-helix stabilized 
peptide. The side chains of unnatural (S)-Cα-methyl-Cα-alkenyl amino acid, S5, 
have been connected with ring-closing metathesis.  
 
Inhibiting the recruitment of coregulatory proteins may also be achieved through 
inhibition of their interactions with transcription factors. In these interactions one 
partner will typically have a relatively concave surface that the other partner 
docks into. The class of amphipathic transcriptional activators, for example, 
contains short domains that comprise the majority of the activation potential. 25-27 
These short peptides are furthermore thought to bind their coactivator targets as 
α-helices,28,29and bind to shallow grooves present in the coactivators.30,31 Thus, 
for the interaction between amphipathic transcriptional activation domains and 
their target coactivators, small molecule ligands that competitively inhibit this 
interaction are far more likely to bind the invaginated surface (the coactivator), 
where hydrophobic contacts can be buried. One consequence of this is that the 
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gene specificity will not be derived from the activator, but instead be defined by 
the binding site on the target coactivator, which may or may not be shared with 
additional activators. With a fewer number of coactivators relative to transcription 
factors,32 the coactivator likely has lower selectivity, although individual 
coactivators can have several distinct interaction domains and binding 
surfaces.33 Coactivator ligands have been discovered in recent years (discussed 
in section 1.6), and recently, an inhibitor that binds the DNA-bound factor and 
precludes coactivator recruitment was also reported34 (Figure 1.3D). 
 
1.5 Tactics and limitations to positively modulate recruitment 
No therapeutics are yet developed that inhibit recruitment of coregulatory 
components by competitive blockage of binding sites, but in contrast a vast 
number of drugs lead to modulation of transcription factor function directly or 
indirectly. These mechanisms can stimulate recruitment or change recruitment 
patterns, rather than merely eliminating a subset of interactions. One class of 
drugs binds directly to a unique family of transcription factors: the nuclear 
receptors (NRs). NRs bind endogenous lipophilic ligands,35 and upon binding, 
these small molecules cause a conformational change in their cognate receptor 
and modulate an interaction surface that recruits coregulatory proteins to elicit a 
transcriptional response. It has proven possible to design synthetic ligands of 
nuclear receptors that stabilize conformations leading to both transcriptionally 
activating and repressing states.36 A fundamental limitation of this approach, 
though, is that the drug acts entirely through the nuclear receptor surfaces to 
intervene in the transcription process; it is unable to orchestrate protein 
recruitment on its own. Thus, mutations in the nuclear receptor can render these 
drugs ineffective, as is observed in androgen-ablated prostate cancers that 
evolve into a lethal, ligand-independent state.37 
 
The nuclear receptors have evolved to respond to binding of ligands, but are 
unique in this ability among transcription factors. In contrast, all transcription 
factors are regulated by intracellular signaling events. Drugs targeting cell 
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surface receptors and enzymes in these signaling cascades constitute the largest 
class of transcription-targeting drugs.38 While these approaches have yielded 
successful drugs, they do not represent a general solution for gene-targeted 
therapy. One disadvantage of targeting the upstream signaling events is that 
there can be significant overlap between signaling networks, resulting in the 
modulation of undesired transcription factors and, consequently, undesired gene 
regulation.39 Additionally, targeting an upstream cascade member is ineffective 
when a downstream member is autonomous or non-functional due to an 
alteration such as a constitutively activating mutation or a gene deletion.9  
 
A case study that highlights the limitation of transcription modulation through TF 
function is evident from the role of the neural repressor REST in 
medulloblastoma, a childhood-associated brain cancer. REST is a transcription 
factor that represses neuronal differentiation genes and the expression of REST 
must be turned off during proper neuronal development.40 It was discovered that 
the cancerous tissue of medulloblastoma results from improperly developed 
neuronal lineage cells that still express REST.41 Inhibition of REST is not 
sufficient to reactivate its target genes and REST does not possess latent 
activation function that can be stimulated through signaling events. In addition, 
no other transcription factor that can bind and reactivate REST target genes is 
known. Thus, none of the drug strategies outlined above could be applied to 
control transcription of REST target genes. However, it has been shown that a 
synthetic chimera of REST’s DNA-binding domain and a strong activation domain 
from the viral transcription factor VP16 does produce an artificial transcription 
factor that can reactivate the neuronal differentiation genes and kill the tumor 
cells.41 Therefore, drug-like molecules that could directly address the 
transcriptional status of REST–regulated genes could be the ultimate goal for 
treating medulloblastoma. 
 
Thus, it is clear that the agents in need of development are artificial transcription 
factors that on their own can localize at target genes and recruit coregulatory 
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complexes. Both of these events - localization and recruitment - simply involve 
binding interactions: binding to DNA or to a DNA-bound protein will localize a 
molecule at the DNA, and binding a transcriptional complex member will recruit 
this complex to the locale of the ligand. Thus, artificial transcription factors are 
bifunctional molecules that can be constructed by linking together DNA-localizing 
moieties with molecules that bind transcription complexes,10 and they differ from 
the majority of drugs: their mode of action is a gain of function; they do not inhibit 
an endogenous process, but aim to orchestrate one. Such bifunctional molecules 
mimic the design of endogenous transcription factors, with distinct DNA-localizing 
and regulatory domains. They are also conceptually related to the chemical 
inducer of dimerization (CID) concept originally developed in the labs of Stuart 
Schreiber and Gerald Crabtree.42 CIDs are made by linking together two ligands 
that each can bind a target protein; the conjugate consequently brings together 
(or dimerizes) the two target proteins. CIDs are excellent general tools as many 
cellular processes occur simply as a consequence of co-localization43, and this is 
also true for events leading to transcription.44 In the case of artificial transcription 
factors, they should reproduce the basic mechanism of transcription: bringing 
together the gene promoter and relevant transcriptional complexes.  
 
The ligands previously described as potential recruitment inhibitors (as well as 
NR ligands) conveniently meet the requirements of each half of an artificial 
transcription factor: these are either ligands of DNA or DNA-bound proteins, or 
they are ligands of coregulatory proteins. With advances being made on both 
fronts, realization of artificial transcription factors is increasingly plausible.45 The 
direct DNA-binding molecules are fundamentally different structures and labs 
specialize in their development.46,47 The following section surveys discoveries of 
ligands of coactivator proteins.  
 
1.6 Discovery of ligands of coactivator proteins 
1.6.1 Synthetic transcriptional activation domain mimics 
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Transcriptional activators recruit coactivator proteins and the Pol2 holoenzyme to 
genes that are selected by its DNA-binding domain. With the goal of developing 
bifunctional molecules that can orchestrate a transcriptional response, much 
effort has been devoted towards understanding which coactivators participate in 
direct binding interactions with endogenous transcriptional activation domains. 
Such knowledge would aid in the identification of ligands of these surfaces, 
ligands that themselves could then be used as artificial transcriptional activation 
domains. The certain identification of direct binding targets, however, has 
remained elusive, and instead nearly all coactivators have been proposed as a 
direct binding target of activators. It appears likely that activators make contact 
with more than one coactivator in an ordered fashion and that these interactions 
are dependent on the promoter context.48,49 With this presumptive scenario of 
multiple elusive binding partners, we and others have pursued strategies for 
discovering artificial activation domains in which essential features of natural 
activation domains are incorporated into synthetic structures, rather than 
screening for ligands of putative activation domain targets.29,50-52  
 
Amphipathic peptides 
Early studies of natural transcriptional activators identified short sequences of 
interspersed acidic and hydrophobic residues that could reproduce most of the 
activation potential when fused to a DNA-binding domain. These short 
sequences can be fused to heterologous DNA-binding domains, which on their 
own lack activation function, transforming them into transcriptional activators.25-27 
Further studies have identified other classes of minimal activation domains, but 
the acidic activators remain the largest and most potent class in all eukaryotes. 
Comparison of such minimal acidic activation domains from different activators 
revealed no sequence homology. Instead, a pattern emerged that these 
sequences could fold as alpha helices in which acidic or polar residues would 
align on one face of the helix and the hydrophobic residues on the other side, 
forming what is termed an amphipathic helix. Indeed a 15-mer peptide was 
designed as a test of this hypothesis that did not share sequence homology with 
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any identified activators, but was predicted to form a similar amphipathic helix 
(Figure 1.4A). This 15-mer peptide, termed amphipathic helix (AH), activates 
reporter genes to 20% the level of full length Gal4 activator when fused the Gal4 
DNA-binding domain.29 This was the first rationally designed artificial activation 
domain and it gave credence to the idea that the amphipathic helix and not a 
particular sequence of amino acids was the determining factor in the activation 
potential of this class of activators. Taken together with the multi-partner binding 
profiles of activators, it could be proposed that multiple coactivator proteins 
contain permissive binding surfaces for such amphipathic helices.29,53,54  
 
 
Figure 1.4 Amphipathic activation domain mimics A. An amphipathic helix 
with polar residues (blue) on one face of the helix and hydrophobic residues 
(yellow) on the other. The sequence of a peptide is shown below; B. Structure of 
an isoxazolidine based transcriptional activation domain mimic (iTAD). 
Hydrophobic and polar moieties are highlighted.  
 
A small molecule transcriptional activation domain mimic 
In order to create a small synthetic molecule that would mimic the 
physicochemical nature of amphipathic helices, our lab decorated a 5-membered 
heterocyclic scaffold with combinations of polar and hydrophobic amino acid side 
chains commonly featured in minimal activation domains (Figure 1.4B). Members 
of this small series of isoxazolidines demonstrated activation potential in an in 
N O
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vitro assay comparable to a minimal activation domain of a natural acidic 
activator, and they represent the first examples of small-molecule activation 
domain mimics.50,51 Since an organic molecule cannot easily be attached to a 
protein DNA-binding domain; the isoxazolidine was attached to a second small 
molecule, methotrexate, that can bind a protein fusion of dihydrofolate reductase 
and a DNA-binding domain. Thus in this iteration of a chemical inducer of 
dimerization, one end of the molecule binds an engineered protein, while the 
other binds native transcriptional components. The isoxazolidine-based 
transcriptional activation domain mimic (iTAD) also demonstrated activity in cell-
based assays in which it activates a luciferase reporter 80-fold above a control 
lacking the activation domain.55 In further cell-based studies of iTAD analogs, an 
amphipathic balance proved to be a critical determinant for function.52 While 
hydrophobic contacts have been proposed to be the strongest contributors of 
binding affinity to coactivator targets,56 it appears that in a small molecule they 
must be balanced by polar groups for activation potential. This property is similar 
to natural activation domains and it is plausible that increased hydrophobicity 
causes the structures to become sequestered by non-specific interactions in the 
cell. A photo-crosslinker has been incorporated in the linker between an iTAD 
and a DNA localizing functionality to capture its direct binding targets. Out of 
several yet unidentified proteins that are cross-linked to the iTAD, the 
mammalian coactivator CBP was demonstrated to be one of its targets. By an 
HSQC-NMR experiment with a domain from CBP, the iTAD was shown to bind a 
site shared by several natural activators.57 Thus, a small molecule designed to 
mimic the amphipathic nature of natural transcriptional activation domains shares 
at least one binding surface with these, and further demonstrates the permissive 
nature of these. This increases the likelihood that additional coactivators with 
permissive binding surfaces are amongst the additional uncharacterized binding 
partners, and the multi-binding partner profile may be a functionally determining 
feature of iTADs. 
 
1.6.2 Screening for coactivator ligands 
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An alternative strategy to rationally design mimics of natural activation domains is 
to screen for structures with innate activation potential. Given the power of 
modern molecular biology, large libraries of peptide fragments attached to DNA-
binding domains can be generated. For example, a screen of peptides encoded 
by random DNA-fragments from E. coli, yielded potent activators that appear by 
sequence to be prototypical amphipathic activation domains.27 In principle, it is 
possible to conduct a similar screen to identify small molecules that activate a 
given reporter gene (screening without a defined binding target). However, in 
order to be successful, each member of the screening library would need to 
possess a DNA-localizing functionality that targets the small molecule to the 
reporter gene. In essence, each library member would need to be a bifunctional 
molecule. To circumvent this issue, current screening efforts first involve 
screening for binding to putative coactivator proteins, a challenging task in itself 
given our limited knowledge of transcriptionally relevant binding interactions. The 
hits obtained from these screens must then be incorporated into bifunctional 
molecules to test their activation potential (Figure 1.5C). The following cases are 
representative examples illustrating high-throughput screening (HTS) efforts in 
which ligands of individual transcriptional coactivator proteins were successfully 
identified. 
 
 14 
 
Figure 1.5 Coactivator ligand discovery A. An activator bypass experiment 
can be used to identify coactivator targets whose direct recruitment suffices to 
activate transcription; B. Ligands of coactivators can be identified from screening 
for inhibitors of interaction between TAD and coactivators; C. A ligand of a 
coactivator target can be tethered to a DBD to test its ability to recruit 
coactivators to the DNA; D. Examples of cofactor proteins for which ligands 
(small molecules or peptides) have been identified (bold: ligand has been 
demonstrated to function as an artificial TAD). 
 
Ligands of the CBP KIX domain 
The coactivator CREB binding protein (CBP) is one of the known direct binding 
targets of mammalian transcriptional activators. It is a direct binding target of 
CREB, which binds to the KIX domain in CBP.58 Biochemical evidence suggests 
that CBP is a direct binding target for numerous other activators, and there is 
surmounting evidence that CBP acts as a transcriptional hub interacting with 
hundreds of transcription factors and coactivators.33 CBP functions as both a 
scaffolding component and as a chromatin modifier via its intrinsic histone 
acetyltransferase (HAT) domain. This hub-like role of CBP indicates that its direct 
recruitment to promoters may suffice for recruitment of other necessary cofactors 
and nucleation of PIC assembly. To test this hypothesis, ligands of CBP were 
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sought through screening efforts. A peptide phage display selection was used to 
discover peptides that bind the KIX domain of CBP.59 An eight amino acid 
peptide was discovered that binds to the KIX domain with a 16 µM affinity (Figure 
1.5D). This is comparable to the affinity reported for natural activation domains 
that, in general, have weak affinity for their coactivator targets. The 8-mer peptide 
activates transcription in cells to levels comparable to natural TADs. The 
sequence of this peptide is amphipathic like most natural activation domains and 
shares a binding surface on KIX with several of these.  Because of this 
resemblance, it is likely to have a multi-partner binding profile.  Our lab has 
studied peptidomimetic versions (d-peptide, beta-peptide, peptoid) of the same 
sequence.60 Unexpectedly, the binding affinity for KIX is largely unchanged in 
these analogs, indicating that the binding surface in the KIX domain is permissive 
of structural differences in the ligands. Thus, it appears that the amphipathic 
character is the important feature. The CBP KIX domain was also used in an 
NMR-based screen for small molecule ligands and the molecule KG-501 (napthol 
AS-E phoshate) (Figure 1.5D) was discovered as a high micromolar binder that 
competes with CREB for binding.61 While not yet reported, it would be interesting 
if this ligand binds other coactivators and if it can function as an activation 
domain when used as part of a bifunctional molecule that localizes it to DNA. 
Other notable synthetic biopolymer and peptoid ligands of the KIX domain have 
been reported that potently activate transcription.62,63  
 
Ligands of human mediator subunit Med23 
One coactivator complex is believed to play an essential role in all transcriptional 
activation by bridging transcription factors to the general transcriptional 
machinery. This complex is named Mediator. A screen for small molecule 
inhibitors of the interaction between the human transcription factor Elf3 and its 
binding target within the mediator complex, Med23, was performed. Evidence 
suggests that Elf3 binds Med23 through an 8-mer alpha-helix containing a critical 
tryptophan residue and a small molecule, adamanolol (Figure 1.5D), was 
discovered that blocks this interaction.64 Similar to the discovery of KG-501, the 
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purpose of this screen was to discover inhibitors of the activator:coactivator 
interaction. As found with several other inhibitors of activator-coactivator 
interactions, adamanolol binds the coactivator. The researchers subsequently 
used a derivative of this molecule as part of a bifunctional DNA-localizing 
conjugate to show that it can activate transcription in vitro and in cells.65,66 
Through a series of synthetic derivatives, the authors found a molecule with 
enhanced transcriptional activation potency as well as enhanced binding to the 
original target coactivator Med23. As the authors point out, it will be valuable to 
learn if the derivative is more potent due to a more selective binding of Med23 
over other non-productive cellular components or whether the enhanced potency 
stems from increased binding to other coactivators (the original molecule, 
adamanolol, was shown to bind multiple proteins in cell extracts).64  
 
Ligands of activator masking proteins 
A different example of the multi-partner binding profile of a transcriptional 
activation domain is seen with masking proteins. Some transcriptional activators 
are kept inactive by binding of the activation domain to a masking protein. 
Unmasking of the activation domain, then, is under the control of signaling 
events. One of the best examples of this interaction is between the yeast 
activator Gal4 and its masking protein Gal80.67 Gal4 can bind its target genes in 
the absence of galactose, but Gal80 binds to and masks the activation domain of 
Gal4. In the presence of galactose, Gal80 binds Gal3 and its repression of Gal4 
is relieved. A phage display library was screened to select peptides that bind to 
Gal80.68 Two peptide binders identified from this screen were then attached to 
the DNA binding domain of Gal4 and found to activate transcription to 
approximately 35% the level of the minimal activation domain of Gal4. Although 
the peptides do not share significant homology with the Gal4 activation domain, 
they share at least one coactivator target, Gal11, and Gal80 masks their activity 
in yeast.  
 In mammalian cells, another TAD-masking protein has received significant 
attention with regards to discovery of small molecule ligands. Hdm2 is a masking 
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protein of the human tumor suppressor and transcriptional activator p53. The 
masking of p53 by Hdm2 helps cancer cells evade apoptosis. Intense efforts 
towards finding small molecule inhibitors of this interaction have therefore been 
undertaken and yielded a number of drug candidates that have progressed to 
clinical trials.69 Analogous to the Gal80 ligands, it is conceivable that these Hdm2 
inhibitors could be used as transcriptional activation domains. However, the 
inhibitors facilitate p53 transcription, indicating that they are selective for Hdm2 
over essential p53 coactivators. Nonetheless, it may be a fruitful effort to take a 
further look at some of the many structures related to the current lead drugs, as 
some of these may be less selective for the masking protein compared to 
coactivator targets. Hypothetically, the discovery of ligands that bind to both 
coactivators and masking proteins could yield artificial transcription factors that 
additionally are responsive to physiological signals. 
 
Coactivator ligands that bind non-competitively with activators 
For all of the above discovered artificial activation domains, it is unclear if they 
function by binding one coactivator (the one they were screened against) or by 
binding multiple coactivators. While the multi-partner binding profile of activators 
is well supported, there is evidence that direct recruitment of a single coactivator 
can suffice to activate transcription. Evidence for this comes from so-called 
activator bypass studies (Figure 1.5A). In these studies a DNA-binding domain is 
fused directly to a coactivator and the chimera is tested for activation potential. In 
yeast, such a study identified several coactivator fusions that activate 
transcription.70 This is not to say that other coactivators are not recruited to the 
promoter, but it would have to be indirectly. The important point is that a ligand of 
those coactivators that function in the bypass experiment should, on its own, 
function as an activation domain.  
 
In a yeast activator bypass study, the coactivator with the strongest activation 
potential was the mediator subunit Med15. A peptide library was screened in our 
lab for binding against Med15 and two motifs were discovered that bind Med15 
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and possess activation potential.71 These peptides bind to separate surfaces on 
Med15, compared to a naturally-derived activator, and it would therefore not 
necessarily be expected that they, like natural activation domains, would bind 
other coactivators. These novel Med15 ligands had lower levels of activation 
potential than a minimal natural activation domain, despite having similar binding 
affinity. It may be that the binding orientation of Med15 is important, but it may 
also indicate that binding a larger set of coactivators is needed for higher 
activation. To discover a ligand for a coactivator complex that synergizes with 
Med15 in bypass experiments, a SAGA-complex member (Tra1) was screened 
for peptide ligands.72 In this case, however, the discovered peptides bind the 
same site as a natural activator and thus may be considered a typical amphipatic 
TAD. Indeed the activity of the Tra1 ligands is dependent on other coactivators, 
such as Med15, in addition to Tra1. Nevertheless, at least one of the Tra1 
ligands synergizes with the previously mentioned Med15 ligands. 
 
1.7 High affinity, drug-like ligands of transcriptional coregulatory proteins 
Inhibitors of chromatin modifying enzymes as potential recruiters 
One significant challenge in the discovery of molecules that can bind and recruit 
coregulatory transcription complexes is the nature of the shallow protein surfaces 
that comprise the target binding surfaces of transcription factors. The binding 
affinities in the native interactions are often weak (high nanomolar to low 
micromolar), and these structures fall in the regime of traditionally undruggable 
targets.73 Outside of transcription factor interaction surfaces, however, there are 
numerous proteins involved in transcription with known high affinity ligands. 
Chromatin modifying enzymes are emerging drug targets with many active 
inhibitor discovery programs.74 Most numerous among these targets are the 
enzymes responsible for controlling methylation and acetylation patterns of 
residues in the histone tails. These enzymes lack sequence specific DNA binding 
capability and are recruited by transcription factors or by proteins recognizing 
distinct histone modifications. The recruited activity of these enzymes establishes 
patterns of histone tail modifications, and these epigenetic changes are critical in 
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many cancers and establish a therapeutic window despite their ubiquitous 
function in cells. Inhibitors of histone deacetylases were the first members of this 
class and include suberoylanilide hydroxamic acid (SAHA), which is an FDA 
approved drug (Vorinostat).75 The use of these inhibitors as bifunctional 
recruiters has to my knowledge never been proposed and this would perhaps be 
considered unintuitive since their activity would be inhibited by the recruiting 
moiety. I hypothesize that they can nonetheless be useful when recruited, 
because of the prospective corecruitment of their native multi-protein corepressor 
complexes, and this new strategy is explored in Chapter 4 of this thesis.  
Conjugates of SAHA to a DNA-binding pyrrole-imidazole polyamides were 
recently reported, although the rationale for these structures was not to achieve 
recruitment of co-repressor complexes to target genes.76  
 
Other putative druggable domains 
In addition to TF interaction domains and catalytic domains, transcriptional 
coregulatory proteins have been found to contain other conserved domains, 
found primarily in nuclear proteins, or reside in complexes the include these 
domains. One such domain is the bromodomain which recognizes and binds 
acetylated histones.77 Histones are acetylated by histone acetyltransferases 
(HATs) leading to active transcription, opposing the action of HDACs. Although 
these domains are not enzymatic, their binding pockets are not shallow grooves 
like those found in activator-coactivator interfaces. Thus, it is likely that high 
affinity ligands can be discovered for these domains. The use of such ligands to 
recruit a bromodomain containing complex would, unlike the recruitment strategy 
for HDAC complexes, not inhibit any enzymatic function in the recruited complex 
and would even be predicted to recruit complexes in a natural orientation. 
Recently the first bromodomain inhibitors were discovered.78 Although these 
inhibitors do not bind the bromodomains of two of the most common coactivator 
complexes, GCN5 and p300/CBP, or to the general transcription factor, TAFII250 
(subunit of TFIID), I predict that ligands of these bromodomains will soon follow, 
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and it will be exciting to test their potential in bifunctional DNA-localizing 
conjugates.   
 
1.8 Conclusions 
Small molecule ligands of DNA, transcription factors and coregulatory factors all 
have the potential to directly modulate transcription. As single agents they can 
inhibit endogenous interactions, and when combined into bifunctional molecules 
they can themselves control recruitment of coregulators to gene promoters. 
Currently, NR ligands are the only molecules in this category that are effective 
drugs, and few of the remaining structures have drug characteristics. NR are also 
the only DNA-bound proteins with small molecule ligands (peptidic ligands can 
be used in cell culture22 and stabilized peptides may share drug-like attributes 
with small molecules34). The DNA-binding ligands are continuously improved, but 
suffer particularly from cell permeability issues preventing their effective studies 
in live cells. Thus NR ligands are the only drug-like molecules in our arsenal that 
can be included in bifunctional transcriptional regulators to contribute DNA-
localizing function.  
 
The rational design of small molecule transcriptional activation domains have 
proven that this biological event indeed can be controlled by drug-like molecules, 
and has strengthened a model of transcriptional activation occurring through 
multiple coactivators with similar binding surfaces. Furthermore, screening for 
ligands of one of these coactivator surfaces typically yields ligands with similar 
physiochemical characteristics when compared to the amphipathic class of 
activators, and which therefore may also bind other coactivator surfaces and 
function in agreement with this model. As illustrated by the Med15 ligands that 
bind non-overlapping surfaces relative to endogenous activators, it is however 
also possible to recruit specific coregulatory proteins in a non-native orientation 
and achieve transcriptional control.  
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I furthermore believe that there is a large set of available ligands of coregulatory 
proteins, which includes inhibitors of chromatin modifying enzymes, that do not 
bind interfaces typically used for recruitment, but that will be worth testing as part 
of bifunctional molecules. Like the NR ligands these molecules are approved 
drugs or have drug-like properties, and they bind with high affinity to their targets. 
 
1.9 Research goals 
One goal of this research is to expand the class of coactivator ligands. The 
discovery of several small molecule ligands has been encouraging, but none of 
these have yet been successfully applied as a chemical genetic probe and all 
have shown recruiting functionality in only limited scenarios. Different discovery 
strategies may yield ligands with higher efficacy as inhibitors and greater 
versatility as recruiters, and this is explored in Chapter 2 of this thesis. 
 
A second goal is to explore the use of high affinity ligands in bifunctional 
molecules. Direct recruitment of activity to nuclear receptors may greatly 
increase our control of these important drug targets, and this is the topic of 
Chapter 3 and Chapter 4. Exploration of recruitment of coregulatory complexes 
through inhibitors of chromatin modifiers may identify a large number of new 
targets of artificial transcription factors to consider. This class of proteins has 
known drugs, and many more will surely be discovered in the near future. The 
first efforts to incorporate these inhibitors into bifunctional molecules with 
potential to orchestrate their recruitment is described in Chapter 4. 
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Chapter 2 
 
Discovery of coactivator ligands* 
 
2.1 Abstract 
Efforts to modulate transcription directly with small molecules rely on the 
availability of ligands, which ideally are drug-like molecules that bind to a protein 
surface of interest. One of our main objectives is to identify new ligands of 
transcriptional coactivators; the proteins recruited as facilitators by transcriptional 
activators to upregulate gene expression. Such ligands can be tethered to DNA, 
to facilitate recruitment of target coactivators to the tethered location, or they can 
be used to inhibit recruitment of a coactivator by endogenous transcriptional 
activators through direct blockage or allosteric perturbation of the activator-
coactivator contact surface. Discovery of new ligands was pursued through high-
throughput screening. Cell-based assays were explored, because these would 
ensure that molecules identified would be functional in downstream biological 
applications. From empirical and theoretical analysis it was determined that 
effective ligand discovery in cell-based assays would only be facilitated by a 
gain-of-signal assay. An assay was designed in which inhibitors down-regulate 
transcription of a miRNA, and consequent loss of RNAi knockdown provides a 
gain-of-signal for the inhibitors. The assay is functional, but demonstrated poor 
sensitivity and was judged difficult to optimize to satisfactory performance. A 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
* The research described in section 2.5 is a collaborative effort. J.W. Hojfeldt, C.Y. Majmudar, 
S.P. Rowe, W.C. Pomerantz, and A. Lipinski contributed to preparation of proteins and peptides 
as detailed in section 2.7. P.J. Schultz and D. Sherman obtained extracts from Costa Rica for 
study presented in Figure 2.16. C.J. Arevang purified and identified structures shown in Figure 
2.17. All figures are from experiments done by J.W. Hojfeldt. C.Y. Majmudar contributed to work 
presented in Figure 2.11, 2.13, 2.16, 2.18, 2.19, 2.20, and 2.29. W.C. Pomerantz and T. Cierpicki 
assisted with work presented in Figure 2.21 and 2.23.   
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robust biochemical assay was chosen instead to screen for inhibitors of the 
interaction between the activator MLL and the coactivator CBP. A high-
throughput screen with this assay identified sekikaic acid and other lichen-
derived depsides as inhibitors of MLL-CBP. Sekikaic acid was found to bind 
cooperatively to the KIX domain of CBP in competition with activators binding to 
two separate sites on KIX. Sekikaic acid is the most potent molecule ligand of the 
KIX domain identified to date and its binding mode is unique amongst coactivator 
ligands.  
 
2.2 Introduction to coactivators as targets of high-throughput screening 
The protein-protein interaction surface between transcriptional activators and 
coactivators is an attractive target for small molecule ligand discovery. Ligands of 
the activator binding surface on coactivators can be utilized as chemical genetic 
probes1 and, possibly, therapeutic drugs2 that inhibit the native interactions, or 
they can be incorporated into DNA-localizing bifunctional molecules that can 
recruit the target coactivator to a DNA-locus and act as an artificial transcription 
factor.3,4 Ligands that are intended for incorporation into bifunctional recruiters do 
not necessarily need to bind the activator binding surface, but it may be 
functionally beneficial to recruit through this surface to maintain native orientation 
of recruited complexes.5 It may therefore be advantagous to screen for ligands of 
coactivators in assays that report on activator-coactivator inhibition to bias for hits 
against this particular surface.  
 
The majority of protein-protein interactions are traditionally considered 
undruggable6; this classification implies that it is not cost-effective for 
pharmaceutical companies to screen for drugs against this type of surface, and 
although review articles report successful pursuits of such ligands and assert 
progress in the tractability of these targets,7-10 they remain state-of-the-art 
discoveries. Transcriptional coactivators share several challenges general to 
discovery of protein-protein inhibitors. Unlike enzymes and receptors, the 
coactivators have no natural small-molecule ligand or substrate that can be used 
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as starting point for development of new ligands, and the majority of 
characterized protein-protein interactions are large shallow surfaces with typically 
1200-2000 Å2 of buried surface area on each protein.11 Small molecules may 
however not need to bind this entire surface to function as competitive inhibitors, 
as smaller areas in the interface, known as hot spots, contributes the majority of 
binding affinity.11-13  
 
Only a few activator-coactivator interactions have been structurally characterized, 
posing an additional challenge for ligand discovery. Most numerous of these are 
structures of various nuclear receptors (NRs) binding an LxxLL motif in the p160 
family of coactivators: e.g., GRIP114,15, NCOA1,16 TIF217. In the NR-p160 
interactions a short LxxLL motif-containing peptide binds in a groove in the 
activator, and it would be difficult to find a small molecule that binds the 
interaction partner with the non-invaginated surface, i.e. the coactivator in this 
case. This is, however, opposite of the relationship assumed for most typical 
amphipathic transcriptional activation domains; since the function of these are 
comprised within a short peptide,18-20 they likely bind grooves on their coactivator 
targets. Indeed, the remaining activator-coactivator interactions that are 
structurally characterized show this relationship (Figure 2.1), including solution 
NMR structures of short α-helical transcriptional activation domains from several 
different activators (and p160 coactivators) bound to domains of one coactivator, 
the CREB binding protein (CBP),21-26 as well as a crystal structure of the STAT6 
transcriptional activation domain (TAD) bound to a p160 coactivator (NCOA1).27 
These structures reveal that the buried surface between activator and coactivator 
are smaller (e.g. 600 Å2)21 than typical protein-protein interfaces. Such small 
shallow binding surfaces are predicted to involve weak and transient binding 
interactions,11 which is also in agreement with affinities measured by us and 
others for minimal transcriptional activation domains binding domains of CBP.28 
The low binding affinities measured in vitro may not be accurate estimates of 
native interactions that involve full-length interacting proteins within a context of 
	   31	  
additional protein complexes and DNA, and this must be considered as a 
possible challenge for discovered ligands to function as inhibitors in cells.  
 
Figure 2.1 Structures of activator-coactivator complexes Only a few 
structures of activator-coactivator complexes are available. Two representative 
structures of the amphipathic class of transcriptional activation domains binding 
to a target coactivator are shown: A. Crystal structure of STAT6 activation 
domain (helix) binding a groove on PAS-B domain of NCOA1 (PDB:1OJ5)27; B. 
The KIX domain of the coactivator CBP has two activator binding spots. Solution 
NMR structure of MLL and cMyb activation domains (helices) binding to their 
respective grooves (PDB:2AGH)29. Hydrophobic residues in the helices that are 
critical for binding affinity are colored red.  
 
A handful of small molecule ligands of coactivators have been identified in the 
past decade. From our lab, the isoxazolidine-based transcriptional activation 
domain mimics (iTADs) have emerged as the only designed ligands,30-32 while 
other ligands have been discovered in high-throughput screens.33-38 The iTADs 
are thought to bind several coactivators at binding surfaces shared with natural 
TADs, and indeed they have been cross-linked to several intracellular targets. 
The coactivator CBP is the only identified target, and the affinity of one iTAD for 
this surface is in the low millimolar range (W. C. Pomerantz, unpublished results). 
The low affinity and promiscuous binding profile makes the iTADs ambiguous 
probes of individual activator-coactivator interactions. In experiments performed 
in our lab, in which I have participated, the ability of iTADs and iTAD-derivatives 
to inhibit natural TADs have been evaluated, but direct effect on targets can only 
be inferred.39,40 As a transcriptional activation domain, the activity of iTADs has 
only been demonstrated in cells when tethered to the ligand binding domain of 
MLL cMyb
A B
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the glucocorticoid receptor.41,42 The surface of the receptor may contribute to this 
activity, which is further evidenced by the inability of iTAD to activate transcription 
when tethered via a GR antagonist (J. W. Hojfeldt, A. R. Van Dyke, Y. Imaeda, 
unpublished results). We have limited experience with ligands discovered in 
other labs, but few reports of studies with these ligands, subsequent to their initial 
discovery, exist. Chetomin, which was discovered as inhibitor of the interaction 
between hypoxia-inducible factor 1α (Hif1α) and the coactivator CBP,34 may act 
through zinc ejection rather than binding the coactivator43 and chetomin 
additionally has other notable intracellular interactions.44 Thus, available ligands 
do not currently represent a satisfactory arsenal in terms of numbers, potency 
and specificity, and we have therefore explored high-throughput screening 
options to discover new classes of coactivator ligands.     
 
2.3 Cell-based assays for transcriptional inhibitors 
Design of a luciferase-based reporter assay 
Cell-based assays, when they can be designed with satisfactory sensitivity and 
precision for a high-throughput screening format, have the advantage of 
identifying only compounds that are cell permeable and that function within the 
complex environment of the cell. Cell-based assays on the other hand face 
additional challenges; since many intracellular targets may influence the assay, it 
is important to design assays with minimal response to off-target effects. 
Transcriptional activators are the downstream effectors of signaling cascades, 
which not only include multiple proteins, but the majority of these signaling 
components have enzymatic function and are considerably more druggable.6 
Signaling cascades must therefore be uncoupled from the transcriptional output 
of the chosen assay, so that off-target hits do not predominate screening hits 
(Figure 2.2).  
 
We decided to use a minimal transcriptional activation domain, defined as a 
polypeptide sequence from an endogenous activator that comprises the majority 
of its activation function, and fused it a heterologous DNA-binding domain (DBD) 
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taken from the yeast activator, Gal4 (residues 1-147). By only including a small 
portion of the native mammalian activator, many signal responsive domains are 
excluded. This fusion activator is introduced into a human cell line together with a 
luciferase reporter plasmid with five Gal4-binding sites in the promoter. In the 
assay, inhibition of transcription by the fusion activator would be seen as a drop 
in luciferase signal. While many potential off-target proteins are eliminated by the 
use of a signal-independent activator, inhibitors of the general transcription or 
translation machinery as well as cytotoxic compounds, would also produce a 
drop in signal (Figure 2.2). We reasoned that a comparison of hits to data from 
other screening campaigns would facilitate filtering of cytotoxic compounds. In 
fact, many screening centers have tested their libraries in cell viability assays to 
help filter such compounds. An alternative option is to simultaneously use an 
orthogonal assay for cell viability. 
 
 
Figure 2.2 Schematic of a cell-based luciferase reporter inhibition screen A 
minimal transcriptional activation domain, TAD, is fused to heterologous DNA-
binding domain (DBD). Inhibitors of the activator-coactivator interaction, which is 
TAD
DBD
Prototypical signaling cascade
uncoupled in assay to minimize
off-target hits
Screening target:
Activator-coactivator interactions
Inhibitor Decreased luciferase activity
mRNA Luciferase
Remaining source of false positives: 
General transcription and translation
machinery, luciferase, and cell death
Luciferase signal
Cell-surface
receptor
Signal 
cascade
Modulation of 
activator
Transcription Translation
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necessary for transcription of the luciferase reporter gene, will cause a decrease 
in luciferase activity. Use of a minimal TAD and a heterologous DBD largely 
uncouples the fusion protein from regulation by cellular signaling. 
 
 
The activation domain (residues 413-490) from the herpes simplex virion protein 
16 (VP16) is one of the strongest known activation domains in mammalian 
cells.45,46 The strength of VP16 is beneficial in a HTS, because it can produce a 
strong signal. The direct coactivator binding partners of VP16 and other 
activators have been difficult to affirm47,48, although many have been proposed.49 
Identification of ligands that inhibit VP16 would help elucidate these coactivator 
targets, and discovery of ligands to coactivators that mediate such strong 
activation potential could lead to structures that can recruit these same proteins 
and make very potent artificial transcriptional activators when incorporated into 
DNA-targeting bifunctional conjugates. The VP16 activation domain has 
advantages in a HTS assay over two other activation domains that were 
considered: the activation domains from the human activators RelA (NF-κB p65) 
and Elf3, both of which are studied in our lab. 
 
RelA is a well-studied transcriptional activator with several proposed coactivator 
targets that could facilitate follow-up studies,50-52 and it is a therapeutically 
relevant target for inhibitors.53 The C-terminal activation domain, residues 508-
550,54,55 however, is the direct target of NF-κB signaling events.56,57 It is therefore 
possible that a Gal4 fusion protein would still respond to regulation by 
endogenous kinases, and indeed a GST-RelA(TAD) fusion protein is 
phosphorylated in vitro by the inhibitor of kappaB kinase (IKK).56 The Elf3 
activation domain58 was considered because two small molecules already have 
been discovered that inhibit the transcription of the breast-cancer associated 
ErbB2 oncogene33,39, whose transcription is proposed to be driven by Elf3.59-61 If 
these small molecules could inhibit a Gal4-Elf3 activation assay, they would be 
useful controls in a screen, and screening hits may add to the list of ErbB2 
transcription inhibitors. An additional attraction to Elf3 was the discovery of 
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Med23 as an essential coactivator target62, which would present an immediate 
candidate target protein in secondary assays. 
 
Preparation of assay for a high-throughput pilot screen 
The primary advantage of VP16 over the two mammalian activators was its 
potency. The future goal with the assay was to make a stable cell line with an 
integrated reporter and fusion-activator expression construct. We therefore 
tested the activators in a commercially available HeLa derived cell line, HLR 
(Stratagene); HLR cells have an integrated reporter with 5xGal4 binding sites 
and a minimal TATA-box containing promoter upstream of the Photinus pyralis 
(American firefly) luciferase gene. The number of integration sites and location 
are not characterized. Gal4(DBD)-RelA(522-551) and Gal4(DBD)-Elf3(129-159) 
activated transcription 8- and 20-fold respectively, measured as luciferase activity 
relative to activity in untransfected HLR cells. In comparison Gal4-VP16(413-490) 
activated transcription 70-fold above background (Figure 2.3). This difference is 
significant since the assay format was not yet reduced to a 384-well format to be 
used in the high-throughput screen, and generation of stable cell lines would 
most likely result in lower expression than seen with the transiently transfected 
cells. An early attempt to make stable cell lines with Gal4-Elf3 and Gal4-RelA 
lead to only two clones of Gal4-RelA expressing cells. Because the activity in 
these clones was only 3-4 fold above untransfected HLR cells (Figure 2.3), this 
effort was not pursued further.  
 
Figure 2.3 Activity of three fusion 
activators Expression plasmids for 
three fusion activators was 
transfected into a cell line with an 
integrated luciferase reporter gene 
and the activity determined.    
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The two reported inhibitors of ErbB2-gene transcription (N2-biphenyl iTAD39 and 
adamanolol33) were synthesized and tested for their ability to inhibit the activity of 
Gal4-Elf3, but showed no inhibition in this assay. Any reduction in relative 
luciferase expression was a consequence of the compounds being cytotoxic as 
determined from the activity of a coexpressed Renilla reniformis luciferase gene 
and a simultaneous WST-1 viability test (Figure 2.4). Complicating this analysis 
is the fact that they may be cytotoxic through inhibition of various activator-
coactivator interactions. A small library (~ 50 compounds) of small molecules 
made by various members of the Mapp lab, which included isoxazolidines and 
spirooxindoles functionalized with both hydrophobic and hydrophilic groups to 
mimic the amphipathic nature of natural TADs, was tested for the ability to inhibit 
fusion activators of Gal4 with Elf3/RelA/VP16 as well as 5 other natural TADs. 
However, none of these compounds functioned as inhibitors for any of the 
activators. The consequence of these tests was that no real positive control was 
available for the screen. Instead, the translation inhibitor, cycloheximide, was 
used as a surrogate control.  
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Figure 2.4 Test for inhibition of Gal4-Elf3 Adamanolol and N2-biphenyl iTAD 
were added to HeLa cells transfected with a firefly luciferase reporter, a Gal4-Elf3 
activator and a Renilla reniformis luciferase expression plasmid. A; The activity of 
the Gal4-Elf3 induced firefly luciferase normalized to Renilla reniformis luciferase 
was determined. The activity is reported relative to the DMSO control; B. The two 
ErbB2 transcription inhibitors; C. The Renilla reniformis luciferase activity is 
affected by the small molecules; D. The drop in normalization gene is likely due 
to cell death.  
 
Because VP16 is the most potent activator with no known signal-responsiveness, 
Gal4-VP16 was chosen for a pilot screen. HLR cell lines were transiently 
transfected with a Gal4-VP16 expression plasmid. In the 384-well format with the 
translation inhibitor, cycloheximide, as a surrogate control, an 8-fold dynamic 
range was obtained with a Z’-factor of 0.55. The Z-factor (calculated from screen 
data) and Z’-factor (controls only) are measures of the variability of samples in an 
assay relative to the dynamic range of the assay, and a Z-factor > 0.5 is 
considered a excellent assay for HTS.63  
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Figure 2.5 Performance of a high-throughput Gal4-VP16 inhibition assay 
Bar graph shows average luciferase activity measured for 320 samples treated 
with 0.5% DMSO (negative control) and average activity for 64 samples treated 
with 10 µg/mL cycloheximide (mock positive control). Error bars represent one 
standard deviation. Z’-factor is calculated from the mean and standard deviation 
of luciferase activities of positive and negative controls.  
 
Evaluation of the assay in a pilot screen 
A library of 2000 compounds (Spectrum library, MicroSource), which includes 
50% approved drugs, 30 % diverse collection of natural products and 20 % other 
bioactive small molecules, was screened at 7.5 µM to characterize assay 
performance. This screen had a Z-factor of 0.58, with 71 initial hits based on a 
2.5 standard deviation cut-off. The activity of the hits was compared to the 
activity against two other mammalian cell-based loss-of-function assays used in 
the same screening facility. One of these assays also uses a luciferase reporter 
gene, and the other assay uses a luciferase-based viability reporter. 14 
compounds remained as hits after filtering, with 9 of the hits inhibiting more than 
50% and more than 3 standard deviations. Of the 9 top hits, 5 are steroids. To 
more closely monitor the effects of some of the hit compounds on the cells and 
the assay output, three of the top 9 hits were purchased (including two estradiol 
derivatives) as well as one cytotoxic hit that was filtered out (Figure 2.6B).  
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Figure 2.6 Pilot screen of 2000 compounds A. Luciferase activity measured for 
2000 compounds; B. Structures of 4 hits tested in follow-up studies. The four 
compounds are all false-positives in the screen.  
 
The dose-response of these four compounds was tested in the assay. As 
previously determined the WST-1 viability reagent can be used prior to addition 
of the luciferase reagents without interfering with the later, and this was included 
to simultaneously monitor if the compounds were cytotoxic. The filtered hit 
compound, chelidonine, was indeed very toxic, while the other non-steroid hit 
compound tested, tranilast, was neither toxic nor inhibited the assay. Thus, 
tranilast is a false positive that would likely have been eliminated in a larger 
screen during confirmatory tests of initial hits. The two estradiol derivatives 
showed reduction of luciferase activity, but this was associated with cell death.  
 
This pilot screen demonstrated the difficulty of accurately eliminating cytotoxic 
compounds in a loss-of function cell-based assay. It was not surprising that the 
library contained many cytotoxic compounds (especially since these are tested at 
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a single dose), but it is problematic that these cannot be easily eliminated by 
comparison to other cell based assays. Further complicating this is the possibility 
that a true positive hit is also cytotoxic and should not be eliminated, and since 
many cell-based assays are reporter gene-based assays, non-selective inhibition 
relative to these assays may also eliminate true positives. It appears that the best 
option for this assay format would be to use an internal control for cell viability. 
Cotransfection of a second orthogonal luciferase reporter is commonly used in 
our lab to control for variation in transfection efficiency and cell numbers, and 
could in a high-throughput assay report on viability or non-selective inhibition of 
transcription against the second luciferase construct. However, my experience 
with dual-luciferase assays that have been used to test a small number of 
potential inhibitors is, that the activities of the two luciferases aren’t always 
closely matched to each other in response to a significant drop in viability. This 
can make samples appear as either inhibitors or enhancers of transcription.   
 
Evaluating a novel gain-of-signal transcription assay 
Cytotoxicity poses a problem in the cell-based loss-of-signal assay, because it 
can’t be distinguished from inhibition. In addition, the inhibitors that we seek may 
indeed be cytotoxic as a consequence of their specific function. An assay, in 
which the inhibition event leads to a rise in signal, would solve the issue of 
cytotoxic false-positives and could still detect cytotoxic true-positives. A novel 
gain-of-function assay was designed (Figure 2.7): a luciferase gene is expressed 
from a constitutively active promoter; this signal is however suppressed by a 
microRNA transcribed by the transcription factor of interest.  
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Figure 2.7 A gain-of-signal assay for activator-coactivator inhibitors A. The 
transcribed luciferase gene is knocked down by a microRNA, whose expression 
is controlled by the activator of interest (red TAD); B. An inhibitor blocks 
transcription of the miRNA but not the luciferase gene, and the luciferase activity 
increases.  
 
MicroRNAs are endogenously expressed small single stranded RNA sequences 
that mediate gene silencing through components shared with the RNAi 
pathway64-66 In contrast to short hairpin RNA (shRNA), which must be transcribed 
from a plasmid by RNA polymerase III, endogenous miRNA are processed from 
Pol2 transcripts.67 Recently, Pol2-driven vectors were developed to express 
engineered miRNAs.68 In these expression vectors, an engineered miRNA 
sequence (designed against target transcript)69 is cloned in between flanking 
regions based on murine miR-15570, which facilitate processing of mature 
miRNA. The engineered miRNA and miR-155-based flanking regions are located 
in a gene intron, and the exons can simultaneously code any gene of interest. 
This allows fluorescent proteins to be simultaneously expressed in the same 
transcript as the miRNA to serve as a control for the transcription of this gene.  
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A miRNA was designed to target firefly luciferase (miR-luc), and when this was 
expressed from a highly active CMV promoter in cells cotransfected with a 
luciferase expressing plasmid, the luciferase signal was reduced to 9% (Figure 
2.8).  
 
 
Figure 2.8 Knock-down of firefly 
luciferase gene by miR-luc Luciferase 
activity in cells transfected with 
luciferase expression plasmid and a 
plasmid encoding either a miRNA 
against luciferase (miR-luc) or a non-
targeting miRNA (miR-non). 
 
 
 
 
 
The CMV enhancer of the miRNA expression vector was replaced with a 
tetracycline responsive enhancer (TRE).71,72 The TRE has high activity when 
bound by tetracycline-responsive transcriptional activator, tTA, which contains a 
VP16-derived transcriptional activation domain. The promoter becomes nearly 
silent when tetracycline (or tetracyclin analog, doxycyclin) binds tTA and disrupts 
its ability to bind DNA. Thus, miRNA expression in this promoter can be blocked 
by the addition of doxycyclin. To study the transcriptional dose-response of the 
TRE to doxycyclin, a TRE-regulated luciferase reporter was used (Figure 2.9A). 
Addition of doxycyclin reduced the luciferase activity 100-fold in a dose-
responsive fashion with an IC50 of 2.5 ng/mL and over 92% inhibition at 10 
ng/mL. When the tetracycline-regulated miR-luc expression vector was used to 
knockdown the signal from a cotransfected luciferase (with a constitutive SV40 
enhancer), a doxycyclin dose-response showed a 3-fold gain in signal with an 
EC50 of 33 ng/mL (Figure 2.9B). The level of luciferase activity at high 
concentration of doxycycline was equivalent to the activity when pTRE-miR-non 
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was used (TRE-regulated expression of non-targeting miRNA), and this signal 
was independent of doxycyclin concentration.  
 
Figure 2.9 Dose response of transcriptional inhibition and gain-of-signal A. 
Luciferase activity in cells transfected with luciferase expression plasmid and a 
plasmid encoding either a miRNA against luciferase (miR-luc) or a non-targeting 
miRNA; B. Transcriptional dose-response of doxycyclin determined in cells 
cotransfected with a doxycyclin-responsive activator tTA (inhibited by doxycyclin) 
and a luciferase reporter with binding sites for tTA; C. The gain of luciferase 
activity in response to different doses of doxycyclin, when miR-luc is expressed 
from a tTA regulated gene.  
 
The >10-fold dynamic range demonstrated by the CMV-driven miRNA 
suppression is likely sufficient for a HTS assay. It is also in agreement with 
typical RNAi results, which provide knockdowns from 90-98%. The 3-fold 
induction of signal obtained with doxycyclin regulated inhibition of miRNA 
production is too low, but can likely be improved. In these assays, three plasmids 
are introduced into cells in a co-transfection, and if a small number of cells 
receive the luciferase expression plasmid but little or none of either pTRE-miR-
luc or tTA expression plasmid, a high baseline is obtained from this population. 
The signal-to-background ratio of the gain-of-function experiment was 1000, and 
thus the signal can be greatly reduced in attempts to optimize the dynamic range 
of knockdown. Ideally stable cell lines should be made, which must receive three 
plasmids: expression of tTA activator, luciferase and miR-luc. If the assay is 
modified to report an endogenously expressed transcriptional activator, only the 
luciferase and a miR-luc plasmids would need to be introduced, where the 
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enhancer of the miR-luc plasmid would be changed to include binding sites for 
the activator of interest. The more concerning result from the dose-response 
study is the shift in IC50/EC50 (the dose at which half of the maximal response is 
seen). At 10 ng/mL doxycyclin, transcription from the TRE promoter is reduced to 
10% (based on luciferase activity), while there is no rise in signal at this 
concentration in the gain-of-function assay. The EC50 for doxycyclin is raised 
>10-fold in the gain-of-function assay. Thus, in a screen, only compounds that 
inhibit transcription by at least 90% would be seen as hits. This is particularly 
concerning because full inhibition of a single activator-coactivator interaction may 
only partially reduce the activity of the activator.73  
 
Optimization of the assay was judged too difficult to pursue further. The levels of 
the expressed miRNA likely need to be controlled to a level of strong knockdown, 
yet still limiting to show a response to low levels of inhibition. Such balance is 
difficult to obtain with transient transfections and with the low dynamic range 
found initially. Creation of numerous stable cell lines is likely necessary to 
achieve such balance, but may be practically unfeasible in the system with three 
separate plasmids.  
 
2.4 Conclusion and discussion of efforts with cell-based HTS assays 
For identification of inhibitors of individual transcriptional activation domains in 
cells, a loss-of-function assay will yield unsatisfactorily high false positive hit 
rates. If these are eliminated by an internal viability control or comparison to 
screening data, a significant fraction of true hits may be lost. These problems 
are, at least in theory, overcome by a gain-of-signal assay. A gain-of-signal 
assay for inhibitors can be constructed by making the target component suppress 
a constitutive signal, which was attempted for an activator-coactivator interaction 
via an RNAi knockdown mechanism. The gain-of-signal mechanism is functional, 
but the added complexity makes the assay difficult to optimize. Most cell-based 
HTS assays use a signal produced from a luciferase or fluorescent protein, but a 
viability assay could also be used and would simplify the assay since no added 
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reporter gene is needed. The assayed component could in this case induce a 
toxic gene, and inhibitors would increase the cell number. Regardless of the 
chosen signal or suppression mechanism, it will be critical to adjust the level of 
suppression to a starting point that is sensitive to inhibitors. The dose response 
of the suppression mechanisms will additionally determine if the assay output is a 
graded response or an active/inactive type of response. 
 
We have additionally realized that data for inhibitors of transcriptional activation 
domains may already exist in screening databases. Many assays use 
transcription as an output coupled to the intended target function. Transcription 
inhibitors would likely be eliminated from such screens in secondary assays, and 
labeled as false positives in those assays. Thus data mining of publicly available 
HTS results may be a fruitful effort in place of or in combination with a primary 
screen for inhibitors. 
 
2.5 Identification of a lichen natural product as ligand of the coactivator 
CBP from a biochemical high-throughput screen 
Introduction to the multi-domain CBP/p300 coactivators 
The cell-based assays explored in the previous sections were designed to 
discover inhibitors of a specific transcription factor, but with no specific 
coactivator as target. This was done because the direct binding targets of most 
activators are unknown. There are, however, coactivator proteins that are known 
to be direct targets of some activators, and these activator-coactivator 
interactions can be assayed for inhibitors in biochemical assays. The highly 
homologous human transcriptional coactivators CREB binding protein (CBP or 
HGNC: CREBPB) and E1A binding protein p300 (p300 or HGNC: EP300) are 
considered to be transcriptional hubs.74 They consist of 9 conserved domains: a 
histone acetyltransferase domain gives the protein intrinsic chromatin modifying 
ability, while the remaining domains are protein interaction domains that are 
proposed to interact with several hundred transcription factors and coactivators 
(Figure 2.10).74,75 The role of CBP/p300 in animal physiology has been difficult to 
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study using standard genetic approaches, as knockouts of either protein cause 
embryonic lethality.76,77 Cells lacking both proteins can be generated but do not 
divide.78 These observations are expected as a consequence of the proteins’ 
ubiquitous role in transcription of numerous genes in all cell types.  
 
Disruption of individual interaction domains of CBP or p300, in contrast, show 
more restricted phenotypes, indicating that they are each utilized by only a 
subset of transcriptional activators. Knock-in mice have been generated in which 
CBP or p300 is replaced by a protein with a mutation that disrupts an activator 
interaction surface in the KIX or the CH1 domain.79,80 Mice with mutations in 
p300’s KIX domain that disrupt binding to transcriptional activators cMyb and 
CREB, are viable but show mild defects in hematopoiesis79 and impairment of 
long-term memory.81 Mutations in the CH1 domain of p300 and CBP block 
activation of hypoxia-responsive genes by Hif1alpha.80 The restricted use of 
individual activator interaction sites within p300/CBP is encouraging from a 
perspective of probing activator function with small molecule inhibitors of these 
domains. It also increases the likelihood that ligands to these domains can have 
therapeutic value, since a limited set of genes will be affected by their disruption.  
 
Complicated genetic strategies were needed to demonstrate the domain specific 
interactions of p300/CBP. The two proteins can often complement each other, 
and to study the role of the KIX domain of either p300 or CBP in CREB mediated 
transcription, mice had to be generated with three mutant alleles and one loxP-
flanked allele, which is eliminated in isolated cells by transfection of Cre 
recombinase.73 The influence of these CBP/p300 KIX-mutants can only be 
studied through this genetic strategy in the generated mouse cell lines, and the 
employment of such strategy in any human cell line would be impossible. Thus, 
to complement genetic strategies, small molecules that bind to domains of 
CBP/p300 and block interactions with transcription factors would have great 
value to help elucidate the complex network that these proteins function within. 
Indeed, several groups have reported discoveries of ligands/inhibitors of 
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CBP/p300 domains (Figure 2.10), including the nuclear receptor interaction 
domain (NRID) (ICG-001: inhibitor of β-catenin-CBP)36, TAZ1 domain (chetomin: 
inhibitor of Hif1alpha-CBP, not shown in figure)34, KIX domain (Napthol AS-E 
phosphate: inhibitor of CREB-CBP)35, HAT domain (C646, histone 
acetyltransferase inhibitor).82 In addition, our lab determined that iTAD1 interacts 
with the MLL binding site in the KIX domain of CBP.42  
 
 
Figure 2.10 The CBP/p300 coactivator and its ligands The CBP/p300 
coactivator contains multiple interaction domains. Domain labels are above the 
schematic representation of the protein (NRID: nuclear receptor interaction 
domain; HAT: histone acetyltransferase domain; NCBD: NR-coactivator 
interaction domain) Domains that interact with numerous transcriptional 
activators and coactivators are shown in pink, and representative examples are 
listed below (NRs: nuclear receptors; p160: p160 class of NR coactivators). 
Structures of four molecules that bind to individual domains are shown 
(references in text). 
 
The KIX domain of CBP has two interaction surfaces.83 Several activators bind to 
a surface shared with CREB, and other activators bind a surface shared with 
MLL (Figure 2.1B).21,84 Two activation domains can bind simultaneously to their 
respective target sites in a cooperative fashion.28,83 The p53 transcriptional 
activator binds to both sites of KIX with two separate activation domains,85 and 
the FOXO3A TAD can bind both sites with similar affinity.86 Of the two sites, the 
MLL site presents a deeper cleft, which likely makes it easier to target with small 
molecules. The binding affinity of iTAD for this site is weak (1-4 mM, W.C. 
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Pomerantz, unpublished data) making it unlikely to function as an inhibitor, and 
since no other ligands of the site is known, we wished to screen for inhibitors of 
the KIX-MLL interaction. 
 
A fluorescence polarization assay of the MLL-KIX interaction 
To screen for ligands that interact with the MLL binding site in the KIX domain of 
CBP, we used a fluorescence polarization-based assay87,88 with bacterially 
expressed KIX-domain and a fluorescein-labeled version of the MLL 
transcriptional activation domain. The principle of the fluorescence polarization 
assay is illustrated in Figure 2.11. The assay is attractive in a high-throughput 
format because the readout is a ratio of emitted light measured through two 
perpendicular filters and this ratio is stable to variations in concentrations, total 
volumes, and compounds that absorb light, thus producing a signal with robust 
tolerance to interference. In a solution NMR structure of the KIX-MLL complex, 
MLL makes contact to KIX via a short peptide (residues 2840-2858)28: Eleven 
amino acids of the 19-mer peptide fold as an alpha helix when bound to KIX and 
the majority of residues in the helical portion in addition to 3 N-terminal residues 
are critical for the binding interaction.83 The 19-mer MLL peptide (2840-2858) 
was synthesized with fluorescein attached to the N-terminus (Fl-MLL19). A direct 
binding experiment was used to determine that Fl-MLL19 binds to KIX with a 
dissociation constant (Kd) of 1.2 µM (Figure 2.11B), which is in agreement with 
published values.28,89 A 15-mer unlabeled peptide, corresponding to the 14 
critical residues in MLL (2844-2857) and a C-terminal tyrosine for accurate 
determination of concentration, was used in a competition assay to inhibit Fl-
MLL19 (Figure 2.11C). MLL15 peptide inhibits with an IC50 of 10.9 µM, and the 
inhibition curve can be fitted to a theoretically derived equation88 from which a Ki 
of 1.2 µM is determined (the fitted values of anisotropy of free and bound tracer 
closely match the anisotropies from the maximum and minimum values in the 
direct binding experiment, and the goodness of fit is: R2 = 0.9841). Thus, with 
similar binding affinity of Fl-MLL19 and MLL15, it appears that fluorescein does 
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not contribute to the binding affinity, and false-positives in the HTS will not be 
found due to inhibition of fluorescein binding.  
 
Figure 2.11 Fluorescence polarization assay of the MLL-KIX interaction A. 
In the FP assay, the MLL peptide is labeled with a fluorophore. When the 
fluorophore is excited with polarized light, the light emitted will be polarized to a 
degree that depends on the rotational frequency of the molecule in solution. 
When the molecule is bound to a large protein, rotation (or tumbling) is slowed 
down significantly and light remains polarized; B. Dose-response curve for KIX 
binding to Fl-MLL19. With increasing concentration of KIX, more tracer is 
tumbling slowly and the emitted light is polarized (measured in anisotropy units); 
C. Competitive inhibition with MLL15. 
 
In the inhibition assay, the concentration of KIX (5 - 10 µM) is chosen so that 80 - 
90% of ligand is bound. This ensures that the assay is sensitive to detect 
inhibition while maintaining a large dynamic range. An equation that defines the 
Competitive inhibition of Fl-MLL19 - KIX
0.1 1 10 100
0.00
0.02
0.04
0.06
0.08
0.10
Concentration of MLL15 (µM)
An
iso
tro
py
Fast tumbling free tracer
Emitted light is depolarized
Slow tumbling bound tracer
Emitted light is polarized
Target protein
Competitive inhibitor
A
B
Fast tumbling Slow tumbling
KIXMLL19WT-Fl
ni
so
tro
pyMLL15
Fast tumblingSlow tumbling
C
+
FP assay principle
Binding curve for protein (KIX) to tracer (Fl-MLL19)
0.001 0.01 0.1 1 10 100
0.00
0.02
0.04
0.06
0.08
0.10
An
is
ot
ro
py
Concentration of protein (micromolar)
	   50	  
fraction of bound tracer in presence of inhibitors as a function of total input 
concentrations and binding affinities of assay components is derived in a 
theoretical treatment of FP assays.88 A curve was generated from equation 17 in 
this paper to show the theoretical fraction of bound Fl-MLL19 as a function of the 
binding constant, Ki, of a competitive inhibitor present at 22 µM, which will be the 
concentration of small molecules in the high-throughput screen (Figure 2.12). 
Notice that the starting fraction (at 5 µM KIX) is 80% bound tracer. From this 
curve the detection threshold of the assay is determined, when it is assumed that 
15% change in anisotropy (equivalent to a change in bound tracer from 80% to 
68%) can be detected: the assay is sensitive to detect inhibitors with a binding 
constant of 18 µM. 
 
 
Figure 2.12 Theoretical detection limit of KIX-MLL FP assay In the HTS, 
compounds will be tested at 22 µM. A competitive inhibitor with a Ki < 18 µM will 
be detected in the assay.  
 
The FP-assay was tested in a 384-well, 10 µL format with DMSO as a negative 
control and no added protein as a surrogate positive control. With exclusion of 
KIX, the tracer is unbound and gives same low anisotropy value as complete 
inhibition by MLL15. The no KIX control makes assay setup easier, saves on 
peptide reagent, and defines the dynamic range of the assay. The assay has a 
Z’-factor of 0.71 (Z-factor > 0.5 is an excellent HTS assay)63 (Figure 2.13).  
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Figure 2.13 Variability of KIX-MLL FP assay The mean mP values for positive 
and negative controls in a 384-well test plate.  
 
A high-throughput screen with the KIX-MLL FP assay 
66882 samples were screened at the University of Michigan Center for Chemical 
Genomics, which includes 50562 commercially available compounds with known 
identity, and 16320 natural product extracts with high biodiversity deposited by 
the laboratory of Dr. Sherman at our institution. The Z-factor during the screen, 
which was done in multiple sessions ranged from 0.69 to 0.88 (Figure 2.14A). 
Threshold values for initial hits and the number of hits that met the criteria are 
shown in Figure 2.14B. Fluorescent molecules interfere with the assay, and 
samples with a total fluorescence signal higher than 3 standard deviations from 
the mean of the total fluorescence of all samples were eliminated from hits after 
the primary screen. The filtered hits were retested in triplicate to confirm their 
activity. Of the confirmed hits, only the commercial compounds were tested for a 
dose-response, as the natural product extracts are too sparse. Three potent 
compounds were purchased, but their activity was determined to be an artifact of 
their fluorescence, meaning that they had escaped the early filtering of 
fluorescent compounds. The 64 confirmed hits from the natural product extract 
collection were tested for inhibition of an unrelated protein-peptide interaction 
used by another group at the screening facility. This assay also uses a short 
fluorescein-labeled peptide, but unlike MLL19 the peptide is not believed to bind 
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as an α-helix. 22 of 64 natural product extracts were selective for the MLL-KIX 
assay. These extracts all originate from lichens collected in Costa Rica.  
 
 
Figure 2.14 High-throughput screen of 66882 compounds for inhibitors of 
KIX-MLL A. Graphical representation of the % inhibition of all samples from initial 
screen; B. Flow-chart of hit selection.  
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Identification of two depsides as selective ligands of the KIX domain 
To facilitate follow up studies, additional aliquots of the 22 lichen extracts were 
requested from the National Institute for Biodiversity in Costa Rica (INBio), who 
were able to provide 13 of these, of which 7 had shown more than 50% inhibition 
in the confirmatory screens. For one of the 13 lichen samples, the major 
component in the extract had previously been identified as 2’-O-methylanziaic 
acid and this was supplied in pure form (Figure 2.15). This compound belongs to 
a common class of secondary lichen metabolites called depsides (named by Emil 
Fisher in 191090); the defining structure of depsides is two condensed phenol 
carboxylic acids.   
 
 
Figure 2.15 Structure of the lichen depside 
2’-O-methylanziaic acid  
 
 
 
 
Of the 12 remaining samples received, 7 were received as both crude extracts 
and HPLC separated fractions. All crude extracts and fractions were tested in the 
MLL-KIX FP assay at 3 concentrations to confirm the activity and identify the 
most active fractions. In addition to 2’-O-methylanziaic acid, 6 of the extracts 
shows activity (Figure 2.16), and it is possible to identify individual fractions with 
highest activity that likely contain the active compound(s) of the extract (Figure 
2.16, 3rd column). Although the hits are selective for KIX-MLL inhibition over the 
counter screen used in the assay, they were tested against two additional FP-
assays of activator-coactivator interactions: cMyb-KIX (cMyb binds to the other 
site on KIX) and VP2-Med15 (VP2 is an artificial dimer derived from the VP16 
TAD sequence, Med15 is a yeast coactivator). They were also tested against a 
protein-DNA binding interaction (Gal4-DNA). Based on these tests, extract 2 
appears to contain a compound in fraction 4, which selectively inhibits the two 
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KIX interactions (with MLL and cMyb), and the same selectivity is observed for 
extract 6 fraction 5.  
 
 
Figure 2.16 Activity of lichen extracts in MLL-KIX and other FP assays 
Orange color indicates high level of inhibition; yellow indicates mild inhibition.     
 
 MLL-KIX Counter screen KIX-MLL KIX-cMyb Med15-VP2 Gal4-DNA
Extract 
# Type
0.8 
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0.08 
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0.008 
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1 2'-O-methylanziaic acid 88 -9 58 70 N.I. 57 20 61
Fraction 1 N.I. N.I. N.I.
Fraction 2 6 N.I. N.I.
Fraction 3 50 N.I. N.I.
Fraction 4 65 57 N.I. 45 68 13 -20
Fraction 5 77 8 N.I.
Crude 73 4 N.I.
Fraction 1 N.I. N.I. N.I.
Fraction 2 31 N.I. N.I.
Fraction 3 53 11 N.I.
Fraction 4 65 39 N.I. 38 63 29 42
Fraction 5 65 28 N.I. 77 72 29 27
Crude 74 1 N.I.
Fraction 1 N.I. N.I. N.I.
Fraction 2 52 N.I. N.I.
Fraction 3 37 6 N.I.
Fraction 4 53 84 N.I. 68 47 55 2
Fraction 5 54 29 N.I. 71 44 24 -17
Crude 62 56 2
Fraction 1 N.I. N.I. N.I.
Fraction 2 67 41 N.I.
Fraction 3 78 25 N.I.
Fraction 4 67 22 N.I.
Fraction 5 80 64 N.I. 40 7 29 31
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Fraction 1 N.I. N.I. N.I.
Fraction 2 71 N.I. N.I.
Fraction 3 65 62 N.I.
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The HPLC fractions received from Costa Rica were not pure and the same active 
component was present in more than one fraction. The fractions and crude 
extract was therefore re-purified on HPLC, and pure fractions tested in the MLL-
KIX FP assay.  Extract 2 contained primarily one compound and this compound 
was active in the assay. Through NMR and mass spectrometric analysis, the 
active compound was determined to be sekikaic acid, which is also a depside 
(Figure 2.17). Extract 6 contained two active compounds, which were determined 
to be the depsides: microphyllinic acid and 5’-O-demethylmicrophyllinic acid 
(Figure 2.17). Based on HPLC peak intensities, extract 6 also contained other 
compounds in comparable amount to the microphyllinic acid compounds, but 
these compounds lacked activity. The UV absorption spectrum collected on the 
HPLC of these compounds are similar to the depsides with peak absorptions at ~ 
250 nM and 320 nM, and although their structures were not determined they are 
likely depsides or related compounds.  
 
 
Figure 2.17 Structures of sekikaic acid and microphyllinic acids    
 
Study of the binding interaction between sekikaic acid and the KIX domain 
The identified depsides are similar in structure and activity, and the first identified 
compound with KIX selectivity, sekikaic acid, was chosen for further studies. In 
order to characterize the binding mode of sekikaic acid to the KIX domain, a 
dose-response inhibition curve was generated using purified sekikaic acid 
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(Figure 2.18A). This showed that sekikaic acid inhibits KIX-MLL with an IC50 of 58 
µM. The Hill-slope is significantly higher for sekikaic acid than the MLL-peptide. 
High Hill-slopes are indicators of cooperativity, but can alternatively be caused by 
irreversible inhibitors or by small-molecule aggregators, found to be common 
promiscuous inhibitors in high-throughput screening libraries.91,92 As the 
depsides lack reactive groups that would irreversible react with amino acid side 
chains in a protein, it was assumed not to be an irreversible inhibitor (It is also 
evident in NMR studies presented below that the binding is not kinetically 
irreversible). With the large Hill-slope and the activity against both binding 
surfaces of the KIX domain, it is important to consider the possibility that the 
active species could be a promiscuous aggregate species. Early evidence 
against this, is the fact that the HTS was done in an assay buffer containing 
0.01% NP-40 detergent to help prevent such aggregates, and the identified 
depsides had shown selectivity for KIX in the tests summarized in Figure 2.16. 
To further study the effects of detergents on the inhibition curve by sekikaic acid, 
buffers with varying amounts of Tween-20 were used (Figure 2.18B). The most 
shallow dose-response curve was seen with 0% Tween-20. Addition of 0.01-
0.02% Tween-20 did not affect the IC50 significantly, but the Hill-slope increased 
dramatically. This observation does not point to activity from an aggregate 
species; detergents have the potential to disrupt aggregates making them less 
potent (increasing the IC50).92 Furthermore, the high Hill-slope of aggregators is 
due to cooperativity of aggregate formation as well as high binding affinity of the 
aggregate for proteins, and detergents would be expected to lower this 
cooperativity. Thus, the steeper dose-response curves with added detergent are 
not consistent with an active aggregate species. The inhibition of Fl-MLL19 – KIX 
interaction by both MLL15 and sekikaic acid was studied in a buffer that 
contained only 0.001% NP40 (which comes from the protein stock). MLL15 
inhibits with an IC50 of 13.3 µM and a Hill-slope of 1.18. It is worth noting that 
with a protein concentration of 5 µM and a Ki of MLL15 at ~ 1 µM ([KIX]:Ki  5:1) 
the Hill-slope is expected to be slightly higher than 1.93,94 The IC50 for sekikaic 
acid in this buffer is 52.1 µM and the Hill-slope is 2.8. The Hill-slope was even 
	   57	  
lower (1.6) in the detergent experiment (Figure 2.18B), but this may be due to the 
fewer data points used for the fit. Because of the high Hill-slope, a Ki for sekikaic 
acid cannot be determined by fitting the data to theoretical equations. For 
comparison, a hypothetical inhibitor that binds to only one binding site and has 
an IC50 of 52.1 µM would have a Ki of 3.1 µM (determined with equation: Ki = 
(Lb)(IC50)(Kd)/((Lo)(Ro)+Lb(Ro-Lo+Lb-Kd)); Lb = concentration of bound tracer, 
Kd = Kd of tracer, Lo = total concentration of tracer, Ro = total concentration of 
protein).95 
 
Figure 2.18 Inhibition of Fl-MLL19 – KIX interaction by sekikaic acid A. Dose 
response of purified sekikaic acid in assay used in the screen; B. Dose-response 
of sekikaic acid with different concentrations of detergent; C. Dose-response of 
MLL15 and sekikaic acid in low detergent buffer.    
 
A mutant version of the MLL15 peptide had been generated in the lab (by W.C. 
Pomerantz), through a systematic mutation of amino acids to yield a peptide with 
higher affinity for the MLL site on KIX. This peptide, named MLL15dm, contains 
M2850Nle (Nle: norleucine) and V2853I mutations, and binds with 3-fold higher 
affinity. A fluorescein-labeled version was made, Fl-MLL15dm, and used as 
Effect of detergent
10 100 1000
0.00
0.02
0.04
0.06
0.08
0.10
An
iso
tro
py
Sekikaic acid (µM)
0% Tween-20
0.01% Tween-20
0.02% Tween-20
0.05% Tween-20
0.1% Tween-20
Inhibition of Fl-MLL19 - KIX in 0.001% NP-40
1 10 100 10000.1
0.00
0.05
0.10
Concentration of inhibitor
An
iso
tro
py MLL15Sekikaic acid
Inhibition of Fl-MLL19 - KIX
0.1 1 10 100 1000
0.00
0.02
0.04
0.06
0.08
Inhibitior concentration (µM)
An
is
ot
ro
py Sekikaic acid
MLL15
A
B C
	   58	  
tracer in an inhibition assay with sekikaic acid (Figure 2.19). The higher affinity 
gives this tracer the advantage of allowing a 5-fold dilution of KIX in the assay 
while maintaining a good dynamic range. Sekikaic acid inhibits Fl-MLL15dm – 
KIX with an IC50 of 37 µM, which is compared to its IC50 of 52.1 µM against Fl-
MLL19 – KIX, where the concentration of KIX is 5-fold higher. If the active 
species is an aggregate with very low Ki (Ki << [KIX]), the IC50 is expected to 
change nearly linearly with change in protein concentration (in this case it should 
change approximately 5-fold).91 This is further evidence that the active species is 
not an aggregate. 
 
Figure 2.19 Inhibition of Fl-MLL15dm – KIX interaction by sekikaic acid A. 
Direct binding of KIX to the Fl-MLL15dm tracer; B. Dose-response of sekikaic 
acid and MLL15 on inhibition of Fl-MLL15dm – KIX. 
 
These binding studies all suggest that the binding mode of sekikaic acid is 
cooperative, and this can only be achieved if sekikaic acid has more than one 
binding site on KIX, since KIX is believed to be a monomer in solution. Because 
natural TADs can bind cooperatively to two separate sites on KIX it is appealing 
to suggest that sekikaic acid may also bind these same two sites. To determine if 
sekikaic acid can inhibit binding of a TAD to the other site on KIX, a 29-mer 
phosphorylated peptide derived from CREB, KID29, was used as tracer (Fl-
KID19, Kd = 1.37 µM) in an FP assay (Figure 2.20). Sekikaic acid inhibits Fl-
KID29 – KIX with an IC50 of 63.7 µM and a Hill-slope of 2.7 (KIX at 2.5 µM). A 
previously reported inhibitor of KIX – KID interaction, 2-napthol-AS-E-phosphate 
(Figure 2.10), was also tested in the assay. From a fitted curve, this compound 
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has an IC50 of 387 µM and a Hill-slope of 1.7 (only a partial inhibition curve was 
observed in the tested concentration range).  
 
 
Figure 2.20 Inhibition of Fl-KID29 – KIX interaction by sekikaic acid A. Direct 
binding of KIX to the Fl-KID29 tracer; B. Dose-response of sekikaic acid and 2-
napthol AS-E phosphate on inhibition of Fl-KID29 – KIX. 
 
To determine if the binding of sekikaic acid to KIX is reversible, and can be 
inhibited by MLL15dm and KID29 peptides, a ligand-observed 1D-1H-NMR 
experiment was used. Upon addition of KIX to sekikaic acid, the chemical shifts 
of protons in sekikaic acid are perturbed (Figure 2.21). Most diagnostic are the 
chemical shifts of the aromatic protons, which are isolated in the spectrum from 
KIX and peptide chemical shifts. The chemical shifts of these three residues shift 
and broaden slightly in presence of KIX. The change in chemical shift and mild 
broadening are both evidence of a bound species of sekikaic acid. A single peak 
is observed as an average of bound and unbound sekikaic acid, because the 
exchange of bound and unbound species is fast relative to time scale of the NMR 
acquisition parameters, consistent with a KD > 0.1 µM (approximated by the 
IC50).96 In above analysis of data presented in Figure 2.18 it was determined that 
the IC50 of sekikaic acid would be identical to a single site competitive inhibitor 
with a Ki of 3.1 µM. If it is assumed that sekikaic acid binds to only one binding 
site on KIX with this affinity the fraction of bound sekikaic acid in the 1D-NMR 
experiment (+KIX trace) can be determined to be 26%, by using equation 6 from 
Roehrl et al.88 Addition of either MLL15dm or KID29 at equimolar amounts 
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relative to sekikaic acid, does not cause a significant change in the fraction of 
bound sekikaic acid as determined by the lack of perturbation of chemical shifts 
towards the chemical shifts of unbound sekikaic acid. When both peptides are 
added, however, the chemical shifts change significantly towards the spectrum of 
free sekikaic acid. Thus, this experiment shows that the binding of sekikaic acid 
to KIX is reversible and can be inhibited when both MLL15 and KID29 are added, 
but not as readily when each of the peptides are added alone. Competition by 
single peptides at twice the concentration gives the same result. The cooperative 
binding mode of sekikaic acid is stronger than the binding of either peptide alone. 
The two peptides also bind KIX cooperatively,83 and this may explain how they 
can compete with sekikaic acid binding when added together.  
 
 
Figure 2.21 1D-1H-NMR of sekikaic acid binding to KIX The chemical shifts of 
aromatic proton resonances of sekikaic acid are isolated from other proton 
resonances in the presence of KIX and TAD peptides. Binding to KIX perturbs 
the resonances of sekikaic acid as shown in green trace. Addition of MLL15dm 
and KID29 peptides (purple) but not either of peptide alone (red and blue), 
inhibits binding of sekikaic acid to KIX.  
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To map the binding sites of sekikaic acid on the KIX domain, an HSQC-NMR 
spectrum of 15N-labeled KIX in the absence and presence of increasing relative 
equivalents of sekikaic acid was recorded. This type of protein observed NMR 
experiment is preferably done with high concentration of protein to achieve good 
signal-to-noise spectra. At high concentrations of both KIX and sekikaic acid, 
however, the protein precipitated out of solution (visibly observed), this was  
confirmed by loss of detectable protein resonances by NMR. The exact limits in 
concentrations of KIX and sekikaic acid were difficult to ascertain, but in general 
sekikaic acid concentrations higher than 150-175 µM tended to cause 
precipitation of protein, and the precipitation was more predominant with KIX 
concentrations above 35 µM. The cause of the precipitation is not known. It is 
possible that precipitation is caused by aggregates of sekikaic acid, which may 
form at high concentrations of sekikaic acid. It is also possible that the 
conformation of KIX associated with fully bound sekikaic acid is prone to self-
aggregation, which would explain the dependence on protein concentration. In 
fact the KIX protein is difficult to concentrate beyond 100 µM on its own and is 
perhaps only a semi-stable fold.97 A 1H-NMR spectrum of sekikaic acid at 500, 
250 and 125 µM in D20 was recorded (Figure 2.22). These spectra show very 
mild line broadening of sekikaic acid chemical shifts, and no change in the 
chemical shifts of sekikaic acid except for an emergence of weak, broad peaks in 
the aromatic proton region. The later peaks could be evidence of aggregates. 
The 500 µM solution was slightly turbid, and this turbidity was also observed as 
light scattering in a UV/VIS absorption spectrum (not shown). Light scattering 
was not seen for samples at 125 or 250 µM. All protein observed NMR 
experiments are therefore done at a low concentration of KIX (10-25 µM) to allow 
≥ 5-fold equivalents of sekikaic acid to be added. 
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Figure 2.22 1H-NMR of sekikaic acid to monitor indications of aggregation 
at high concentration A. All peaks; B. Aromatic resonances.   
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A 1H-15N HSQC spectrum was recorded of KIX using 10 µM protein with 0, 1, 2.5, 
and 5 equivalents of sekikaic acid added. Binding of sekikaic acid is evident from 
perturbation of a chemical shift observed of protein backbone amides for a few 
residues.  The majority of shifts are unchanged indicating that any conformational 
change associated with binding to the protein is subtle (Figure 2.23). The 
assignment of the spectrum is done by comparison to reported spectra, and the 
majority of peaks can be assigned in this way, although with less certainty in 
assignments.89,97 Chemical shift changes for individual peaks are quantified as 
((0.2*Δδ15N)2+ (Δδ1H)2)0.5, which is a weighted length of the vector from free KIX 
to 1, 2.5, or 5 equivalents of sekikaic acid. The 0.2 fractional weight of Δδ15N in 
this vector is also used by others,89 and correspond in this experiment to the 
relative differences in standard deviations of  Δδ15N and Δδ1H. The chemical shift 
changes for KIX with 5 equivalents of sekikaic acid are graphed in Figure 2.23C. 
The threshold on the graph is based on the average chemical shift change + 3 
standard deviations from the sample with 1 equivalent of sekikaic acid (this 
sample had no large changes in shifts, and the variation is a better indicator of 
random variation). Significant chemical shift changes are observed for 5 
residues. These are identified in spectra and mapped onto a structure of KIX 
(Figure 2.24). Of the peaks with shifts close to the threshold, several do not 
observe systematic changes when comparing to sample with 2.5 equivalents of 
sekikaic acid, and some are caused by low peak height and imprecise peak 
placement. These may reveal true but mild perturbations, but none of them map 
closely together on KIX to indicate a binding site. Although not all peaks are 
assigned and some peaks are not identified because they overlap, no other 
peaks show as significant shifts as the 5 identified residues. Mapping of the 
backbone amides of these 5 residues indicate that sekikaic acid may bind in a 
pocket formed by three helices, to which it can bind on the inside (2.24A) or 
outside (2.24B) face relative to MLL. It is also possible that a molecule binds on 
both faces, but this is speculative. In a solution NMR structure, this region was 
found to be the most flexible.21  
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Figure 2.23 1H-15N HSQC of KIX with sekikaic acid A. Overlayed spectra of 
free KIX (red) and KIX + 5 eq. sekikaic acid (blue); B. An enlarged view of 
regions with residues that observe significant chemical shift changes. Spectrum 
from 2.5 eq. sekikaic acid (green) is added; graph of chemical shift changes for 
each residue in KIX. Unassigned residues are represented with a grey bar with 
an average shift change as height.  
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Figure 2.24 Map of chemical shift changes in sekikaic acid-bound KIX KIX 
(grey) with perturbed backbone amides (red) (PDB:2AGH).29 MLL is blue and 
KID (Superimposed from PDB:1KDX)21 is turquoise.  
 
Cell-based studies with sekikaic acid 
Sekikaic acid was identified as a new ligand of the CBP KIX domain in a 
biochemical screen, but it remains to be seen if cellular activity can be 
demonstrated. Sekikaic acid’s effect on viability of human cell lines, HeLa and 
HEK293T, was studied to define concentrations at which functional studies can 
be carried out (Figure 2.26). The concentration of sekikaic acid that causes 50% 
cell death (LC50) is 37 µM and 32 µM in A549 cells at 24 and 48 hours treatment 
respectively, and it is 25 µM and 18 µM in HEK293T cells at 24 and 48 hours 
respectively.  
 
Sekikaic acid was tested in HEK293T transfected with a luciferase reporter 
plasmid and a Gal4-fusion activator with either the MLL or the CREB activation 
domain. Cells transfected with Gal4-CREB also received an expression plasmid 
encoding protein kinase A (PKA), which phosphorylates the CREB TAD and is 
necessary for CREB binding to the KIX domain of CBP/p300.98 At concentrations 
A B
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of up to 20 µM sekikaic acid, no inhibition of Gal4-CREB was observed. The 
activity of Gal4-MLL looks to be inhibited to a small degree, and further 
experiments will assess the significance of this result (Figure 2.27).  
 
 
Figure 2.26 Cytotoxicity of sekikaic acid The viability of two human cell lines 
at varying concentrations of sekikaic acid is determined with WST-1 viability dye 
added 24 or 48 hours after addition of compound. Values are relative to DMSO.  
 
 
Figure 2.27 Effect of sekikaic acid on MLL and CREB activated 
transcription A. Gal4-MLL fusion activator introduced together with luciferase 
reporter with Gal4-binding sites into HEK293T cells. The activity of sekikaic acid 
treated samples relative to DMSO treatment is shown. B. Same as in A, except 
fusion activator is Gal4-CREB and it is cotransfected with PKA. Data is from one 
experiment individual samples done in triplicate.  
 
It is not known to what extend the activators are depended on CBP, and in fact 
CBP dependent CREB activity is context dependent.73 To explore an assay that 
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would be entirely depended on MLL-KIX interaction, a mammalian-two-hybrid 
assay was tested (Figure 2.28). Fusions of MLL and KIX with Gal4-DBD and with 
the strong VP16 activation domain were made, and these were cotransfected 
with a luciferase reporter into HeLa cells. Gal4-MLL activates transcription, but 
with no increase in transcription when cotransfected with VP16-KIX, despite 
VP16 being a stronger activation domain. Gal4-KIX did not activate transcription, 
either on its own or when cotransfected with VP16-MLL. Thus, the KIX-MLL 
interaction is not detected by this two-hybrid assay. It is possible that the 
interaction is too weak and a two-hybrid assay may give better result in presence 
of a peptide that binds cooperatively with MLL to KIX.  
 
 
Figure 2.28 KIX-MLL two-hybrid An 
interaction between KIX and MLL is 
probed with a two-hybrid assay. 
 
 
 
 
 
   
  
 
 
Test of a few sekikaic acid related structures 
The only hits from the high-throughput screen were 22 lichen extracts. In the two 
most KIX selective extracts, the depsides sekikaic acid and microphyllinic acid 
were identified. Depsides are common secondary metabolites of lichens, and it 
wouldn’t be surprising if all the active lichen extracts contain a depside or related 
structure as its active component. In fact, one of the extracts was already known 
to contain the depside, 2-O-methylanziaic acid, which is active in the MLL-KIX 
competition FP assay and not in the counter screen, and thus displays some 
level of target specificity, despite inhibiting VP2-Med15 and Gal4-DNA 
interactions. These interactions are not completely unrelated to KIX-MLL; VP2-
Activity of two-hybrid pairs
Ga
l4-
ML
L +
 VP
16
-KI
X
Ga
l4-
ML
L +
 VP
16
Ga
l4 
+ V
P1
6-K
IX
Ga
l4-
KIX
 + 
VP
16
-M
LL
Ga
l4-
KIX
 + 
VP
16
Ga
l4 
+ V
P1
6-M
LL
1
0.01
0.001
0.1
R
el
at
ive
 a
ct
ivi
ty
 (l
og
 s
ca
le
)
	   68	  
Med15 is an interaction between an amphipathic helix and a coactivator that 
binds multiple other amphipathic activators, and amphipathic helices are also 
known to bind the DNA-binding domain of Gal4. Commercially available depsides 
or depside-related compounds could be a useful source for further studies with 
this class of compounds as KIX ligands. Two compounds were purchased 
(Figure 2.29): Lecanoric acid is a depside whose most obvious difference from 
the three depsides identified in the screen, is the lack of an aliphatic chain (it has 
a methyl group) on each aromatic ring; Lobaric acid is a depsidone, which is 
another common secondary metabolite of lichens and is made from a depside 
precursor. The two aromatic rings in depsidones are connected by both an ester 
and an ether linkage and are consequently more conformationally restrained. 
Lobaric acid has aliphatic chain substituents. The two structures were tested for 
inhibition potential in the FP assays (Figure 2.29). Lobaric acid (blue curve), but 
not lecanoric acid (red curve), displayed similar inhibition potential as sekikaic 
acid and inhibited MLL binding with an IC50 16.9 µM and inhibited KID binding 
with an IC50 of 24.7 µM. The Hill-slope is ~ 2.5.  
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Figure 2.29 Competitive inhibition of KIX tracers with lecanoric acid and 
lobaric acid A. Lecanoric acid; B. Lobaric acid; C. and D. Competitive inhibition 
curves of lobaric acid (blue) and lecanoric acid (red). 
 
The carboxylic acid of sekikaic acid is important for binding 
One ultimate goal with ligands of coactivator proteins is to link them to DNA-
localizing molecules. The depsides contain a carboxylic acid, which is an easy 
chemical handle to use for conjugations, but may be important for binding to KIX. 
As a first test to see if the acidic group is needed, the carboxylate was 
methylated with trimethylsilyldiazomethane.99 The methylated sekikaic acid 
(Figure 2.30), however, had poor solubility in water with visible precipitation 
above 75 µM. In an FP competition assay, no inhibition was seen below 75 µM. 
Thus, the polar group helps with solubility, but it cannot be determined from this 
modification if the acid group is important for binding to KIX. The carboxylic acid 
group was instead reacted with an amine of cystamine to link cystamine to 
sekikaic acid with an amide. The goal with this molecule was to functionalize 
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sekikaic acid with a disulfide, which can undergo reversible disulfide exchange 
with other thiols, including cysteines in proteins. If a thiol-functionalized ligand 
binds a spot on a protein surface that is within sufficient proximity of a cysteine 
for a disulfide bond to form, the disulfide can tether the molecule to the protein 
and greatly enhance its apparent affinity. This has been utilized to facilitate 
fragment-based screening100 and covalent tethering has also been used to 
enhance inhibitor potencies.101 To my knowledge, the same principle has not 
been used to map binding sites of discovered ligands. The proposed strategy 
was to use the disulfide-modified sekikaic acid (Sek-SSEA) in binding studies 
with multiple different KIX proteins bearing different cysteine point mutations. 
Identification of individual mutants to which Sek-SSEA has enhanced inhibition 
potency would effectively map the binding site to a region in proximity of the Cys-
mutation. Sek-SSEA is water soluble and can be tethered to KIX with Cys-
mutations (by mass spec), but Sek-SSEA does not inhibit the MLL – KIX 
interaction in an FP competition experiment. Thus, it appears that the derivative 
has lost its ability to interact with KIX.   
 
 
Figure 2.30 Carboxyl-derivatives of sekikaic acid A. Methylated sekikaic acid 
(Sek-OMe); B. Cystamine-modified sekikaic acid (Sek-SSEA). 
 
2.6 Conclusion and discussion of sekikaic acid discovery 
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components in extracts from lichen, which are part of a unique natural product 
library available at the University of Michigan Center for Chemical Genomics. 
One of these depsides is sekikaic acid, which showed selectivity for inhibiting 
interactions between the CBP KIX domain and activators binding to two distinct 
sites over other protein-peptide interactions. The binding mode of sekikaic acid 
was studied, and a steep dose-response curve appears to be the product of 
cooperative binding of sekikaic acid to the KIX domain. 
 
From ligand observed 1D-1H-NMR spectra, reversible binding of sekikaic acid to 
KIX is evident. Furthermore, the cooperative binding of sekikaic acid is likely the 
reason that peptides to each of the two binding sites of KIX, added at equimolar 
(or double) concentration of sekikaic acid, do not effectively compete with 
sekikaic acid binding, despite showing lower IC50 values in competition FP 
experiments. Simultaneous addition of peptide ligands to both binding sites, 
however, effectively competes off sekikaic acid. This result rejects a model, 
where a sekikaic acid molecule binds to each to the two TAD-KIX interaction 
sites on KIX and achieves cooperative binding through the same allosteric 
conformational change that accompanies cooperative binding of MLL and KID. If 
this was the case, MLL would bind cooperatively with sekikaic acid bound in the 
KID site, and vice versa for KID, and MLL and KID should be able to compete 
effectively with sekikaic acid bound at their respective binding sites to produce 
partial competition in the 1D-NMR experiment. Thus, the cooperative binding of 
sekikaic acid must be a consequence of either: A) two (or more) molecules of 
sekikaic acid binding close together on KIX with favorable interactions with each 
other and KIX (allostery not necessary); B) two (or more) molecules of sekikaic 
acid binding distant sites that allosterically influence each other, but with an 
associated conformational change in KIX that is different from conformational 
change associated with MLL and KID cooperativity. In scenario A, protein 
allostery is not necessary to explain the cooperative binding behavior, but two 
molecules of sekikaic acid binding close to each other can not overlap with both 
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binding sites on KIX. There must therefore still be an allosteric effect on at least 
one of the two binding sites. 
 
In an HSQC experiment, residues within a small region of KIX observed chemical 
shift perturbations when sekikaic acid was bound. This is a likely binding spot of 
sekikaic acid. It is not clear if two molecules of sekikaic acid bind this region, but 
in no other region of KIX can sekikaic acid binding be detected. It is puzzling that 
the KID-binding site appears unperturbed by sekikaic acid, but perhaps changes 
occur without changing the chemical environment of the backbone. 
 
Some structure-activity relationships have emerged from the studies. Since 22 
lichen extracts were active, several depside or depside-like structures likely make 
up a class of compounds with ability to bind KIX. Differential activity of the 
extracts suggests that the active components are not identical. The structure of 
only a few of these was determined. In the active depsides the ester-linked 
aromatic rings have both phenolic groups and extended aliphatic chains as 
substituents. Lecanoric acid, which lacks the aliphatic substituents, is not active. 
The depsidone, lobaric acid, was active, despite its more conformationally 
restricted structure. The cyclic ester-ether connection of the two aromatic rings 
may also make this compound more stable in biological studies, although 
depsides are thought to be stable structures resistant to non-enzymatic 
hydrolysis.102 The depsides (and depsidone) all contain a carboxylic acid, which 
for sekikaic acid was not tolerant of substitutions. The substitutions may not be 
tolerated because of steric clashes in binding site, or perhaps the acidic group 
participates in ionic interactions. In the later case, acyl sulfonamide derivatives 
may be tolerated.103 
 
We were not able to show effects in cell culture indicative of inhibition of KIX 
recruitment. Sekikaic acid is toxic above 10 µM, but the extend to which it is cell 
permeable can’t be deduced. The CBP dependence of activators at individual 
genes or reporters is difficult to determine, which is one reason that we are 
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pursuing inhibitors. Parallel efforts in our lab are aimed at exploring such 
dependence through knockdowns and competition with expressed single 
domains of CBP. Activators identified through these efforts to be dependent on 
the KIX domain, will be valuable model systems to test the activity of sekikaic 
acid and related structures in cells.  
 
Since sekikaic acid does not appear to bind in the binding sites for MLL of KID, 
although proximal to MLL, there is a better chance that it will not bind 
promiscuously to other coactivators, unlike TAD mimics. This selectivity was 
even evident from experiments (Figure 2.16). The cooperative binding is most 
likely unique to the KIX domain. This may be the result of an inherent property of 
the KIX domain, as cooperativity is also found for TADs binding the two canonical 
binding sites.28,29,83 The cooperativity could provide sekikaic acid with an 
additional level of specificity. The human mediator protein, Med15, also contains 
a KIX domain, and could be a second target of sekikaic acid.  
 
2.7 Materials and methods 
2.7.1 Materials and methods used with cell-based assays 
Materials for loss-of-signal luciferase reporter assays 
HeLa cells were purchased from ATCC. HEK293T cells were a gift from Gary 
Glick (University of Michigan). HLR cells (Pathdetect HLR cell line) were 
purchased from Stratagene. All cells are grown in Dulbecco’s Modified Eagle 
Medium (DMEM) (Invitrogen, 11965) supplemented with 10% fetal bovine serum 
(Invitrogen, 16000) in 37°C incubator with 5% CO2. HLR cells are grown in media 
additionally supplemented with 100 µg/mL hygromycin B (Calbiochem). 
Hygromycin B is not included in media at any step of the assays. OptiMEM 
media (Invitrogen) and Lipofectamine 2000 (Invitrogen) was used in 
transfections. G418 (Research Product International Corp.) was used for 
selection of stable HLR-derived cell lines at 800 µg/mL.  
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The Gal4-fusion vectors are from lab stocks. pGal4-VP16 is identical to 
pM3VP16104. pGal4-RelA and pGal4-Elf3 were made by subcloning DNA 
oligomers (Integrated DNA Technologies, IDT) encoding RelA(522-551) and 
Elf3(129-159) into BglII and NotI digested pGal4(1-147)-hGR(499-777)105 (Gift 
form Thomas Kodadek, The Scripps Research Institute). 
 
N2-biphenyl-iTAD and adamanolol were synthesized according to published 
procedures.39,106. Cycloheximide was purchased from Sigma-Aldrich. Luciferase 
activities are measured using Dual-Luciferase Assay Reporter System or One-
Glo substrate (Promega) on single cuvette luminometer (Lumat LB 9507, 
Berthold), or plate luminometers (Genios Pro, Tecan or PheraStar Plus, BMG 
Labtech). Cell viability is measured with WST-1 reagent (Roche) at 440 nm on 
multi-well spectrophotometer (Genios Pro, Tecan). 
 
Activation potency of Gal4-fusion activators 
15,000 HLR cells were plated in 96-well plate with 100 µL DMEM + 10% FBS. 
After overnight incubation, media is replaced with transfection mix: 100 uL 
OptiMEM media with 1 µg pGal4-VP16, pGal4-Elf3 or pGal4-RelA and 3 µL 
Lipofectamine 2000. After 3 hours media is changed back to DMEM + 10% FBS. 
24 hours after transfection the luciferase activity is measure with Firefly substrate 
from Dual-Luciferase Assay Reporter System on Berthold luminometer. 
 
Generation of stable cell lines 
HLR cells in a 10cm dish were incubated for 3 hours with transfection mix: 10 mL 
OptiMEM with 5ug pGal4-ESX or pGal4-RelA and 15 µL Lipofectamine 2000. 
Following transfection, cells were kept in DMEM + 10% FBS for 24 hours. Cells 
were split onto plates at 1:20 – 1:100 dilutions. After 24 hours, media is replaced 
with DMEM + 10% FBS + 100 µg/mL hygromycin + 800 µg/mL G418. G418 
concentration was previously determined with a kill-curve experiment: 800 µg/mL 
G418 is lowest dose that kills untransfected HLR cells in 7 days. After 9 days, 
massive cell death has occurred and 1:20 split plates have 10-20 resistant 
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colonies. All cells are trypsinized and replated in 96-well plate at 1 cell/well 
density (confirmed by visual inspection after small colonies grew in wells). A 
sample from the suspension of cells for replating showed luciferase activity. Only 
3 clones from pGal4-Elf3 transfected cells and 2 from pGal4-RelA transfected 
cells were isolated from 96-well plates. These clones were tested with firefly 
substrate from Dual-Luciferase Assay Reporter System.  
 
Assay for Ga4l-Elf3 inhibition by N2-biphenyl-isoxazolidine and adamanolol 
15,000 HeLa cells were plated in 96-well plate with 100 µL DMEM + 10% FBS. 
After overnight incubation, media is replaced with transfection mix: 100 uL 
OptiMEM media with 0.5 µg pGal4-Elf3, 0.5 µg pGa5luc, 10ng pRLSV40, and 3 
µL Lipofectamine 2000. After 3 hours media is changed back to DMEM + 10% 
FBS. Compounds are added at 25, 5 and 1 µM final concentration in 1% final 
concentration of DMSO. 24 hours after transfection, WST-1 reagent was added 
to media of one of three replicate samples and the absorption measured on 
Tecan Genios Pro. Following the WST-1 read, the luciferase activity is measured 
with Firefly substrate from Dual-Luciferase Assay Reporter System on Berthold 
luminometer. The WST-1 treated samples did not appear to affect the luciferase 
readout.  
 
Gal4-VP16 inhibition assay used in the pilot screen  
The pilot screen is done at the Center for Chemical Genomics, University of 
Michigan. 1.5*106 HLR cells plated in 10 cm dish with DMEM + 10% FBS. After 
18 hours, the media is replaced by transfection mixture: 5 µg pGal4-VP16, 15 µL 
Lipofectamine 2000, 10 mL OptiMEM. After 5 hours transfection mixture is 
removed, and cells are trypsinized and resuspended in phenol red-free DMEM + 
10% FBS at 300,000 cells/mL. At HTS facility, 20 µL media is added to wells of 
white, sterile, TC-treated 384-well plate (cells were also plated in a clear 384-well 
plate to monitor cells with negative and positive control). Compounds are then 
added to wells with pin-tool, and 20 µL of resuspended transfected cells are 
added to the wells (6000 cells/well). Positive control is added at 10 µg/mL (lowest 
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concentration determined to completely inhibit translation of luciferase mRNA in 
a dose-response test). After 18 hours, the assay is developed by: removal of 30 
µL media, addition of 10 µL One-Glo substrate, and measurement of 
luminescence on PheraStar luminometer.  
 
Materials used in gain-of-signal assay 
HeLa cells, DMEM and OptiMEM are the same as above, but tetracyclin-free 
fetal bovine serum is used (Clontech, 631105). Transfections are done with 
Fugene HD (Roche). Luciferase assay reagents and instruments are the same 
as above. Restriction enzymes and T4 DNA ligase purchased from New England 
Biolabs.  
 
Plasmids 
miRNA expression vectors were purchased from Invitrogen (pcDNA 6.2-
GW/EmGFP-miR, BLOCK-iT Pol II miR RNAi Expression vector Kits). This 
includes a non-targeting miRNA (pcDNA 6.2-GW/EmGFP-miR-neg), which is 
renamed pCMV-miR-non. pCMV-miR-luc was created by cloning purchased DNA 
oligo into the parent vector. The antisense target sequence of pCMV-miR-luc is 
TATTCAGCCCATATCGTTTCA, which targets the luciferase gene (luc+) found in 
Promega’s pGL3 series of luciferase reporter vectors. pTRE-miR-luc is made by 
sub-cloning the gene from pCMV-miR-luc into pTREtight (Clontech) with SacI 
and XbaI restriction enzyme cut sites. pTRE-luc was purchased from Clontech. 
pSV40-luc, was made by sub-cloning the SV40 enhancer from pRLSV40 
(Promega) into pGL3basic (Promega) with BglII and HindIII restriction enzyme 
cut sites. pCMV-tTA is from Clontech (pTet-Off-Advanced).  
 
All plasmid changes were confirmed by sequencing.  
 
Knockdown of firefly luciferase 
12,000 HeLa cells plated in 96-well plate with 100 µL DMEM + 10% FBS 
(tetracycline free) are transfected by addition of transfection mixture: 180 ng 
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pCMV-miRluc or pCMV-miR-non, 20 ng pSV40-luc, 0.8 µL Fugene HD in 10 µL 
OptiMEM. After 4 hours, media is replaced with 100 µL DMEM + 10% FBS 
(tetracycline free). After 24 hours, luciferase activity is measured on Berthold 
luminometer with firefly substrate from Dual-Luciferase Assay Reporter System.  
 
Doxycyclin dose-response on TRE promoter 
12,000 HeLa cells plated in 96-well plate with 100 µL DMEM + 10% FBS 
(tetracycline free) are transfected by addition of transfection mixture: 50 ng 
pTRE-luc, 50 ng pCMV-tTA, 1 ng pRLSV40, 0.4 µL Fugene HD in 10 µL 
OptiMEM. After 4 hours, media is replaced with 100 µL DMEM + 10% FBS 
(tetracycline free) and doxycyclin is added. After 24 hours, luciferase activity is 
measured on Berthold luminometer with firefly substrate from Dual-Luciferase 
Assay Reporter System.  
 
Doxycyclin dose-response on luciferase knockdown by TRE regulated miR-luc  
12,000 HeLa cells plated in 96-well plate with 100 µL DMEM + 10% FBS 
(tetracycline free) are transfected by addition of transfection mixture: 100 ng 
pSV40-luc, 50 ng pCMV-tTA, 50 ng pTRE-miR-luc or pTRE-miR-non, 1 ng 
pRLSV40, 0.8 µL Fugene HD in 10 µL OptiMEM. After 4 hours, media is 
replaced with 100 µL DMEM + 10% FBS (tetracycline free) and doxycyclin is 
added. After 24 hours, luciferase activity is measured on Berthold luminometer 
with firefly substrate from Dual-Luciferase Assay Reporter System. 
 
2.7.2 Materials and methods used in discovery and characterization of sekikaic 
acid 
Protein expression 
Non-labeled KIX protein was expressed and purified by Chinmay Y. Majmudar 
and Steven P. Rowe: An expression plasmid encoding His6-tagged KIX domain 
from mouse CBP (residues 586-672) was described previously (pHis6-PL-KIX).42 
Protein was expressed with IPTG induction from pHis6-PL-KIX transformed 
Rosetta pLysS cells (Novagen), purified using Ni-NTA beads (Qiagen) and buffer 
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exchanged on PD-10 columns (GE Healthcare). The protein is > 90% pure as 
determined by silver stained polyacrylamide gel. The protein is stored as frozen 
aliquots at 51 µM in 10 mM PBS pH 7.2, 10% glycerol, 0.01% NP-40. Protein 
concentration is determined by UV (ε=14440 M-1cm-1) 
 
15N-labeled KIX protein was expressed together with William C. Pomerantz: 
Rosetta pLysS transformed with pHis6-PL-KIX are used to inoculate 3x50 mL LB 
starter cultures with 0.1mg/mL ampicillin and 0.034 mg/mL cloramphenicol. Next 
morning 4x25 mL starter culture is added to 4x1L LB with ampicillin, and bacteria 
are grown at 37 °C until an OD600 of 0.67 is reached. Cells are pelleted and 
washed with M9 minimal media. Cells from 4x1L cultures are resuspended in 1L 
M9 minimal media with ampicillin and BioXpress (Cambridge Isotope 
Laboratories) added. Cells grown in shaker at 37 °C for 1 hr before temperature 
is reduced to 25 °C and 0.1M IPTG is added. After 8 hours cells are pelleted and 
frozen at -80 °C. Pellets from two such expressions are thawed on ice and 
resuspended in in 70 mL 50 mM phosphate pH 7.1, 300 mM sodium chloride, 10 
mM imidazole. Cells are lysed by sonication on ice. Lysates cleared by 
centrifugation at 9000xg, 20 min at 4 °C, and added to Ni-NTA beads. After two 
hours incubation at 4 °C, resin is pelleted with centrifugation at 2500xg, 2 min., 4 
°C and washed with 30 mM imidazole containing buffer. Wash is repeated 5 
times. Protein is eluted with 5 mL, 400 mM imidazole buffer three times, and the 
combined eluates buffer exchanged on PD-10 columns to 100 mM NaCl, 50 mM 
phosphate, 10 % glycerol. The buffer exchanged protein is further purified by 
cation exchange FPLC (Source 15S column, GE Healthcare; 0-1 M NaCl in 50 
mM PBS buffer). FPLC purified protein is buffer exchanged on PD-10 columns to 
10 mM phosphate pH 7.2, 100 mM NaCl and concentrated to 90-100 µM. Protein 
concentration is determined by UV (ε=14440 M-1cm-1). 
 
KIX with 19F-labeled tyrosine incorporated is expressed, purified and 
characterized by William C. Pomerantz.  
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Lab stocks of proteins Med15(1-347) and Gal4(1-100) were used. These have 
been previously reported.107,108  
 
Peptide synthesis 
Peptides are synthesized on CLEAR amide resin (Peptides international) using 
standard HBTU/HOBT/DIEA coupling conditions.   
 
Fl-MLL19 was synthesized and purified by Steven P. Rowe: Fluorescein 
isothiocyanate and beta-alanine was coupled to a sequence containing MLL 
residues 2840-2858 to make FITC-βAla-DCGNILPSDIMDPVLKNTP. The 
concentration of Fl-MLL19 is determined by UV in 10mM Tris pH 9.0, using ε = 
77,000 M-1cm-1 at 494 nM (The Handbook, A Guide to Fluorescent Probes and 
Labeling Technologies, Invitrogen).  
 
MLL15 was synthesized and purified by William C. Pomerantz. The sequence 
contains MLL residues 2844-2857 in addition to a C-terminal tyrosine; the 
sequence is ILPSDIMDPVLKNTY. The concentration of MLL15 is determined by 
UV in in 8M Urea, Tris pH 8.0 using ε = 1420 M-1cm-1 at 280 nM.109  
 
MLL15dm was synthesized and purified by William C. Pomerantz. The sequence 
is ILPSDI(nLe)DPILKNTY. 
 
Fl-MLL15dm was synthesized by Ashley Lipinski. It was purified by Jonas W. 
Hojfeldt by reverse phase HPLC on C18 column with 0.01% trifluoroacetic acid in 
water and acetonitrile as eluents. A gradient of 30-55% acetonitrile over 25 min. 
was used. HPLC traces and mass spec. analysis are placed in section 2.8.  
 
Phosphorylated KID29 was synthesized by William C. Pomerantz. It is the same 
construct reported by others.23 It was purified by Jonas W. Hojfeldt on reverse 
phase HPLC with a 10-35 % CH3CN over 23 min gradient. Spectra attached in 
section 2.8.  
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Fl-cMyb, which encodes cMyb residues 291-315 was made and purified by 
Steven P. Rowe. This is the same construct reported by others.23  
 
Fl-VP2 and Fl-DNA are previously reported.107,108    
 
Fluorescent polarization assay – direct binding experiments 
General: All samples are done in triplicate. The assays are done with a final 
sample volume of 10 µL in a low-volume, non-binding, black, 384-well plate 
(Corning), and read on Tecan Genios Pro with polarized excitation at 485 nm and 
emission intensity measured through a parallel, I(par), and perpendicular, I(per) 
polarized 535 nm filter. The relative intensities of these filters have been 
calibrated with a G-factor110 and the anisotropy is then defined as A=[I(par)-
I(per)]/[I(par)+2*I(per)]. The term I(par)+2*I(per) is directly proportional to the total 
fluorescence intensity of the sample. The data is plotted in Graphpad Prism 5 
and fitted with nonlinear regression using built-in equation “One site – Total and 
nonspecific binding”, from which the Kd is calculated in Prism. 
 
Direct binding of KIX to Fl-MLL19: His6-KIX(586-672) protein is added at 25 µM 
to a solution with 25 nM Fl-MLL19 and assay buffer (10mM PBS pH 7.4, 10% 
glycerol, 0.01% NonidetP-40, 1mM DTT). This solution is serially diluted into a 
solution of  25nM Fl-MLL19 in assay buffer.  
 
Direct binding of KIX to Fl-MLL15dm and Fl-KID29 is done as described for Fl-
MLL19.  
 
Fluorescent polarization assay – competitive binding experiments 
General: Samples are done in triplicate, and the assay is read as in direct binding 
experiments. The data is plotted in Graphpad Prism 5 (Prism) and fitted with 
nonlinear regression using built-in equation “log(inhibitor) vs. response – Variable 
slope (four parameters)” from which the IC50 is calculated in Prism. Inhibition 
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curves with Hillslope near 1 could be fitted with theoretical equation88 to 
determine a Ki. This equation was entered into Prism as:	  	  	  
d=Kd+Ki+10^X+T-P 
e=(10^X-P)*Kd+(T-P)*Ki+Kd*Ki 
f=-Kd*Ki*P 
Root=(d^2-3*e)^0.5 
theta=81rcos((-2*d^3+9*d*e-27*f)/(2*Root^3)) 
C=cos(theta/3) 
Top=(2*Root*C-d) 
Fsb=Top/(3*Kd+Top) 
Y=Fsb*(Ab-Af)+Af 
 
Kd: Binding affinity of tracer; Ki: Binding affinity of inhibitor; X: Log(concentration 
of inhibitor); T: Concentration of tracer; P: Concentration of protein; Ab: 
Anisotropy of bound tracer; Af: Anisotropy of free tracer.  
Ki, Af and Ab are the fitted parameters. 
 
Theoretical detection limit: A theoretical curve is plotted in Prism, in which the 
fraction of bound tracer is defined as a function of Ki (X).88 Equation is entered in 
Prism as: 
 
d=Kd+10^X+I+T-P 
e=(I-P)*Kd+(T-P)*10^X+Kd*10^X 
f=-Kd*10^X*P 
Root=(d^2-3*e)^0.5 
theta=81rcos((-2*d^3+9*d*e-27*f)/(2*Root^3)) 
C=cos(theta/3) 
Top=(2*Root*C-d) 
Fsb=Top/(3*Kd+Top) 
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Competitive inhibition of Fl-MLL19 – KIX with MLL15: MLL15 at 30 µM in a 
solution of 25 nM Fl-MLL19 and 5 µM KIX in assay buffer (10mM PBS pH 7.4, 
10% glycerol, 0.01% NonidetP-40, 1mM DTT) is serially diluted into wells with 
same components except MLL15.  
 
Determination of Z’-factor: This was done on equipment at the Center for 
Chemical Genomics, University of Michigan. To columns 1-22 of a low volume, 
NBS, black, 284-well Corning plates (#3676) is added 5 µL of KIX at 20 µM in 
assay buffer (10mM PBS pH 7.4, 10% glycerol, 0.01% NonidetP-40, 1mM DTT), 
and to columns 23-24 is added 5 µL assay buffer with multi-channel, automated 
liquid handlers. DMSO (200 nL, 2% final) is added with pin-tool, followed by 
addition of 5 µL, 50 nM Fl-MLL19 in assay buffer with liquid handlers. Samples 
are incubated for 30 min before reading on PheraStar Plus (BMG Labtech) with 
Fl-FP module (485nm/520nm). The performance was improved by addressing 
two sources of error: (1) The tubing of the liquid handlers used to fill plates with 
assay reagents, bound one or more assay components and had to be 
equilibrated prior to plating by passing assay reagent through. (2) The largest 
source of variability turned out to be a mis-alignment in the plate-reader, which 
was apparent from a systematic drift pattern of data from control plates, and this 
was corrected by repair of the instrument. 
 
High-throughput screen: The Fl-MLL19 – KIX inhibition assay was set up as 
during determination of Z’factor. Compounds are added in the pin tool step. Initial 
hits were analyzed with consultation of Paul D. Kirchhoff (Vahlteich Medicinal 
Chemistry Core, University of Michigan) and Martha Larsen (Center for Chemical 
Genomics, University of Michigan). The confirmation tests were done in an assay 
with identical final components, but with a different order of addition. For this, the 
tracers are added first, followed by compounds, and the plates are read once 
before addition of protein. This read is used to determine if any of the compounds 
quenches the fluorescence of the tracer. The counter screen used to determine 
selectivity of natural product extracts is an assay developed by Jolanta 
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Grembecka’s lab (University of Michigan). Details of their assay are not 
presented here.   
 
Specificity tests with lichen extracts from Costa Rica: 13 extracts and fractions 
received from Costa Rica were tested in the FL-MLL19 – KIX FP assay as 
described above and three other FP-assays. For these, Fl-cMyb and Fl-VP2 
were used at 25 nM and Fl-DNA was used at 10 nM. KIX and Med15 were used 
at 10 µM and Gal4 was used at 50 nM.  
 
Competition studies with sekikaic acid (and derivatives): Inhibition of FL-MLL19 – 
KIX FP assay studied as above. In experiments with varying detergents the 
detergents were added to detergent free assay buffer at defined concentrations. 
The NonidetP-40 (NP-40) present in stocks of KIX was not removed. Fl-MLL15 – 
KIX inhibition curves were done with KIX at 1 µM, and no added detergent. Fl-
KID29 – KIX inhibition curves were done with KIX at 2.5 µM.  
 
Compounds purchased for comparative competitive binding studies: 2-napthol-
AS-E-phosphate (Sigma-Aldrich), lecanoric acid(ChromaDex), lobaric 
acid(ChromaDex).  
 
Identification of depsides 
HPLC purification and compound identification was done by Carl J. Arevang 
(Sherman lab). HPLC fractions were tested in FP assays for activity and only 
active fractions were characterized. HPLC traces and NMR spectra are attached 
in section 2.7. A UV spectrum of sekikaic acid was recorded, and ε260nm = 12196 
M-1cm-1 was measured and used for determination of concentrations.  
 
1D-1H-NMR studies of sekikaic acid in presence of KIX and inhibitors 
Spectra were recorded on a Bruker Avance III 600-MHz spectrometer equipped 
with cryogenic probe with advice from Tomek Cierpicki (University of Michigan). 
The spectra are properly referenced as determined by identical shift of d5-DMSO 
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peak. Stocks of sekikaic acid and KID29 used, were made in d6-DMSO, and 
MLL15dm was used as a non-deuterated DMSO stock.  
 
15N-1H-HSQC NMR studies of KIX in presence of sekikaic acid 
Spectra were recorded on a Bruker Avance III 600-MHz spectrometer equipped 
with cryogenic probe with help from Tomek Cierpicki (University of Michigan).  
 
1D-15F-NMR studies of 15F-labeled KIX in presence of sekikaic acid 
Collection and assignment of spectra was done by William C. Pomerantz. 
 
Viability studies 
3000 A549 cells or 4000 HEK293T cells were plated in 96-well plate with 
phenolred-free DMEM. Compounds are added from a DMSO stock (final conc. of 
DMSO is 1%). After 24 or 48 hours, 10 µL WST-1 (Roche) is added to media. 
After 45 min. incubation, the absorbance at 440nm is read with Tecan Genios 
Pro. Background (absorbance from wells with no cells, but with media and WST-
1 added) is subtracted from all values. % viability is determined as 
absorbance(sample)/absorbance(DMSO).  
 
Plasmids for luciferase reporter studies 
pGal4(1-147)-MLL(2829-2883) was made by William C. Pomerantz by same 
method used for pGal4-Elf3 described above. pGal4-CREB and pPKA were 
purchase from Stratagene (Product: Pathdetect HLR cell line). pG5luc (Gal4-
luciferase reporter) and pRLSV40 (constitutive Renilla luciferase control) are 
purchased from Promega. 
 
For two-hybrid constructs, commercial vectors pAct (VP16(411-456)-fusion 
vector) and pBind (Gal4(1-147)-fusion vector) (Promega) were modified to allow 
ligation-independent cloning.111 The following oligos were annealed and ligated 
to EcoRI and BamH1 digested pAct and pBind: 5’- GAT CTT GGG AAG CAC 
CGG TTC TGG TGA -3’ and 5’-CTA GTC ACC AGA ACC GGT GCT TCC CAA -
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3’. The resulting vectors are termed pVP16-LIC and pGal4-LIC. KIX (CBP(586-
672) and MLL(411-456) were cloned out of vectors previously described with 
PCR, using primers with the following sequences appended to the 5’ end of each 
primer to facilitate LIC cloning: (sense strand primer – LIC appendage) 5’ - GGG 
AAG CAC CGG T ; (antisense strand primer – LIC appendage) 5’ CAC CAG 
AAC CGG T. The PCR products and linearized LIC vectors are processed with 
T4 DNA polymerase (Novagen), combined, and used to transform E. coli cells. 
The resulting vectors are called pGal4-KIX, pVP16-KIX, pGal4-MLL, pVP16-MLL.  
 
Gal4-MLL and Gal4-CREB luciferase reporter studies 
20,000 HEK293T cells are plated in 96 well plate and transfected the following 
day by replacing media with 50 ng pG5luc, 50 ng pGal4-MLL, 1.5 ng pRLSV40, 
0.3 µL Lipofectamine 2000, 100 µL OptiMEM (Gal4-MLL) or 50 ng pG5luc, 25 ng 
pGal4-CREB, 25 ng pPKA, 1.5 ng pRLSV40, 0.3 µL Lipofectamine 2000, 100 µL 
OptiMEM (Gal4-MLL). After 4 hours transfection mix is replaced with normal 
media, and compounds are added. After 24 hours, assay is read with Dual 
Luciferase Assay Reporter-System (Promega). 
 
KIX:MLL two-hybrid assay 
12,000 HeLa cells are plated in wells of 96-well plate. Transfection was carried 
out by addition of 20 µL of transfection mix with (in OptiMEM): 30 ng pG5luc, 10 
ng pGal4-KIX/MLL/LIC, 10 ng pVP16-KIX/MLL/LIC, 0.2 µL Lipectamine LTX. 24 
hours post transfection, media was replaced with regular media and compounds 
added. After 24 hours, luciferase activities were determined with the Dual 
Luciferase Assay Reporter-System (Promega). 
 
Synthesis of sekikaic acid derivatives 
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Sek-OMe (methyl 2-hydroxy-3-((2-hydroxy-4-methoxy-6-propylbenzoyl)oxy)-4-
methoxy-6-propylbenzoate):  
To sekikaic acid (1mg, 2.4 µmol) dissolved in 300 µL toluene and 200 µL 
methanol, is added a 2M ethereal solution of trimethylsilyldiazomethane (3 µL, 6 
µmol). Reaction monitored by persistence of yellow color. After 30 minutes of 
stirring at room temperature, reaction is concentrated, dissolved in acetonitrile 
and 0.1% aqueous TFA, filtered, and purified by reverse phase HPLC with 
elution gradient 5-75 % acetonitrile over 30 min. The product is confirmed by 
ESI-MS (observed m/z (M+Na+): 455.1), and by 1H-NMR. HPLC chromatogram 
and 1H-NMR spectrum are attached in section 2.8.  
 
 
Sek-SSEA (3-((2-((2-aminoethyl)disulfanyl)ethyl)carbamoyl)-2-hydroxy-6-
methoxy-4-propylphenyl 2-hydroxy-4-methoxy-6-propylbenzoate):  
Cystamine dihydrochloride is dissolved in 1M NaOH and extracted with 
dichloromethane. Dichloromethane solution is passed through Pasteur pipette 
packed with Na2SO4, concentrated and weighed. Cystamine (4.5 mg, 30 µmol) 
dissolved in 150 µL dichloromethane is added to a solution of sekikaic acid (2mg, 
4.8 µmol) in 150 µL dichloromethane. Distilled trimethylamine (4.2 µL, 30 µmol) 
and PyBroP (2.5 mg, 5.2 µmol) are added. After 3 hours starting material is 
consumed and crude product is purified on reverse phase HPLC with elution 
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gradient 20-50 % acetonitrile over 25 min. The purified product is a mix of 
disulfide and reduced species, with the major component being the disulfide. 
These two species can both participate in reversible disulfide exchange 
reactions, and were not separated for initial studies. The product is confirmed by 
ESI-MS (observed m/z (M+H+): 553.3), and by 1H-NMR. HPLC chromatogram 
and 1H-NMR spectrum are attached in section 2.8. 
 
2.8 Characterization of compounds made or purified by Jonas W. Hojfeldt 
HPLC chromatograms 
Analytical HPLC chromatogram of purified KID29 
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Analytical HPLC chromatogram of purified Fl-MLL15dm 
 
 
Analytical HPLC chromatogram and 1H-NMR of purified Sek-OMe 
 
RP HPLC Chromatogram
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Analytical HPLC chromatogram and 1H-NMR of purified Sek-SSEA 
 
RP HPLC Chromatogram
Detection at 254 nM
Gradient: 30 min 20-50 % acetonitrile
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Chapter 3 
 
Extrinsic recruitment of transcriptional coregulators  
by bifunctional nuclear receptor ligands* 
 
3.1 Abstract 
Nuclear receptors (NRs) are ligand-regulated transcription factors. They offer a 
means to directly affect the transcription of their target genes with small 
molecules without simultaneous involvement of signaling cascades, and this 
property underlies their success as drug targets. Transcriptional control is 
achieved through recruitment of transcriptional coregulators. The conformation of 
the receptor, which is modulated by ligand binding, determines which cofactors 
are recruited. Synthetic ligands have been discovered that can stabilize either 
active or repressive conformations and bind selectively to receptor subtypes, and 
these ligands consequently induce gene expression patterns that differ from the 
natural ligands and can have improved therapeutic effects and tissue 
specificities. The current strategies for ligand discovery, however, limit the 
transcriptional control to that defined by patterns of coregulator recruitment 
intrinsic to the available receptor conformations. This is particularly problematic in 
diseases where receptor function becomes insensitive to the ligand through 
mutation or dominant aberrant post-translational modifications.  We have shown 
that bifunctional molecules, made as conjugates of NR ligands to ligands of 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
* This chapter presents research from a collaborative effort. J.W. Hojfeldt, A.K. Mapp and J.A. 
Iñiguez-Lluhí planned experiments. J.W. Hojfeldt, A.R. Van Dyke, and Y. Imaeda synthesized 
compounds. Data presented in Figures 3.9, 3.10, 3.11, and 3.12 was obtained by O. Cruz and 
J.A. Iñiguez-Lluhí. All other data figures are from experiments done by J.W. Hojfeldt. Y. Imaeda 
contributed with experiments presented in Figures 3.5, 3.6, and 3.7. A.R. Van Dyke contributed to 
experiment presented in Figure 3.15. J.P. Carolan assisted with experiments presented in Figure 
3.13 and 3.14. 
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transcriptional components that are non-native to NRs, are able to recruit these 
non-native targets to the NR and affect transcription. This strategy holds promise 
to greatly expand the functional control that can be achieved by the important 
class of NR-targeting drugs. 
 
3.2 Introduction to nuclear receptors as ligand-regulated factors 
Nuclear receptors (NRs) are members of a large family of multi-domain1 
transcription factors, characterized by a conserved DNA-binding domain (DBD) 
and a moderately conserved ligand-binding domain (LBD).2 The DNA-binding 
domain defines the genomic sites that the receptors can bind to, while the 
receptor’s influence on transcription of target genes is modulated by integration 
of multiple signals by the receptor, including variations in the target DNA-
sequence,3 intracellular signaling cascades,4 and, uniquely, small cell-permeable 
ligands.2 The canonical mode of action of endogenous ligands involves their 
binding to the NR LBD and consequent reorientation of one of this domain’s 12 
α-helices (helix 12).5 This conformational change alters what was an interaction 
surface for corepressors to an interaction surface for coactivators, and it is these 
coregulatory proteins that are responsible for controlling chromatin remodeling 
and transcriptional activation.6  
 
NRs are critical regulators of a variety of physiological processes, including 
embryonic development, growth, homeostasis of differentiated phenotypes, 
metabolism and reproduction, and consequently many pathological processes, 
such as obesity, inflammation, cardiovascular disease and cancer.7 In these 
processes, NRs are key determinants of gene expression patterns and 
consequently cellular phenotype. This central role, coupled to their ability to be 
influenced directly by exogenous ligands with attractive pharmacological 
properties, has made them a very successful class of drug targets. Roughly 13% 
of FDA approved drugs target NRs.8 Besides the evolved property of NRs to 
respond to ligands that can be exogenously supplied as drugs, the success of 
targeting the receptors has been enhanced by the realization that synthetic 
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ligands can be developed to minimize undesired side effects. Synthetic ligands 
have been discovered that share the full or partial agonistic properties of cognate 
ligands or antagonize (partially or fully) the function of natural ligands. 
Furthermore, some of these synthetic ligands selectively bind to specific receptor 
paralogs or isoforms, thus providing them with a more narrow range of effects.9 
These ligands modulate their target receptor according to the canonical model: 
they stabilize the active (full agonist) or inactive (full antagonist) conformation of 
helix 12. Partial (ant)agonistic effects can be achieved by ligands that establish 
mixed populations of active and inactive helix 12 conformations, or ligands that 
stabilize one conformation, but with a slight distortion compared to the native 
conformation.10 
 
Although the nuclear receptor targeting drugs are very successful they still face 
difficulties of undesired side effects11 as well as resistance in cancers.12-14 One 
clear limitation of all of the discovered ligands is that they act solely through 
modulation of receptor conformations, and consequently their control over 
recruitment of coregulatory complexes is limited to interactions that are native to 
the surface of the receptors. The promoters of NR target genes are however 
often co-occupied by other transcription factors that recruit their own set of 
coregulatory proteins, and the receptors themselves recruit proteins in a manner 
dependent not only on the conformation of the LBD but also through binding-
surfaces modulated by post-translational modifications such as phosphorylation 
and sumoylation.4,15-17 These ligand-independent events can indeed be the 
culprit of transcriptional misregulation.18 Thus, the nuclear receptor ligands 
provide a means for targeting critical genes, but are not always able to confer 
control of the transcriptional status of these genes. A novel solution to this 
problem is explored in this chapter: ligands of nuclear receptors are chemically 
linked to molecules that can recruit coregulatory proteins independent of 
interaction surfaces in the NR. These bifunctional NR ligands are tested for their 
ability to recruit functionality that is extrinsic to the nuclear receptor. The 
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glucocorticoid receptor is chosen as a representative member of nuclear 
receptors for these studies.  
 
3.3 The glucocorticoid receptor 
The glucocorticoid receptor (GR) is expressed in nearly all human cells and binds 
to glucocorticoids, which are steroidal hormones produced in the adrenal 
cortex.19 GR has a modular structure similar to other steroid receptors20 which 
includes an N-terminal regulatory domain with a transcriptional activation domain 
(AF-1), a DNA-binding domain (DBD) and a ligand-binding domain (LBD). The 
ligand-binding domain also contains a transcriptional activation domain (AF-2) 
which is accessible for binding to co-factors in agonist-bound conformations. The 
unliganded receptor is localized in the cytosol, where it is complexed with the 
Hsp90 chaperone protein and co-chaperones p23 and FKBP5, which keep the 
receptor in a hormone-binding competent state, and several additional 
chaperones and co-chaperones are involved in GR homeostasis, cellular 
trafficking and nuclear function.21,22 Upon binding of ligands, GR translocates to 
the nucleus and binds as a homodimer to DNA-sequences termed GR-response 
elements (GRE) and agonist-bound receptor upregulates the majority of GRE-
regulated genes (this process is called GR transactivation).23 Ligand-bound GR 
also binds as a monomer to pro-inflammatory transcription factors, such as AP-1 
and NF-κB, 24,25 and can represses their target genes (GR transrepression). In 
transrepression, GR does not bind DNA directly, but is instead tethered by the 
transcription factor to which it binds. GR-targeting drugs are the most common 
therapeutics used to treat inflammatory diseases.26 The transrepresssion of pro-
inflammatory transcription factors mediates numerous desirable anti-
inflammatory effects, while transactivation is the cause of most adverse effects 
that limit the use of the most potent GR drugs to topical treatment such as 
inhalation for treatment of asthma. Efforts to improve on GR targeting 
therapeutics are therefore focused on development of GR ligands with altered 
transcription profile of both transactivated and transrepressed genes.11  
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3.4 Nuclear receptor extrinsic recruitment 
The focus of this study is not to pursue dissociated ligands of GR, but rather to 
use GR as a model receptor for a new strategy of modulating receptor function. 
This strategy is aimed to be general for all the steroid nuclear receptors, each of 
which, as a therapeutic target, has desired functions as well as undesired off-
target effects. The nuclear extrinsic recruitment strategy involves linking nuclear 
receptor ligands to a ligand of a second protein. If this conjugate can 
simultaneously bind to both of its target proteins, it will effectively recruit its 
second target protein to NR and to the target genes of NR (Figure 3.1).  
 
 
Figure 3.1 Nuclear receptor extrinsic recruitment A. A NR ligand binds to its 
receptor, and the dimerized receptor binds to DNA and recruits target complexes 
to control transcription; B. A NR ligand, which is conjugated to a ligand of a 
second target protein, binds to the receptor and the dimerized receptor binds to 
DNA at its target genes. The principle of the extrinsic recruitment strategy 
involves the recruitment of the second protein or complex directly by the 
conjugated ligand and aims to have the extrinsic factors influence transcription of 
the target gene. 
 
A
B
NR recruits coregulatory complex
+
NR NR ligand - conjugate
NR extrinsic 
recruitment
NR recruits coregulatory complex
?
+
NR NR ligand
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The first goal of the project is to synthesize bifunctional molecules, which are 
conjugates of GR ligands and a ligand that can bind a protein, whose presence 
at GR target genes will affect transcription and provide proof-of-principle of the 
extrinsic recruitment strategy.  
 
3.5 Recruitment of non-native proteins to the glucocorticoid receptor 
The ligand-binding domain of the glucocorticoid receptor (GR) has previously 
been used in a mammalian three-hybrid assay; a synthetic GR ligand, 
dexamethasone, conjugated to the natural product, FK506, facilitates 
dimerization of the GR LBD and FK506-binding protein 1A (FKBP).27 In this 
experiment, GR-LBD was fused to the strong transcriptional activation domain of 
VP16 and FKBP was fused to a DNA-binding domain. Dimerization of the two 
fusion proteins therefore assembles a transcriptional activator that can activate a 
reporter gene (See Figure 3.2B for an analogous three-hybrid assay, except with 
the ligand binding domains swapped relative to DBD and TAD). Based on this 
three-hybrid experiment, it is expected that FKBP-fusion proteins can likewise be 
recruited to full-length GR. Such recruitment will facilitate studies to test if 
transcriptional regulatory factors recruited indirectly to GR (fused to FKBP) can 
influence transcription of GR-target genes in a context that is also influenced by 
intrinsic GR activity. The first aim of the project therefore was to conjugate 
ligands of these proteins to obtain bifunctional molecules that could be studied 
for recruitment potential. The GR ligands, dexamethasone (Dex) and RU486, as 
well as the FKBP ligand, FK506, were chosen for conjugates and can initially be 
tested in an analogous three-hybrid assay (Figure 3.2). 
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Figure 3.2 Ligands for constructing bifunctional molecules A. The GR 
ligands, dexamethasone (Dex) and RU486, and the FKBP ligand, FK506, are 
chosen for conjugation. Their conjugates should recruit FKBP to GR; Initial 
evaluation of ligands can be achieved through the use of a three-hybrid assay. 
The assembly of DBD and TAD will activate transcription of a reporter gene.  
 
Synthesis of conjugates of GR-ligands and FK506 
The synthetic GR agonist, dexamethasone, was discovered in 195828 as a more 
potent alternative to the natural ligand, hydrocortisone, and synthetic ligand, 
prednisolone. Dexamethasone can be modified with a thioether linked 
isothiocyanate (SDex-ITC), which facilitates easy coupling of various amine-
functionalized molecules and is reported to maintain partial agonist activity and 
full potency of dexamethasone.29 This derivative has been shown to have higher 
NR ligand - conjugate
+
O
HO OH
HF
H
O OH
Dexamethasone (Dex)
O
OH
H
N
RU486
O
O N
O
O
MeO
OHH
MeO
O
H
OH H OMe
OH
O
FK506
FKBP
GR
GR LBD
Gal4 DBD
VP16 TADFKBP
A
B
Gal4 DBD
VP16 TAD
	   108	  
binding affinity than another common derivative, OxDex, used for conjugations.30 
Thus, SDex-ITC was prepared to facilitate conjugation to linkers and FK506 
(Figure 3.3).  
 
RU486 is an antagonist of GR (and the progesterone receptor) discovered by 
scientists at Roussel-Uclaf, who had previously published work on 11β-
substituted 19-norsteroids.31 It binds competitively with dexamethasone to GR, 
and has very low transactivation potential that is dependent on the GR AF-1 
domain. It does mediate transrepression but is less effective than 
dexamethasone.32 RU486 is derived from the synthetic antiprogestin, 
norethindrone, and has a 4-dimethyl-amino-phenyl substitution at the 11β-
substitution. The aniline amine of RU486 has previously been used as a 
conjugation point of bile acids, to make a bifunctional molecule that targets liver 
tissue (via the bile acid) with unperturbed activity of RU486,33 and this aniline 
was therefore also used in our conjugation of linker and FK506. One methyl 
group of the dimethylaniline was oxidized to the N-formyl amide which was 
subsequently hydrolyzed to yield the monomethyl aniline (Figure 3.3). This 
secondary amine will allow coupling to a linker functionalized with a 
methylsulfonic ester (Figure 3.4).  
 
FK506 is a bacterially produced immunosuppressive macrolide34,35 that binds to 
a family of FK506-binding proteins.36 These are peptidyl-prolyl isomerases with 
diverse functions, including the Hsp90 co-chaperone function of FKBP5 as 
mentioned above. The predominant binding target of FK506 in human cells is the 
12 kDa FKBP1A (FKBP),37-40 to which FK506 binds with a dissociation constant 
of 0.6 nM.41 The first bifunctional small molecules designed to dimerize two 
fusion proteins, termed chemical inducers of dimerization, were homodimers of 
FK506.42 In this and later studies, an allyl substituent in FK506 is functionalized 
with an amine reactive N-hydroxysuccinimidyl carbonate for convenient linkage 
to conjugate partners (Figure 3.3). This modification does not interfere with 
FKBP1A binding, but disrupts binding to calcineurin, which otherwise binds to the 
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FK506-FKBP complex (an interaction also critical for the immunosuppressive 
properties of FK506).42 This derivative of FK506 was prepared. 
 
 
Figure 3.3 Functionalization of ligands The commercially available ligands of 
GR and FKBP are functionalized to facilitate conjugation: A. Dexamethasone is 
converted to the amine reactive SDex-ITC; B. RU486 is converted to the 
nucleophilic RU486-NHMe; C. FK506 is converted to the amine reactive NHS-
FK506-TBS2. 
 
The functionalized GR ligands and FK506 were conjugated with linkers as shown 
in Figure 3.4. These linkers must be long enough to allow simultaneous binding 
of the linked ligands to their respective proteins. Optimization of the length, 
hydrophobicity and rigidity of linkers can affect the efficacy of conjugates, but no 
clear general design strategies have emerged from previous studies.42-44 One of 
these studies43 found that the shortest linker long enough to allow simultaneous 
binding, had the highest potency. This study, however, used homodimeric 
ligands and fusion proteins with multimerized ligand binding domains (LBDs), 
and the lower activity of conjugates with long linkers may stem from an ability to 
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bind two fused LBDs instead of LBDs of two different target fusion proteins. We 
have chosen to use either straight alkyl or polyethylene glycol linkers of varying 
lengths that are comparable to those used in previous GR LBD – FKBP 
dimerizers.27  
 
Evaluation of GR ligand-FK506 conjugates in a three-hybrid assay 
The conjugates of RU486 or SDex with FK506 were first evaluated in a 
mammalian three-hybrid assay (Figure 3.2B). In this experiment, HeLa cells were 
transfected with a luciferase reporter with 5 Gal4-binding sites upstream of a 
minimal promoter, as well as expression vectors for Gal4 – GR-LBD and FKBP - 
VP16 fusion proteins. The conjugates were tested for their ability to dimerize GR 
LBD and FKBP, which will bring the strong VP16 activation domain to the Gal4 
fusion protein and activate the reporter gene. The experiment is similar to a 
previous three-hybrid assay reported in yeast,27 with the notable difference that 
the GR LBD in this assay is fused to the DNA-binding domain. Ligands of GR 
may therefore activate transcription through the AF-2 domain in the GR LBD as 
well as through recruitment of FKBP-VP16.  
 
Dexamethasone (Dex) activated the reporter approximately 60-fold compared to 
DMSO (Figure 3.5B). This activation is expected to stem from the AF-2 function 
in the LBD and has been be demonstrated in cells that are not transfected with 
VP16-FKBP (data not shown).  Addition of FK506 affected the activation by Dex, 
but only partially. This may be an effect of FK506 inhibition of FKBP5 and 
FKBP4, which are Hsp90 co-chaperones that are required to maintain GR in a 
ligand binding competent state.45 As controls for the conjugates, the 
unconjugated mono-functional ligands were prepared and tested (Figure 3.5): 
The activity of SDex-C7, showed partial agonistic activity. RU486-O3-N3 and 
FK506 showed no activity (Figure 3.5C). 
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Figure 3.4 Conjugates of GR ligands with FK506 A. Amine-functionalized 
linkers are coupled to SDex-ITC. A second amine in the linker is then Boc-
deprotection and coupled to amine reactive NHS-FK506-TBS2. The final step is a 
removal of TBS-protecting groups; B. Electrophilic linker mesylates are coupled 
to RU486-NHMe. The linker’s azido group is then reduced to the free amine and 
coupled to FK506 as was done for SDex.  
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Figure 3.5 Activity of unconjugated ligands in the three-hybrid assay 
Compounds are tested in a three-hybrid assay in which HeLa cells have been 
transfected with a Gal4 luciferase reporter, a Gal4-GR(LBD) expression plasmid, 
and a VP16-FKBP expression plasmid. A. Structures of unconjugated ligands; B. 
Dexamethasone activates transcription 60-fold relative to DMSO, and FK506 
only partially affects the activity of Dex; C. SDex-C7 shows partial agonist activity, 
while no activity is seen from RU486-O3-N3 or FK506. All data points are from 
triplicate samples and error bars represents the standard deviation of the three 
samples. 
 
In contrast to the unconjugated ligand, SDex-C7, the three SDex-FK506 
conjugates activated transcription potently (Figure 3.6A). The C10-linked 
conjugate was weaker than the other two conjugates, which have comparable 
potencies that are higher than Dex activity. This enhanced activity is due to 
recruitment of VP16-FKBP, as evidenced by the ability of free FK506 to inhibit 
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The molecules also self-inhibit at high concentration, which is expected since the 
monovalent interactions will dominate the bivalent.46  
 
 
Figure 3.6 Activity of SDex-FK506 conjugates Same assay as in Figure 3.5. A. 
SDex-O2-FK506 and SDex-C7-FK506 show high activation potential that is self-
inhibited at high concentrations. SDex-C10-FK506 shows weaker activity; B. The 
activity of 100 nM SDex-C7FK506 is inhibited by titration of free FK506 and 
demonstrates VP16-FKBP activity dependence. All data points are from triplicate 
samples and error bars represents the standard deviation of the three samples. 
 
The three RU486-FK506 conjugates also showed transcriptional activation. The 
activation levels were lower than for Dex and SDex-FK506 conjugates, but was 
fully dependent on VP16-FKBP recruitment, since RU486-O3-N3 showed no 
activation. Despite having an intermediate linker length in the series, the RU486-
O4-FK506 showed lower activity than the other two conjugates. For the most 
accurate comparison, these compounds will in the future be tested 
simultaneously since transfection conditions can vary and affect the results.  
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Figure 3.7 Activity of RU486-FK506 conjugates RU486-O3-FK506 and RU486-
O5-FK506 show comparable activation in three-hybrid assay. The lower activity 
and potency of RU486-O4-FK506 is likely due different levels of fusion proteins, 
as data is from separate transient transfection.  
 
The mammalian three-hybrid experiment showed that both agonistic and 
antagonistic GR ligands fused to FK506 can bring together their respective 
binding targets. From the agonist-conjugate series of linker variations, SDex-O2-
FK506 was chosen for further studies, as it was the most potent compound. 
SDex-O2-OMe was chosen as a control compound, to help discern the role of 
linked FK506. The antagonist-conjugate series showed minor influence on linker 
length, and the shorter RU486-O3-FK506 was chosen along with RU486-O3-N3 
as control compound. These structures are shown in Figure 3.8. 
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Figure 3.8 Overview of compounds chosen for studies with full-length GR  
 
Binding affinity of conjugates to GR 
The affinity of the conjugates for GR was determined in a competition binding 
assay using radio-labeled Dex and cell lysates with overexpressed GR (Figure 
3.9). SDex-O2-OMe bound to GR with an affinity (48.3 nM) that is one order of 
magnitude lower than Dex. SDex-O2-FK506 bound with 2-fold lower affinity 
compared to SDex-O2-OMe. The RU486 conjugates bound with similar affinity to 
each other and to the SDex-conjugates (83.6 and 93.9 nM). This is also an order 
of magnitude lower binding affinity compared to the parent compound, RU486.  
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Figure 3.9 Binding affinity of conjugates for GR The binding affinity of 
conjugates and GR ligands was measured in a competition assay with radio-
labeled ligand. A. Dex-derived compounds; B. RU486-derived compounds. 
Curves are fitted with GraphPad Prism 5.0 (Competition Binding, One-site – fit 
Ki) 
 
Bifunctional GR ligands can recruit non-native functionality to the full-length 
receptor 
In order to determine if extrinsic transcriptional control via VP16-FKBP can be 
recruited in the same manner to the full-length receptor as was seen in the three-
hybrid assays, the effects on GR-responsive luciferase reporters were studied. A 
!"#$%&'&'(%)*'+,'+-)".),%/0#%&102"+%),%3'(0&'(%2
!"# !"" !"$ !% !& !' !( !) !* !+
$
"
#
+
!"+4%+&30&'"+)".)4"#$%&'&"3)56"-)78
$#
"6
)9)
#
-)
%/
&30
4& :;%/<=#<>?@AB
:;%/<=#<=7%
;%/
!"
#$%&'()*
+'&%()*
,&$()*
!"#$%&'&'(%)*'+,'+-)".)/0123),%4'(5&'(%6
!"# !"" !"$ !% !& !' !( !) !* !+
$
"
#
+
/012378+79:
/012378+7;<=>3
/0123
!"+?%+&45&'"+)".)?"#$%&'&"4)@A"-)BC
$#
"A
)D)
#
-)
%E
&45
?&
!"
#$%&'()
*$%*'()
+$%,'()
A
B
	   117	  
reporter that contains the endogenous enhancer element from the FKBP5 gene, 
which includes two GREs,23 was transfected into human embryonic kidney 293T 
cells (HEK293T) together with a GR (full-length) expression plasmid, and with or 
without co-transfection of a VP16-FKBP expression plasmid. The activity of 
conjugates and ligands in these cells are shown in Figure 3.10 – 3.12. In all the 
figures, the activity is shown as a percentage of the activity of Dex at 100 nM. 
SDex-O2-FK506 and SDex-O2-OMe showed partial agonistic activity (nearly full 
agonistic activity) with reduced potency (by 2 orders of magnitude) compared to 
Dex in cells with no VP16-FKBP (Figure 3.10A). In cells cotransfected with the 
fusion protein, SDex-O2-OMe showed no change in potency or efficacy, but 
SDex-O2-FK506 activated transcription to levels over 150% relative to Dex, and 
with increased potency as well (10-fold relative to SDex-O2-OMe)(Figure 3.10A, 
right panel). The enhanced activation potential beyond that of Dex is evidence for 
recruitment of VP16-FKBP. The fusion protein is being recruited by the 
conjugated FK506 moiety as evidenced by the ability of free FK506 to lower the 
maximal response and potency of SDex-O2-FK506 in the presence of the fusion 
protein (Figure 3.10C). FK506 has no effect on SDex-O2-OMe activity apart from 
a raised baseline that is seen in all samples with FK506 at 1 µM. As mentioned 
previously, FK506 can affect endogenous proteins such as GR-associated 
FKBP4 and FKBP5 co-chaperones.  
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Figure 3.10 Functional recruitment of VP16-FKBP to GR by SDex-
conjugates HEK293T cells were transfected with a GRE-luciferase reporter and 
GR-expression plasmid. In experiments represented with figures on right, a 
VP16-FKBP expression plasmid was also cotransfected into the cells. The 
compounds and concentrations are indicated on graphs. In figure B and C, blue 
and red curves are from addition of both SDex-conjugate and constant 
concentration of FK506. Activity is normalized to % of 100 nM Dex. 
A
B
C
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The antagonist derived RU486-O3-FK506 and RU486-O3-N3 were also tested in 
the above described luciferase reporter assay (Figure 3.11). In the absence of 
VP16-FKBP fusion protein they both showed activity identical to RU486 with only 
very modest activation (10% or less). In the presence of the fusion protein, 
however, RU486-O3-FK506 became a potent activator (Figure 3.11A, right 
panel), and the enhanced activation potential could be completely blocked by 
FK506 (Figure 3.11B, right panel). Similar to what was observed in the three-
hybrid assay the RU486-FK506 conjugate self-squelched at high concentrations. 
Compared to SDex-O3-FK506, RU486-O3-FK506 activated at a slightly lower 
concentration, and self-squelching is evident at 1 µM. The shifted dose-response 
is likely not related to the binding affinity for GR, since the measured binding 
affinities for GR are nearly identical.  
 
The RU486 compounds showed ability to compete with Dex for binding to GR 
and antagonized activity in absence of the VP16-FKBP fusion protein (Figure 
3.12, left panel). In the presence of the fusion protein, RU486-O3-FK506 showed 
enhancement of activity beyond that achieved by dexamethasone (Figure 3.12, 
right panel), despite showing a maximal 80% relative activity when it was added 
alone (Figure 3.11). The enhanced activity may stem from hetero-liganded GR 
dimers that can combine the agonistic effect of Dex-bound GR with the GR-
extrinsic activity of VP16-FKBP recruited via FK506.  
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Figure 3.11 Functional recruitment of VP16-FKBP to GR by RU486-
conjugates HEK293T cells were transfected with a GRE-luciferase reporter and 
GR-expression plasmid. In experiments represented with figures on right, a 
VP16-FKBP expression plasmid was also cotransfected into the cells. The 
compounds and concentrations are indicated on graphs. In figure B, blue and red 
curves are from addition of both RU486-conjugate and constant concentration of 
FK506. Activity is normalized to % of 100 nM Dex. 
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Figure 3.12 Effect of competitive binding of RU486 conjugates in the 
presence of Dex Cells are transfected as in Figures 3.7 and 3.8. The 
concentration of compound on the x-axis refers to the RU486 compounds. Dex is 
added at a constant 100 nM. Activity is normalized to % of 100 nM Dex. 
 
These studies demonstrated that direct recruitment of the VP16-FKBP fusion 
protein to GR can be achieved by a bifunctional GR ligand, and that the 
transcriptional activation ability of VP16 influences transcription of the target 
gene. Impressively, the antagonist RU486 was converted into a potent activator. 
 
Effects of VP16-FKBP recruitment to GR transrepressed genes 
Ligand-bound GR represses NF-κB-mediated transcriptional activation of several 
genes including the proinflammatory interleukin-8 (IL-8) gene in a process known 
as transrepression.47 In its transrepression function, GR binds directly to DNA-
bound NF-κB rather than to DNA.25,48 Both Dex and RU486 cause 
transrepression, although RU486 is less effective at this. The maximal 
suppression by RU486 is lower than that of Dex, which may be explained by lack 
of recruitment of HDAC2 by RU486,32 but the level of GR expression can also 
influence the transrepression ability of RU486.49 To study the effects of VP16-
FKBP recruitment to transrepressed genes, an NF-κB-regulated luciferase 
reporter was used. HEK293T cells were transfected with this reporter together 
with GR and +/- VP16-FKBP. Cellular NF-κB was activated by treating cells with 
tumor necrosis factor alpha (TNFα).50 We observed that the GR ligands and 
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conjugates all cause transrepression, but the transrepression is not affected by 
the presence of VP16-FKBP. This was observed in only a single preliminary 
experiment and should be explored further as levels of GR (transfected) and of 
TNFα (added to media) affects the degree of transrepression and could influence 
the receptiveness to modulation by recruited VP16 activity.  
 
It is possible that VP16-FKBP recruitment is blocked in the NF-κB – GR complex, 
or alternatively, that the strong transcriptional activation domain of VP16 cannot 
counter the transrepression mechanism. Although a VP16 fusion protein can 
reactivate genes silenced by deacetylated and repressively methylated 
chromatin,51 simultaneous co-localized HDAC-associated repressors can be 
dominant over VP16 activation potential.52,53 It should also be remembered that 
both NF-κB and agonist-bound GR contain strong activation function as well that 
is repressed in this context. Studies have revealed that RNA polymerase II (Pol2) 
is indeed recruited to some GR-transrepressed genes (preinitation complex is 
formed), but GR interferes with phosphorylation of serine 2 of the Pol2 C-terminal 
domain (CTD) and Pol2 is stalled at the promoter.25 In agreement with this, 
promoter association of CyclinT1 and cyclin-dependent kinase 9 (Cdk9), which 
together form the positive transcription elongation factor b (P-TEFb) responsible 
for CTD Ser2 phosphorylation, is also blocked in a GR dependent fashion.54 The 
altered recruitment of CyclinT1 and Cdk9 could be the primary cause of 
transrepression, or it could be just a symptom of another repression mechanism. 
In an attempt to answer this question, the CyclinT1 and Cdk9 genes were each 
cloned into an FKBP-fusion vector. If SDex/RU846-FK506 conjugates can 
mediate recruitment of CyclinT1-FKBP or Cdk9-FKBP and if these can form an 
active P-TEFb complex with their respective endogenous binding partner, it can 
be hypothesized that they would phosphorylate CTD Ser2 and initiate promoter 
release of Pol2 at transrepressed genes.  Cotransfection of HEK293T cells with 
these fusion proteins in the transrepression assay, however, did not reduce the 
transrepressive potential of FK506 conjugates. In the absence of an effect, the 
study is not conclusive as the recruitment of these fusion proteins could be 
	   123	  
sterically hindered or the association of the native binding partner to the fused 
protein could be blocked by the fusion. Ideally, their recruitment would be studied 
with chromatin immunoprecipitation, which could also be used to reveal if the 
CTD Ser2 phosphorylation is occurring.  
 
Effects of conjugates on endogenous genes 
A human adenocarcinoma lung epithelial cell line, A549, which expresses 
endogenous GR and is commonly used to study the effect of GR on GRE-
regulated genes as well as transrepression function, was stably transfected with 
a VP16-FKBP-myc6 expression plasmid. The myc6-tag does not interfere with the 
function of the fusion protein in the mammalian three-hybrid assay or the GR-
luciferase assays, and they were included to potentially help facilitate chromatin 
immunoprecipitation (ChIP) studies. The stable cell line ensures expression of 
the fusion protein in all cells. This is in contrast to a transient transfection of A549 
cells, for which the optimized transfection conditions used by us only achieve 
delivery of plasmids to 50-60 % of cells in each transfection. In studies with 
transiently cotransfected reporters, the fraction of cells receiving plasmids are not 
a concern since only the transfected cells contributes to the readout, while 
expression analysis of endogenous genes, involves the entire cell population. A 
total of 37 stable clones were tested for expression of the fusion protein, and one 
clone showed expression (Figure 3.13A). This clone (124.25) has a slightly 
reduced growth rate compared to WT A549 cells, but has so far been cultured 
with over 20 passages without loss of fusion protein expression.  
 
The expression level of the fusion protein in 124.25 cells relative to the levels 
obtained with transiently transfected cells and relative to endogenous FKBP1A 
was determined with a Western blot (Figure 3.13B). The 124.25 cells expressed 
VP16-FKBP-myc6 at ~10-fold lower level compared to endogenous FKBP1A. The 
transient expression in this instance had ~38-fold higher level of expression of 
the fusion protein compared to the stable cell line and ~5-fold higher than 
endogenous FKBP1A. The expression levels in different transient transfections 
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vary, however, and have often been comparable to or lower than FKBP1A-levels. 
The relative expression of fusion protein and endogenous FKBP1A in 124.25 
cells has been consistent. Since FK506 can bind to endogenous FKBP1A there 
is a concern that this protein will compete for binding to conjugates and suppress 
effective recruitment of VP16-FKBP to gene promoters.  
 
 
Figure 3.13 Expression levels of VP16-FKBP and endogenous FKBP1A A. 
Western blot of an A549 cell line stably transfected with VP16-FKBP-myc6 (Clone 
124.25). The blot probed with α-FKBP (left) show expression of both introduced 
fusion protein and endogenous FKBP1A. A blot probed with α-myc confirms 
identity of the fusion protein; B. Relative expression levels of fusion protein and 
endogenous FKBP1A in stably and transiently transfected cells. Background 
subtracted pixel-counts are determined with ImageJ. Non-saturated bands are 
used to estimate relative amounts.  
 
RU486-O3-FK506 previously showed the biggest fusion-protein dependent 
change in activation potential of the luciferase reporters and was therefore tested 
in A549 cells transiently transfected with VP16-FKBP-myc6 or in the stable 
124.25 clone. The mRNA levels of two GR target genes (GILZ and FKBP5) that 
show high levels of induction by Dex55 were quantified by RT-qPCR. GILZ mRNA 
levels were induced quickly, with significant levels observed after 1 hour of 
treatment (data not shown) and has stable expresion between 6 and 24 hours 
(Figure 3.14A). The induction of the FKBP5 gene was slower, but was significant 
after 6 hours of treatment and slightly higher after 24 hours. Endogenous genes 
in transiently transfected (VP16-FKBP) A549 cells were not induced by the 
VP16-FKBP-
myc6
Apparent ~ 38 kDa
Expected 30.3 kDa
Endogenous
FKBP1A
α-FKBP α-myc
100 47 10 87 34 10
26 240 138 39
VP16-FKBP-myc6
FKBP1A
124.25 lysate
10 μg 2 μg 0.4 μg
Transiently transfected
A549 lysate
10 μg 2 μg 0.4 μg
Relative intensity
Relative intensity
A B α-FKBP
A549 124.25A549 124.25
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RU486-O3-FK506 conjugate. The lack of induction was evident after both 6 and 
24 hours and within the treatment range of 1 - 100 nM of the conjugate. Two 
additional genes were included in the study, SDPR and SLC19A2, because 
these genes have GREs proximal to their transcriptional start sites, and they may 
resemble the luciferase reporters in this manner. The genes in the stable clone 
(124.25), which expresses lower levels of the fusion protein, were also not 
inducible by RU486-O3-FK506. The SDex-O2-FK506 conjugate was also tested 
and showed higher potency than its linker-only analog, but this activity was not 
dependent on the VP16-FKBP fusion protein. It may instead be through an effect 
of linked FK506 on cell permeability or through interaction with endogenous 
FKBPs.  
 
 
Figure 3.14 Effect of RU468-O3-FK506 on expression of endogenous genes 
mRNA levels are determined using RT-qPCR and comparative ΔΔCT analysis. 
Determined CT levels for genes are normalized to RPL19 and Δ.CT values of 
samples are compared to Δ.CT of DMSO. Fold over DMSO is: 2^(-ΔΔCT) A. The 
endogenous genes, FKBP5 and GILZ, are Dex-responsive in A549 cells; B. The 
effect of RU486-O3-FK506 on Dex-responsive genes in A549 cells transiently 
expressing the VP16-FKBP-myc6 fusion protein. Data represent the average of 
three qPCR samples prepared with mRNA isolated from one experiment.  
 
In an attempt to detect recruitment of fusion the protein at endogenous genes 
chromatin immunoprecipitation (ChIP) was used. Recruitment may be occuring 
A B
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even though no effects on transcription of genes were seen. ChIP showed that 
Dex induces binding of endogenous GR to GREs in A549 cells (Figure 3.15B). 
When a myc6-tagged GR is expressed in A549 cells, ChIP with an α-myc 
antibody also detects the Dex-induced binding of GR to the GREs of the FKBP5 
gene (Figure 3.15A). In A549 cells with transiently expressed VP16-FKBP-myc6, 
the SDex-conjugates were tested and induce GR-binding to GREs of the GILZ 
gene (Figure 3.15C) and the FKBP5 gene (Figure 3.13D). The VP16-FKBP-myc6 
fusion protein, however, could not be detected (Figure 3.13C-D). The absence of 
fusion protein at the promoter is consistent with lack of VP16-FKBP dependent 
transcriptional activity, but it is not conclusive evidence; VP16-FKBP would be 
predicted to be more difficult to cross-link to the promoter, since it would be 
tethered to GR via a chemical spacer, and be expected to lack direct association 
with DNA and maybe even with other DNA-bound proteins.  
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Figure 3.15 Chromatin immunoprecipitation of GR and VP16-FKBP-myc6 
Chromatin immunoprecipitation at GRE-regions of FKBP5 (A,B,D) or GILZ (C) 
enhancers. A. ChIP of Dex or DMSO treated A549 cells transiently transfected 
with GR-myc6 using α-GR and α-Myc antibodies; B. ChIP of Dex or DMSO 
treated untransfected A549 cells using α-GR antibody; C and D. ChIP of SDex-
conjugate treated A549 cells transiently transfected with VP16-FKBP-myc6 using 
α-GR and α-Myc antibodies.  
 
3.6 Conclusion and discussion 
Conjugation of GR agonist ligand dexamethasone and antagonist ligand RU486 
to FK506 facilitated recruitment of an FKBP-fusion protein to GR. When SDex-
O2-FK506 was used to recruit VP16-FKBP, the transcriptional activation was 
higher than full agonistic effects. VP16 may provide the sole activation potential 
in place of an intrinsic effect, or both mechanisms may contribute. Conjugation of 
A B
C D
25.3 1.3Fold / IgG: 9.3 1.7
20.8 10.7Fold / IgG: 1.6 1.7
39.1 1.1Fold / IgG:
33.4 28.9Fold / IgG: 1.2 1.2
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antagonistic RU486 to FK506 also facilitated recruitment of VP16-FKBP to a 
reporter gene. The intrinsic activation potential of RU486 is very low, and RU486 
potently antagonizes Dex (Figure 3.12). The activity induced by recruitment of 
VP16-FKBP is therefore likely entirely an effect of VP16, and this activity is 
nearly the same as the full agonistic effect of Dex. The activation potential of 
VP16 may be higher, as a self-inhibition effect of RU486-O3-FK506 overlaps and 
becomes dominant at high concentrations. Additionally, it is possible that a 
repressive mechanism of RU486-bound GR suppresses a higher activation 
potential of VP16 to the level observed. When Dex and RU486-O3-FK506 are 
added simultaneously to cells transfected with VP16-FKBP, an activation level 
that is higher than from either compound alone is seen (Figure 3.9, right panel). 
This can best be explained to be a result of the two GREs in the reporter being 
occupied by GR dimers with a combination of both Dex and RU486-O3-FK506 
bound (a heterodimer or two different homodimers) consistent with a scenario in 
which intrinsic GR agonism (from Dex-bound GR) can synergize with activity 
form VP16. 
 
The different dose response curves for SDex and RU486 conjugates are not a 
result of different affinities for GR. FK506 was functionalized as has been 
previously reported, and it has been documented for FK506 conjugates made via 
this functionalization that they do not alter the binding affinity for FKBP.42 We 
have therefore assumed that the binding affinities (for FKBP) are identical for the 
SDex and RU486 conjugates, but this would be useful to confirm. A differential 
binding affinity could also stem from different interactions between FKBP and GR 
depending on the ligand bound to GR. The binding studies (Figure 3.9), however, 
were done in lysates that contain endogenous FKBP1A. Another factor that may 
influence the dose response, is an allosterically altered association of GR with 
DNA that is different for Dex and RU486.56  
 
Collaborative efforts are still ongoing aimed at demonstrating functional 
recruitment of VP16-FKBP to endogenous genes. The inability of the conjugates 
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to show activity in A549 cells may be related to the relative levels of both GR and 
VP16-FKBP. In addition to studies of endogenous genes presented in Figure 
3.14, preliminary experiments with transfection of GRE-luciferase reporter and 
VP16-FKBP into A549 cells did not demonstrate a VP16-FKBP dependent 
activity of conjugates (J.W. Hojfeldt and J.P. Carolan). This at least indicates a 
challenge in A549 cells not related to a difference between recruitment to 
plasmid DNA and endogenous genes. A lysate of VP16-FKBP transfected 
HEK293Tcells does not show high levels of fusion protein relative to endogenous 
FKBP1A by Western blot (O. Cruz and J.P. Carolan), and this may implicate 
differential levels of GR expression as a cause. A high level of GR expression 
may allow conjugates to bind GR first and translocate to the nucleus, where it 
can bind VP16-FKBP which, unlike FKBP1A, has a nuclear localization sequence 
added. Studies of effects on endogenous genes in HEK293T cells (transfected 
with GR and VP16-FKBP as in reporter assays) are being carried out 
 
The demonstration of direct recruitment of proteins to a full-length nuclear 
receptor with bifunctional molecules is an encouraging result. If this strategy can 
be further extended to conjugates that combine NR ligands and ligands of 
endogenous transcriptional coregulatory complexes, NR targeting drugs with a 
new level of transcription control could be realized. The first efforts towards this 
are presented in Chapter 4. The ongoing efforts to understand the factors 
associated with different activities in HEK293T and A549 cells presented in this 
chapter for VP16-FKBP recruitment will hopefully provide lessons beneficial to 
efforts with other bifunctional recruiters.  
 
3.7 Materials and methods 
Cells 
HeLa (CCL-2) and A549 (CCL-185) cells were purchased from ATCC. Cells were 
cultured in DMEM with 10% FBS at 37°C under 5% CO2. Transient transfections 
were done using Lipofectamine LTX or Lipofectamine 2000 (Invitrogen) with 
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conditions optimized using GFP expression plasmid and Accuri C6 flow 
cytometric analysis.  
 
An A549-derived cell line stably transfected with pVP16-FKBP-myc6 was made 
(clone 124.25): 160,000 A549 cells were plated in wells of a 6 well plate and 
transfected the following day by addition of: 2.5 µg linearized (SalI) pVP16-
FKBP-myc6, 0.125 µg linear hygromycin marker (Clontech), 2.5 µL Plus reagent, 
10 µg Lipofectamine LTX in 0.5 mL OptiMEM. After 24 hours cells were 
trypsinized and replated in 150 cm dishes at 100,000 cells per dish. The following 
day 400 µg/mL of hygromycin B (Calbiochem) was added (concentration 
determined from kill-curve experiment). Media with hygromycin is replaced every 
2-3 days. After 10 days, most cells are dead (all cells on control plates are dead) 
and a total of 37 colonies from 4 plates are picked by use cloning cylinders and 
transferred to 12-well plates. When cells grow to near confluency they are split to 
larger dishes, and lysates used to detect expression of fusion protein by Western 
blot.  
 
Mammalian three-hybrid assay (Figures 3.3, 3.4, and 3.5) 
12,000 HeLa cells were plated in a 96-well plate in 100 µL DMEM. The following 
day they were transfected by replacing media with transfection mix: 100 ng 
pG5luc, 1 ng pRLSV40, 50 ng pGal4-GRLBD, 50 ng pVP16-FKBP, 0.6 µL 
Lipofectamine 2000 in 100 µL OptiMEM. After 6 hours, the transfection mix was 
replaced with DMEM + 10% FBS and 1 µL of a DMSO stock solution of 
compound was added. After 20 hours, media was removed and samples were 
assayed with Dual-Luciferase Reporter Assay System (Promega) using 20 µL 
Passive lysis buffer, and 25 µL of each substrate. Luminescence was measured 
on Berthold Lumat LB 9507 luminometer. Standard deviation from triplicate 
samples is represented by error bars on graph.  
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Western blots 
Lysates were made in RIPA buffer and quantified with BCA assay (Pierce). 
SeeBlue Plus2 and Magic Mark XP protein ladders (Invitrogen) were used to 
estimate molecular weights. SDS-PAGE was done with bis-tris gels (0.35M bis-
tris (Bis(2-hydroxyethyl)-amino-tris(hydroxymethyl)-methane) pH 6.5, 10 % acryl-
amide (30:2)) run in MOPS buffer at 150 V  and transferred to PVDF membrane. 
Membranes were stained with Ponceau S, then blocked with 5% milk in PBST, 
1hr at 4°C. Primary antibodies were incubated over night at 4°C at dilutions: 
1:1000 α-myc (Santa Cruz, sc-40) or 1:2000 α-FKBP (Abcam, ab58072). 
Membrane was washed with PBST and incubated with 1:10000 goat α-mouse-
HRP (Santa Cruz, sc-2005). Membrane was washed with PBST, developed with 
ECL-Plus (GE Health Care) and read on Typhoon 9410. Scanned images were 
analyzed using ImageJ software.  
 
Chromatin immunoprecipitation 
A549 cells in 10cm dishes (10 mL DMEM + 10% FBS) were treated with DMSO 
or compounds at 90% confluency. After incubation with compounds 
formaldehyde was added at room temperature to a final concentration of 1% and 
incubated for 10 min. Glycine was added to 0.125 M and incubated for 5 min. 
before cells were washed 3 times with PBS. Cells were lysed on ice by addition 
of 400 µL SDS lysis buffer (1%SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.0, Halt 
protease inhibitor (Pierce)) and incubated for 15 min. before cells were scraped, 
transferred to a microcentrifuge tube and placed on ice for 30 minutes. The 
lysate was sonicated per optimized conditions to yield sheared chromatin with a 
size range of 200-800bp. Sheared chromatin was cleared by centrifugation (10 
min., 12,000 x g, 4°C). A sample of sheared chromatin was reverse cross-linked 
(see below) and DNA concentration determined. Sheared chromatin 
corresponding to 10 µg of DNA was used for each IP and was diluted with 9 parts 
ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM 
Tris-HCl pH 8.1, 167 mM NaCl, with Halt protease inhibitor). 0.1 µg DNA was 
kept as 1% input sample (treated with IP’ed samples at the elution step below). 3 
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µg of antibody was added and was incubated over night on rotating wheel at 4°C. 
Antibodies used were: α-GR (Santa Cruz, sc-8992x); α-myc (Santa Cruz, sc-40); 
IgG (Santa Cruz, sc-2027x). Next day, 15 µL Protein G MagnaChIP beads 
(Millipore) were added and incubated for 1 hr at 4°C. Supernatant was removed 
from beads with tubes placed in magnetic rack, and 1 mL wash buffer was added 
followed by 5 min. on orbital shaker at 4°C. The beads were washed once with 
each of the following buffers: 1) 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 
mM Tris-HCl pH 8.1, 150 mM NaCl; 2) 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 
20 mM Tris-HCl pH 8.1, 500 mM NaCl; 3) 250 mM LiCl, 1% Igepal CA630, 1% 
deoxycholate, 1 mM EDTA, 10 mM Tris pH 8.1; 4) 10mM Tris-HCl pH 8.0, 1 mM 
EDTA. Chromatin was eluted from beads by 2 incubations with 100 µL Elution 
buffer (1% SDS, 0.1 M NaHCO3). 1 µL 10 mg/mL RNase A was added and 
incubated for 30 min. at 37°C. 8 µL 5M NaCl and 1 µL 10 mg/mL Proteinase K 
was added and incubated at 65°C over night. DNA was purified with Qiagen PCR 
clean-up kit and used in qPCR reactions.  
 
qPCR of ChIP samples 
20 µL qPCR reaction mix: 2 µL DNA, 0.2 µL CXR, 0.4 µL forward primer (200 nM 
final), 0.4 µL reverse primer, 7 µL H2O, 10 µL GoTaq qPCR master mix 
(Promega). qPCR was done on ABI StepOne Plus. Products were analyzed with 
melt curve and on agarose gel. Data analyzed with ΔCT = CT(sample) – CT(input), 
% of input = 2^-(ΔCT). Standard error calculated on % of input values. Primer 
pairs used:  
(FKBP5 intronic enhancer, 350 bp)  
F-Pr 5’- CAGAGCTAATGTCTTTAGGCTGGAGC -3’ 
R-Pr 5’- GCAATCGGAGTGTAACCACATCAAG -3’  
(GILZ, surrounds GRE -1958/-1944, 151 bp)  
F-Pr 5’- GGCCCCAGTACTTTTCCAAT -3’ 
R-Pr 5’- GGTTGAGTCCTGGTTTCCTC -3’ 
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RT-qPCR for mRNA  
50,000 A549 (WT, 124.25, or transiently transfected) cells were plated in 24-well 
plate with 0.5 mL DMEM + 10% FBS. Next day cells were treated with 
compounds or DMSO (0.2% final DMSO for all samples). Total RNA was isolated 
with Qiagen RNAeasy Plus mini kit. cDNA synthesis was done with iScript RT 
Mastermix (Biorad). 2 µL cDNA was used in qPCR as described for ChIP 
samples. Primer pairs used:  
FKBP5: F-Pr 5’- GGAATGGTGAGGAAACGCCG -3’  
FKBP5: R-Pr 5’- CTCTCCTTTCTTCATGGTAGCCACC -3’  
GILZ: F-Pr 5’- CGAACAGGCCATGGATCTGGTGAA -3’  
GILZ: R-Pr 5’- AGAACCACCAGGGGCCTCGG -3’  
RPL19: F-Pr 5’- ATGTATCACAGCCTGTACCTG -3’  
RPL19: R-Pr 5’- TTCTTGGTCTCTTCCTCCTTG -3’  
SLC19A2: F-Pr 5’- AAGTCCCGCAAGGTCAGCGC -3’ 
SLC19A2: R-Pr 5’- GAAACGGCCTCCACGCCACC -3’  
SDPR: F-Pr 5’- AAGTCCCGCAAGGTCAGCGC -3’ 
SDPR: R-Pr 5’- GCAGGGATCTCATTTTCCTCCTGG -3’ 
 
Plasmids 
pG5luc, pRLSV40, and pAct were purchased from Promega. pRShGR was 
purchased from ATCC. Plasmids with CDS for CyclinT157 and Cdk958 were 
purchased from Addgene (14628 and 14640). pGal4-GRLBD, which is a 
mammalian expression plasmid that encodes a fusion of yeast Gal4(1-147) and 
the ligand binding domain of the human glucocorticoid receptor (499-777), was a 
kind gift from Thomas Kodadek (The Scripps Research Institute, Scripps 
Florida).59 pCS2+MT is an expression vector designed for making fusions to six 
copies of the myc epitope60 recognized by the 9e10 monoclonal antibody,61 and 
was a kind gift from David Turner (University of Michigan). All oligos for 
construction of plasmids were purchased from Integrated DNA Technologies.  
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pVP16-FKBP is a mammalian expression plasmid that encodes a fusion of Gal1-
11 (for efficient expression), NLS from SV40 large T antigen (nuclear localization 
signal), VP16(411-456) (potent activation domain, activation domain 1 from the 
herpex simplex virion protein 16), and human FKBP1A(2-107) (FK506 binding 
protein 1A, 12kDa). It was constructed by cloning of FKBP1A into pAct. The 
coding sequence is shown below, with the elements listed above marked with 
capital letters in brackets: 
[ATGAAGCTACTGTCTTCTATCGAACAAGCATGC][CCAAAAAAGAAGAGAAA
GGTAGAT]gaattcccgggg[ATCTCGACGGCCCCCCCGACCGATGTCAGCCTGG
GGGACGAGCTCCACTTAGACGGCGAGGACGTGGCGATGGCGCATGCCGA
CGCGCTAGACGATTTCGATCTGGACATGTTGGGGGACGGGGATTCCCCGG
GTCCGGGA]tcgccaggatcc[GGCGTGCAGGTGGAGACTATCTCCCCAGGAGAC
GGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGG
GATGCTTGAAGATGGAAAGAAATTTGATTCCTCCCGGGACAGAAACAAGCC
CTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGG
GGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGA
TTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCAC
TCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAAGATCTGTCGACTTGACG
CGT] 
 
pLIC-myc6 is an LIC cloning62 vector to facilitate fusion of genes to six myc-tags 
in a mammalian expression vector. It was prepared by performing site-directed 
mutagenesis to pCS2+MT with the primers: 5’- CAA GCT ACT TGT TCT TTT 
TGC ACC ATG GGA AGC ACC GGT TCT GGT GAG ATG GAG CAA AAG CTC 
ATT TCT G -3’ and 5’- CAG AAA TGA GCT TTT GCT CCA TCT CAC CAG AAC 
CGG TGC TTC CCA TGG TGC AAA AAG AAC AAG TAG CTT G –3’. To 
prepare the vector for LIC cloning, it was digested with AgeI and processed with 
T4 DNA polymerase (Novagen) with dTTP added as the only nucleotide. Genes 
to be cloned into the vector were PCR amplified with primers that have 
sequences appended to 5’end of gene specific sequence. These appendages 
are: Sense-primer 5’- GGGAAGCACCGGT; Antisense-primer 5’- 
CACCAGAACCGGT. 
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pVP16-FKBP-myc6 was prepared by performing LIC-cloning of the fusion protein 
from pVP16-FKBP into pLIC-myc6. This fused Gal4(1-11)-NLS-VP16-FKBP N-
terminal to 6 myc epitopes in a mammalian expression vector. 
 
pGR-myc6 was prepared with LIC of human GR from pRShGR into pLIC-myc6.  
 
pLIC-FKBP is a cloning vector designed for making fusions to FKBP (and Gal4(1-
11) and SV40 large T NLS). This was made by cutting VP16 out of pVP16-FKBP 
with EcoRI and BamH1, and ligating in an LIC cassette in the form of annealed 
oligos: 5’- AAT TGG GAA GCA CCG GTT CTG GTG ATC -3’ and 5’- GAT CGA 
TCA CCA GAA CCG GTG CTT CCC -3’. To prepare the vector for LIC cloning, it 
was digested with AgeI and processed with T4 DNA polymerase (Novagen) with 
dTTP added as the only nucleotide. Genes to be cloned into the vector were 
PCR amplified with primers that have sequences appended to 5’end of gene 
specific sequence. These appendages are: Sense-primer 5’- 
GGGAAGCACCGGT; Antisense-primer 5’- CACCAGAACCGGT. 
 
pCyclinT1-FKBP and pCdk9-FKBP were made by LIC of the genes in plasmids 
purchased from Addgene into pLIC-FKBP.  
 
Chemical synthesis 
FK506 was purchased from LC Laboratories. Dexamethasone was purchased 
from Enzo Life Sciences. RU486 (Mifepristone) was purchased from Sigma-
Aldrich. Commercially available reagents and solvents were used as received. 
Chromatographic separations were carried out on silica gel 60 (230-400 mesh, E. 
Merck) or by reverse phase HPLC on C18 column using the indicated eluents. 
Yields are unoptimized. ESI-MS spectra were obtained on Micromass LCT TOF 
mass spectrometer. High-resolution mass spectra (HRMS) were obtained on 
Micromass AutoSpec Ultima Magnetic sector mass spectrometer. 1H-NMR 
spectra were obtained at 400MHz on a Varian MR-400 spectrometer. Chemical 
shifts are given in δ(ppm) values.  
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NHS-FK506-TBS2 was synthesized by Y. Imaeda according to a published 
procedure.42  
 
 
SDex-ITC was synthesized by J.W. Hojfeldt according to a published 
procedure:29  
Dexamethasone (1.00 g, 2.5 mmol) was dissolved in pyridine (7 mL) and cooled 
to 0°C. Methanesulfonyl chloride (0.26 mL, 3.3 mmol) was added to the mixture 
dropwise over 15 min. After stirring at 0°C for 30 min, the reaction mixture was 
poured into water (300 mL) at 0°C. The precipitation was collected by filtration 
and washed with water. The obtained product and tert-butyl 2-
sulfanylethylcarbamate (1.24 mL, 7.3 mmol) were dissolved in acetone (24 mL). 
Triethylamine (2.05 mL, 7.3 mmol) was added to the solution and then the 
resulting mixture was stirred at room temperature for 15 h. The reaction mixture 
was diluted with water and extracted with ethyl acetate. The extract was washed 
with water and brine, dried over sodium sulfate and concentrated in vacuo. The 
residue was crystallized from ethyl acetate-hexane to give a colorless powder. 
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The obtained powder was dissolved in 1.5 M hydrochloric acid in acetic acid (1 
mL) and then the mixture was stirred at room temperature for 15 min. The 
mixture was diluted with water and chloroform and basified with saturated 
aqueous sodium carbonate solution and the slurry was stirred at room 
temperature for 15 min (pH of the slurry should be over 10). Thiophosgene (0.18 
mL, 2.4 mmol) was added to the slurry, and then the resulting mixture was stirred 
at room temperature for 1.5 h. The chloroform layer was separated, and the layer 
was washed with water and brine, dried over sodium sulfate and concentrated in 
vacuo. The residue was purified by silica gel chromatography (ethyl 
acetate/hexane = 1/4 to 1/1) to give product (150 mg, 18%) as a pale yellow 
powder.  1H NMR (400MHz, CDCl3): δ 0.88 (3H, d J = 7.2 Hz), 1.02-1.80 (10H, 
m), 2.01-2.57 (6H, m), 2.81 (2H, t, J = 6.8 Hz), 3.04-3.07 (1H, m), 3.24 (1H, d, J 
= 13.6 Hz), 3.58 (1H, d, J = 14.0 Hz), 3.71 (2H, t, J = 5.8 Hz), 4.34 (2H, d, J = 7.6 
Hz), 6.08 (1H, s), 6.29 (1H, d, J = 8.4 Hz), 7.14 (1H, d, J = 10 Hz). ESI-MS 
calculated for [C25H32FNO4S2 + H]+: 494.1, found 494.0. 
 
 
RU486-NHMe was synthesized by A.R. Van Dyke and Y. Imaeda according to 
published procedure.33 
 
 
SDex-O2-OMe was synthesized by A.R. Van Dyke. 
RU486-NHMe
O
OH
H
H
N
O
HO OH
HF
H
O S
H
N
H
N
S
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O O O
O
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SDex-O2-FK506 was synthesized by Y. Imaeda as outlined in Figure 3.2A. 
 
 
Linker MsO-O3-N3 was synthesized by A.R. Van Dyke and is used in the RU486-
conjugate synthesis below.  
 
 
RU486-O3-N3 was synthesized by J.W. Hojfeldt and Y. Imaeda: 
A mixture RU486-NHMe (22 mg, 0.053 mmol), and Linker MsO-O3-N3 (19 mg, 
0.064 mmol), sodium iodide (10 mg, 0.064 mmol), and N,N-diisopropylethylamine 
(0.03 mL, 0.16 mmol) in acetonitrile (5 mL) was heated at 100°C for 60 h. After 
concentration in vacuo, the residue was purified by silica gel chromatography 
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(ethyl acetate/hexane = 4/6 to 6/4) to give compound 7 (22 mg, 67%) as a yellow 
sticky oil. Product was purified by HPLC (0.1% aqueous TFA/acetonitrile = 80/20 
to 65/35) to give the trifluoroacetic acid salt of compound 7 as a colorless 
amorphous powder.  1H NMR (400MHz, CDCl3): δ 0.53 (3H, s), 1.31-1.47 (2H, 
m), 1.65-1.78 (3H, m), 1.88 (3H, s), 1.89-2.03 (2H, m), 2.18-2.47 (7H, m), 2.55 
(2H, m), 2.74-2.77 (1H, m), 2.93 (3H, s), 3.36-3.78 (2H, m), 3.46-3.48 (1H, m), 
3.59-3.66 (12H, m), 4.32 (1H, d, J = 6.8 Hz), 5.74 (1H, s), 6.61 (2H, d, J = 8.8 
Hz), 6.97 (2H, d, J = 8.4 Hz). HRMS (ESI) calculated for [C36H48N4O5 + H]+: 
617.3697, found 617.3699. 
 
 
RU486-O3-FK506 was synthesized by J.W. Hojfeldt and Y. Imaeda: 
A mixture of RU486-O3-N3 (13 mg, 0.021 mmol) and polymer-bound 
triphenylphosphine (200-400 mesh, 3 mmol/g; 25 mg, 0.075 mmol) and water (1 
drop) in THF (3 mL) was refluxed for 15 h. The mixture was filtered and the 
filtrate was concentrated in vacuo. The product, compound 12 (25 mg, 0.021 
mmol), and N,N-diisopropylethylamine (0.008 mL, 0.042 mmol) were dissolved in 
dichloromethane (1 mL). After stirring at room temperature for 40 h, the mixture 
was purified by silica gel chromatography (ethyl acetate/hexane = 1/1 to ethyl 
acetate). The product was dissolved in methanol (0.5 mL) and water (1 drop) and 
concentrated hydrochloric acid (3 drops) was added. After stirring at room 
O
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temperature for 2 h, the reaction mixture was neutralized with NaHCO3 powder 
and concentrated in vacuo. The mixture was diluted with acetonitrile and filtered. 
The filtrate was concentrated in vacuo and the residue was purified by HPLC 
(0.1% aqueous TFA/acetonitrile = 65/35 to 50/50) to give the product as a 
colorless amorphous powder. 1H NMR (400MHz, CD3OD): δ 0.47 (3H, s), 0.85-
0.98 (10H, m), 1.04-3.01 (58H, m), 3.11-3.68 (30H, m), 3.91-4.35 (5H, m), 4.53 
(1H, m), 4.62 (1H, br s), 4.85-5.24 (4H, m), 5.74 (1H, s), 7.56 (2H, m), 7.82 (2H, 
m). HRMS (ESI) calculated for [C80H117N3O19 + H]+: 1424.8354, found 
1424.8345. 
 
Other conjugates of varying linker lengths described in Figure 3.4 were 
synthesized by Y. Imaeda.  
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Chapter 4 
 
Towards extrinsic recruitment of HDAC-associated  
complexes to the glucocorticoid receptor* 
 
4.1 Abstract 
Bifunctional molecules, comprised of a nuclear receptor (NR) ligand conjugated 
to a ligand with high affinity for a second target protein, can recruit this second 
target protein to the receptor. In addition to the proteins whose recruitment is 
intrinsic to nuclear receptor function, transcriptional coregulatory proteins 
recruited directly by the bifunctional small molecule are influential in determining 
the transcriptional response. These principles were demonstrated with the use of 
an engineered target protein, and the strategy must be extended to recruitment 
of endogenous proteins to provide structures with therapeutic potential. High 
affinity ligands of transcriptional coregulatory proteins exist, and it must be 
assessed if direct recruitment of these targets can influence the transcriptional 
control of target genes. In this chapter, histone deacetylases (HDACs) are 
proposed as endogenous targets of this NR-extrinsic recruitment strategy, and 
conjugates of glucocorticoid receptor (GR) ligands to HDAC inhibitors are 
designed and synthesized. It is shown that conjugation of the two ligands does 
not affect the ability of the HDAC inhibitor to bind and inhibit target HDACs, and 
the conjugated GR ligands retain their ability to bind GR and induce localization 
to endogenous target genes. Ongoing efforts are aimed at demonstrating 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
* The conceptual strategy of recruiting chromatin-modifying complexes via inhibitors of their 
enzymatic subunits was conceived by J.W. Hojfeldt. All experiments were done together with A.R. 
Van Dyke.  
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simultaneous binding of the bifunctional ligands to GR and to an HDAC-
containing corepressor complex.  
 
4.2 Introduction 
In Chapter 3 it was shown that bifunctional molecules can directly recruit target 
proteins to nuclear receptors. The features of these molecules were a mid-
nanomolar (50-100 nM) affinity for the receptor, a subnanomolar (0.6 nM) affinity 
for the engineered and ectopically expressed VP16-FKBP fusion protein, and an 
ability to simultaneously bind to both target proteins. These properties resulted in 
recruitment of VP16-FKBP to GR target genes, and the transcriptional activation 
function of VP16 influenced the regulation of these genes. This recruitment 
principle should be transferable to ligands that bind endogenous proteins.  
 
A defined minimal binding affinity of a ligand for its target protein that would be 
needed to achieve recruitment as part of a bifunctional molecule does not exist. 
Theoretical treatments that allow prediction of relative populations of ligand-
bound monomeric and dimeric species have only been applied to simple systems 
of homodimers, and cannot address different affinities of two distinct ligands or 
different concentrations of their target proteins.1 Intuitively, it would be beneficial 
to have a high proportion of dimerized proteins relative to a species of ligand 
bound only to GR, because these would compete for a limited number of 
genomic binding sites (two binding sites for a gene with one GRE in the entire 
cell). The relative populations of these two species would be dependent on 
protein concentrations as well as affinity of the ligands for their target and off-
target structures, but it will likely be beneficial for the ligand that will be 
conjugated to GR to have similar or lower affinity for its target protein relative to 
the affinity of the GR ligand for the receptor. 
 
A significant challenge to the discovery of small drug-like molecules that can bind 
to and recruit coregulatory transcription complexes is that these proteins, in their 
native biological setting, are recruited by transcription factors through shallow 
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protein-protein interaction surfaces. Small molecules that bind to these surfaces 
with submicromolar affinities have yet to be reported despite considerable effort. 
The artificial recruitment of transcriptional complexes, however, obviates the 
need to utilize the same surfaces for recruitment as are used by natural 
transcription factors. From this perspective, there are numerous transcriptionally 
relevant proteins for which high affinity small molecule ligands have been 
identified. Chromatin modifying enzymes are amongst these and are emerging 
drug targets with many active inhibitor discovery programs.2 These include the 
enzymes responsible for controlling methylation and acetylation patterns of 
residues in histone tails. Numerous histone deacetylase (HDAC) inhibitors with 
various affinities and selectivities for HDAC isoforms have been discovered,3-6 
and the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) is an FDA 
approved drug.7 Examples of a pan-specific HDAC inhibitor and two isoform 
selective inhibitors are shown in Figure 4.1. 
 
 
Figure 4.1 HDAC inhibitors Three representative HDAC inhibitors with varying 
selectivity for HDAC isoforms are shown together with reported Ki and IC50 
values. Red structures are tolerant of modifications and could serve as 
attachment point in conjugate structures.  
 
Histone deacetylase enzymes function within large multiprotein complexes in 
their gene regulation capacities; HDAC1 and HDAC2 are found together in the 
Sin3, CoREST and Mi-2/NuRD corepressor complexes, and HDAC3 and HDAC4 
are members of the NCoR/SMRT complex (Table 4.1).8,9 These complexes 
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SAHA
Ki (HDAC1) = 5.4 nM
Ki (HDAC3) = 7.8 nM
Typical reported IC50 values (HDAC1): 17-68 nM
Class I and II selective
Metal dependent HDACs (Class I, Class II and Class IV)
Class I: HDAC1, HDAC2, HDAC3, HDAC4
Class II: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10
Class IV: HDAC11
HDAC 1,(2) selective
SHI-1:2 (15f)
IC50 (HDAC1) = 6 nM S
HDAC 4,5,7,9 selective
1,3,4-oxadiazole (27)
IC50 (HDAC4) = 30 nM
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contain additional enzymatic subunits: e.g. LSD1 histone demethylase 
(CoREST), Mi-2 chromatin remodeler (Mi-2/NuRD), and JMJD2A histone 
demethylase (NCoR/SMRT).9 Thus, if an HDAC inhibitor were used as part of a 
bifunctional molecule to recruit a target HDAC, enzymatic activity of complexed 
factors that follow may confer transcriptional control, even though the directly 
recruited HDAC is inhibited (Figure 4.2). For the Sin3 complex it has been shown 
that the complex stays largely intact, with only one subunit (non-enzymatic) 
dissociating when treated with an HDAC inhibitor.10 Additionally, immobilized 
HDAC inhibitor SAHA has been used to affinity-capture HDACs from lysates and 
this results in co-enrichment of associated complex subunits.11 Several HDAC 
inhibitors have low-nanomolar binding affinities, and appear to be prime 
candidates for the incorporation into conjugates with glucocorticoid receptor 
ligands. As the first critical step towards bifunctional recruiters based on these 
molecules, we have pursued the synthesis of such conjugates and characterized 
their ability to bind their target proteins.  
 
Complex Sin3 CoREST Mi-2/NuRD NCoR/SMRT 
HDACs HDAC1, HDAC2 HDAC1, HDAC2 HDAC1, HDAC2 HDAC3, HDAC4 
Additional 
enzymatic 
subunits 
 
LSD1 
demethylase 
H3K4me  
Mi-2α/β 
chromatin 
remodeling 
JMJD2A 
demethylase 
(H3K9/36 me3/2) 
Additional 
subunits 
Sin3, SAP30, 
SAP80, ING1/2, 
RBP1, Sds3, 
BRMS1, RbAp46, 
RbAP48 
CoREST, 
 BHC80, 
 CtBP1 
MBD2, MBD3 
MTA1-3, p66α/β,  
RbAp46, RbAP48 
N-CoR/SMRT, 
TBL1/TBLR1, 
GPS2, Kaiso 
Table 4.1 Multi-subunit corepressor complexes HDAC 1, 2, 3, and 4 are 
members of large multi-domain complexes. The multible subunits provide 
enzymatic and scaffolding functions and subunits/domains are involved in 
recognition of epigenetic marks.8,9  
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Figure 4.2 Recruitment of an HDAC complex with HDAC inhibitors A. 
Transcriptional repression domains (RD) recruit HDAC containing corepressor 
complexes, such as Sin3, whose enzymatic subunits modify histones and 
represses transcription; B. In principle, an HDAC inhibitor (red triangle) can 
facilitate recruitment of the Sin3 complex, and uninhibited enzymatic subunits 
may confer a level of transcriptional control. 
 
4.3 Synthesis of GR-ligand - HDAC inhibitor conjugates 
The HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) inhibits all class I 
and II HDACs, which encompass all the metal-dependent HDACs and are the 
principal contributors to histone-related activities.8 A crystal structure of HDAC8 
complexed with SAHA shows that the hydroxamic acid in SAHA chelates the 
metal in the active site and the long aliphatic chain in SAHA mimics the aliphatic 
side-chain of lysine and spans a narrow pocket from the catalytic center to the 
enzyme surface. The aromatic ring of SAHA is termed a capping group and lies 
at the lip of the active site (Figure 4.3). Substitutions to this ring are well-
tolerated, with little change in potency.12 This tolerance was exploited in a study 
where the phenyl ring of SAHA was modified to a photo-inducible cross-linker, 
benzophenone, and this derivative was demonstrated to, after exposure to UV 
light, cross-link to target HDACs as well as HDAC complex members.13 Thus, 
this group extends from the surface of HDACs and is an ideal location for 
tethering to other molecules.  
RD
DBD
Sin3
HDAC1
HDAC2
histone deacetylation histone deacetylation ?
Sin3
HDAC1
HDAC2
A B
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Figure 4.3 The HDAC inhibitor SAHA A. The capping group of SAHA protrudes 
from the binding pocket in the catalytic domain of HDAC8 (PDB:1T69)9; B. 
Structural features of SAHA.  
 
In accordance with results outlined above, we introduced an alkyne in the para-
position of the anilide of SAHA to facilitate conjugation with azide-functionalized 
moieties via Cu(I)-catalyzed 1,3-cycloaddition14 (Figure 4.4A). In the 
cycloaddition products, a flat aromatic triazole is formed attached to the capping 
group of SAHA, and is expected to not significantly alter the binding to HDACs.12 
Formation of the hydroxamic acid in SAHA from a methyl ester intermediate has 
been reported,15 but in our hands this reaction was very slow with triazole-
substituted analogs. Instead the hydroxamic acid was introduced in a 
tetrahydropyranyl-protected form (Figure 4.4A). The functionalized GR ligands, 
SDex-ITC and RU486-O3-N3, were described in Chapter 3. A conjugate of SDex 
and SAHA was made by coupling an azido-functionalized linker to 4-ethynyl-
SAHA-THP with Cu(I) catalysis, followed by one-pot deprotection of the 
trifluoroacetyl-protected amine and coupling of this amine to SDex-ITC (Figure 
4.4C). The RU486 conjugate was made by Cu(I)-catalyzed coupling of 4-ethynyl-
SAHA-THP and RU486-O3-N3 (Figure 4.4D). The THP protecting-group is 
removed in the final step of conjugate syntheses with para-toluenesulfonic acid 
(TsOH).  
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Figure 4.4 Synthesis of GR-ligand - HDAC inhibitor conjugates A. Synthesis 
of THP-protected and alkyne-functionalized SAHA; B. Synthesis of SDex-O3-
OMe; C. Synthesis of SDex-O3-SAHA; D. Synthesis of RU486-O3-SAHA. 
 
4.4 HDAC inhibition by conjugates 
RU486-O3-SAHA was tested for inhibition of commercially available recombinant 
HDAC1 using a Fluor-de-Lys-Green substrate (Enzo Lifesciences) and compared 
to the activity of SAHA (Figure 4.5). RU486-O3-SAHA inhibited HDAC1 with a Ki 
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of 50 nM (95% confidence interval of 27.7-71.9 nM), which similar to the 28 nM 
Ki of SAHA (17.5-38.5 nM). The Ki of SAHA is consistent with reported values,3,6 
and it appears that the triazole does not significantly alter the binding affinity for 
HDAC1. 
 
 
Figure 4.5 Test of HDAC1 inhibition Inhibition of HDAC1 was studied using 
Fluor-de-Lys substrate. Initial velocities were determined for assays with 100 nM 
of HDAC1 and 10 µM of substrate in presence of varying concentration of 
inhibitor, and curves fitted in GraphPad Prism 5 using equation for tight-binding 
inhibitor to determine apparent Ki (Kapp) and Cheng-Prusoff equation to 
determine Ki (competitive inhibition assumed):16 V/Vo=(1-((((Et+[I]+Kapp)-
(((Et+[I]+Kapp)^2)-4*Et*[I])^0.5))/(2*Et))); Q=(Ki*(1+(S/Km))). Km was determined 
to be 2 µM prior to inhibition assays. 95% confidence intervals are 17.5 – 38.5 
nM (SAHA) and 27.7 – 71.9 nM (RU486-O3-SAHA). Goodness of Fit: R2 > 0.965. 
 
An unrelated triazole-SAHA derivative had previously been tested for HDAC8 
inhibition by Sam S. Gattis (Fierke lab, University of Michigan), and was found to 
have a Ki of 50 nM for Zn(II)-HDAC8 which is slightly lower than the Ki for SAHA 
(250nM). We observed the same trend when testing SDex-O3-SAHA against 
Co(II)-HDAC8, but too few data points were used for accurate determination of 
affinities (data not shown). Thus, both the RU486 and SDex conjugates with 
Inhibition of HDAC1
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SAHA have retained affinity for HDACs, and this affinity is lower than the affinity 
of RU486 (84 nM) and SDex (104 nM) for GR.  
 
4.5 SDex and RU486 conjugated to SAHA can induce GR localization at 
GREs  
To investigate if the conjugation of SAHA affects the ability of GR ligands to 
induce GR binding at endogenous target genes, GRE occupancy was 
determined using chromatin immunoprecipitation (ChIP) (Figure 4.6). Both SDex-
O3-OMe and SDex-O3-SAHA were effective at inducing GR localization at the 
FKBP5 intronic promoter (which has two GREs).17 In several ChIP experiments 
we and others18 observe lower enrichment of GR for RU486 treated samples 
compared to Dex treatment, and this is also the case for RU486-O3-N3 and 
RU486-O3-SAHA. RU486-O3-N3 shows very low but statistically significant 
enrichment in the ChIP experiment. The data for this compound is from a single 
experiment (four replicate qPCR samples from one ChIP), while the remaining 
samples are averages of two biological replicates and further experiments will be 
needed to determine if the difference between RU486 with and without SAHA is 
consistent. Since both RU486-O3-N3, and RU486-O3-FK506 were shown to be 
effective antagonists of dexamethasone and have similar binding affinity to SDex 
(Chapter 3), the lower ChIP enrichment with the antagonist ligands may stem 
from a diminished ability of GR to bind GREs,19 but it can also be an effect of the 
epitope (located in the DNA-binding domain) being masked in the antagonist 
bound GR by a different receptor conformation or by different interacting 
proteins.  
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Figure 4.6 Conjugate-induced GR binding to the FKBP5 promoter Cells 
incubated with GR ligands for 2 hours were subjected to chromatin 
immunoprecipitation, and enrichment of DNA from the FKBP5 intronic enhancer 
was determined by qPCR analysis.  
 
Despite considerable effort, we have not yet been able to detect recruitment of 
HDAC1 and HDAC2 to GR target genes via ChIP. Different antibodies for the 
HDACs were tested as well as experiments with transiently transfected myc-
tagged HDAC1 and IP with α-myc. Factors bound indirectly to DNA are generally 
more difficult to detect, because their crosslinking to DNA via DNA-bound 
proteins is less efficient.20-23 If HDACs are recruited via the small molecule 
conjugates any interaction with DNA-bound proteins is likely more difficult to 
capture with crosslinking agents. In addition to various treatments with 
formaldehyde, we have tried protein-protein crosslinkers of various lengths that 
have been reported to improve detection of indirectly associated factors.20 
However, this has not been successful.  
 
The recruitment of HDAC complexes to GR may alternatively be indirectly 
evident from changes in local patterns of acetylation or other histone 
modifications. We probed the effect of conjugate treatment on the acetylation 
levels of histone 3 lysine 9 and 14 (H3K9/14ac), which are elevated in a region 
surrounding the GREs in the FKBP5 gene enhancer and are not affected by Dex 
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treatment and GR binding.18 SAHA increases acetylation levels to a small degree 
as would be expected (Figure 4.7). ChIP with samples treated with SAHA-
conjugates show a decrease in enrichment relative to control (Fold / IgG) when 
compared to both SAHA and DMSO treatment. This would be consistent with 
recruitment of HDAC activity, but further experiments are needed to establish 
statistical significance of the result as well as inclusion of control ligands not 
conjugated to SAHA. 
  
Figure 4.7 Effect on acetylation levels Cells incubated with GR ligands for 2 
hours were subjected to chromatin immunoprecipitation, and enrichment of DNA 
from the FKBP5 intronic enhancer was determined by qPCR analysis.  
 
4.6 Conclusion and discussion 
Conjugates of GR ligands and HDAC inhibitors were synthesized and retain their 
ability to bind to their respective target proteins. The affinity for HDAC1 of 
RU486-O3-SAHA was determined to be 52 nM, which is a higher affinity than the 
affinity of the GR ligands for GR. It is possible that having both ligands of the 
heterodimer bind in the 50-100 nM range is detrimental for ability to dimerize 
target proteins. Both RU486 and SDex derived conjugates induce GR localization 
at endogenous target genes. If RU486-bound GR binds with lower efficiency to 
GREs, which is one explanation for lower enrichment levels in ChIP experiments, 
it will affect the conjugates ability to recruit target proteins to the promoter. In 
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Chapter 3, RU486-O3-FK506 was demonstrated to potently recruit VP16-FKBP to 
a luciferase reporter. In the absence of similar functional data for endogenous 
genes, there is a possibility that RU486-conjugates indeed has limited ability to 
localize at these genes.  
 
The critical ability that remains to be demonstrated for the conjugates is 
simultaneously binding to GR and HDAC-complexes. This has been difficult to 
demonstrate or disprove with chromatin immunoprecipitation experiments which 
are hampered by challenges of crosslinking the indirectly tethered proteins to the 
chromatin. Ongoing efforts by A.R. Van Dyke are therefore focused on using co-
immunoprecipitation experiments and investigate association of both HDACs and 
associated complex members with GR as a function of conjugated ligands.  
  
Evidence for recruitment can also be probed in the form of functional 
consequences. Our efforts so far have been limited to assessment of effects on 
H3K9/14ac levels at the FKBP5 enhancer and effects on the transcription of the 
FKBP5 gene. In preliminary experiments, small but significant effects on 
acetylation levels consistent with HDAC recruitment were observed. By RT-
qPCR analysis effects on transcription of the FKBP5 gene mediated by 
conjugate-SAHA function has not been apparent in preliminary studies (O.Cruz, 
data not shown). As these experiments represent the first attempts of employing 
a general strategy of transcriptional complex recruitment through inhibitors of 
enzymatic subunits, we do not consider the transcriptional effects on individual 
genes as a criterion for success. Rather, if dimerization of nuclear receptors to 
target enzymes with associated complexes can be demonstrated, this should be 
viewed as a significant validation of the recruitment strategy. With the numerous 
possibilities of combining inhibitors with specificities for different subunits within 
specific corepressor complexes, there are many opportunities for subsequent 
efforts to discover combinations that confer transcriptional control.   
 
4.7 Materials and methods 
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HDAC inhibition studies 
Recombinant human HDAC1 (BML-SE456) and Fluor de Lys-Green substrate 
(BML-AK53)) were purchased from Enzo Life Sciences. Inhibition assays were 
done using 10 µM of substrate and 100 nM of HDAC1 in black 384-well plates, 
and fluorescence from product formation was measured at 485/535 on Tecan 
GENios Pro over 25 min at 5 min intervals for each inhibitor concentration. Curve 
fitting of relative initial velocities (v = initial velocity in presence of inhibitor, vo = 
initial velocity in absence of inhibitor) as a function of inhibitor concentration were 
done with Graphpad Prism 5 using equation for tight-binding inhibitor to 
determine apparent Ki (Kapp) and Cheng-Prusoff equation to determine Ki 
(competitive inhibition assumed):16 V/Vo=(1-((((Et+[I]+Kapp)-(((Et+[I]+Kapp)^2)-
4*Et*[I])^0.5))/(2*Et))); Q=(Ki*(1+(S/Km))). 
 
Recombinant human HDAC8 was expressed and purified with helpful advice 
from S. Gattis (Fierke lab, University of Michigan) as previously reported.24 
ApoHDAC8 was preincubated with Co(II) at stoichiometric concentrations and 
the specific activity of Co(II)-HDAC8 at 1 µM with 50 µM substrate was measured 
to 17.5 (pmol substrate/min)/µg enzyme. Although not used for inhibition assays, 
the reactivity of an aliquot of the expressed HDAC8 labeled with DyLight 649 
fluorophore (Pierce) was determined to have a kcat/KM (Co(II)) = 607.2 M-1s-1. 
Inhibition data was generated as for HDAC1 using 100 nM HDAC8 and 50 µM 
substrate.  
 
Chromatin immunoprecipitation 
ChIP was done as described in Chapter 3.  
 
Chemical synthesis 
General methods are described in Chapter 3. Preparation of SDex-ITC, RU466-
O3-N3, and SDex-O3-OMe is described in Chapter 3.   
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1-(4-ethynylphenyl) 8-methyl octanedioate:  
Suberic acid monomethyl ester was used as received, but it contains a significant 
portion of di-acid (suberic acid). Suberic acid monomethyl ester (0.97 g, 5.17 
mmol) was combined with 4-ethynylaniline (0.67 mg, 5.68 mmol), 1-hydroxy-
benzotriazole (HOBT) (0.84 mg, 6.2 mmol) and N,N'-diisopropylcarbodiimide 
(DIC). After 3 hours reaction was added to ice cold water and filtered to collect 
precipitated product. The product was slightly yellow, and could be used crude in 
subsequent reactions. It can be purified on silica column with ethyl acetate / 
hexanes at 1:2. (35% yield of purified product). 
 
 
4-ethynyl-SAHA-THP: 
1-(4-ethynylphenyl) 8-methyl octanedioate (442 mg, 1.54 mmol) was dissolved in 
15 mL THF and 15 mL H2O. LiOH (650 mg, 15 mmol) was added. After 2 hours, 
acid-base extraction yields product used crude in next step. The hydrolyzed 
product was pre-activated with HBTU (569 mg, 1.5 mmol) and DIEA (650 µL, 
3.75 mmol) for 15 minutes in 12 mL DMF. O-THP hydroxylamine (175.7 mg, 1.5 
mmol) was added and reaction stirred overnight. Diethyl ether and water was 
added and phases separated. Aqueous phase was extracted twice with ether, 
and organic phase was dried and concentrated. Product was purified by silica gel 
chromatography with ethyl acetate as eluent and was obtained in 57% yield.  
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RU486-O3-SAHA was synthesized by A.R. Van Dyke. 
 
 
SDex-O3-SAHA was synthesized by A.R. Van Dyke. 
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Chapter 5 
 
Conclusions and Future Directions 
 
5.1 Conclusions 
In my dissertation research I have pursued strategies for controlling the 
transcription of genes with small drug-like molecules. Necessary for this is the 
availability of molecules that interact with the transcriptional machinery. By use of 
a high-throughput biochemical screen of a large library of compounds, sekikaic 
acid was discovered as a new ligand of the multi-domain transcriptional 
coactivator protein CBP. Sekikaic acid binds to the KIX domain of CBP as 
evidenced by both ligand-, and protein-observed NMR, and its binding to KIX 
inhibits the in vitro binding of transcriptional activation domains from the human 
transcription factors MLL and CREB to two distinct sites on KIX. The IC50 values 
for sekikaic against these interactions are in the mid-micromolar range, and 
sekikaic acid is thus the most potent small molecule ligand of the KIX domain 
identified. This affinity likely remains outside of a range useful to artificially recruit 
a target protein to a gene where no cooperative factors contribute to its binding. 
In the screen of over 50,000 compounds no other classes of molecules where 
identified as ligands of the KIX domain, and if high affinity ligands are indeed 
needed for effective small molecule-directed recruitment, more druggable targets 
within the transcriptional machinery may need to be identified.  
 
These considerations have led me to propose and pursue a new strategy for 
small molecule artificial transcription factors: recruitment of transcriptional 
coregulatory complexes through high affinity ligands of their enzymatic subunits. 
Bifunctional molecules capable of binding to both histone deacetylases 
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(enzymatic subunits in corepressor complexes) and the glucocorticoid receptor 
were synthesized, and their binding affinities suggest that they have the potential 
to facilitate recruitment of corepressor complexes to the glucocorticoid receptor 
target genes. 
 
A second criterion of artificial transcription factors is their ability to localize to 
DNA. At the outset of my research efforts, there were no defined strategies to 
achieve this goal without engineered DNA-binding proteins, except through use 
of direct DNA-binding molecules. These later structures, however, face 
challenges yet to be overcome. Instead, nuclear receptors were identified as 
potential targets to not only test strategies of recruitment of coregulators, but to 
themselves be considered as targets of extrinsically recruited functionality. We 
have demonstrated, that bifunctional molecules made by linking nuclear receptor 
ligands to ligands of a second target protein, can recruit this second target 
protein to the nuclear receptor and influence, perhaps in concert with factors 
intrinsic to the receptor, the transcriptional control of target genes. These 
principles have potential for greatly increasing our level of control over the 
therapeutically relevant genes that can be targeted via nuclear receptor ligands. 
 
5.2 Future directions 
Coactivator ligand discovery 
Coactivator ligands are desirable from the perspective of using them as either 
inhibitors of activator interaction surfaces or as recruiting moieties in bifunctional 
molecules. As chemical genetic probes (inhibition function) they must be 
selective for their target protein. This is particularly difficult to achieve for 
coactivator surfaces, because of their promiscuous nature. Unfortunately, it is 
exactly these related surfaces that must be distinguished by probes. The 
discovery of sekikaic acid demonstrates the feasibility of finding hits against 
activator binding surfaces with a biochemical screen, in part because of the 
minimal nature of the assay. The downside is that no information regarding 
selectivity is available for initial hits. Recently, a multiplexed HTS assay was 
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developed to simultaneously screen several protein-protein interactions for 
inhibitors.1 In Figure 5.1 is illustrated how three CBP/p300 interactions could be 
screened simultaneously in such an assay format. Individual domains from 
CBP/p300 would be immobilized on beads that have different internal dye 
intensities (green in figure). The beads can be combined, because they can be 
distinguished via the dye intensities on a flow cytometer. TAD peptides for each 
immobilized domain are labeled with dyes that can be detected by the flow 
cytometer and are orthogonal to the bead color. In Figure 5.1 (lower right) is 
illustrated how the flow cytometry data would appear in the presence of an 
inhibitor for a one of the interactions (KIX-CREB).  
 
 
Figure 5.1 Multiplex screening of coactivator-activator interactions Domain 
structure of CBP/p300 is shown at the top. The NRID and KIX domains are 
immobilized on beads with different dye intensities (lower left). TAD peptides are 
labeled with compatible fluorophores (blue or red stars). Addition of a CREB 
inhibitor will cause a drop in red fluorescence associated with dark green bead.   
 
The coactivator ligands that have been discovered, including sekikaic acid, have 
modest binding affinities, and this is may a barrier to their efficient use as either 
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an inhibitor or a recruiter. Medicinal chemistry can be applied to optimize hits, but 
is a laborious process. Modifying inhibitors with reactive groups that can 
covalently react with proteins has been used to enhance potency and selectivity 
of ligands.2-4 In our studies of sekikaic acid, we attempted to use a disulfide 
tethering strategy to locate the binding site on the protein surface. This strategy 
could also be used in the form of a mutational scan of surface exposed lysines to 
cysteines.  An increased potency of a thiol-modified inhibitor against a specific 
mutant, will approximate the binding site (within a distance spanned by the linker) 
and simultaneously demonstrate that a nucleophilic amine is located near the 
binding site (in the WT protein) that could react with an electrophilic group 
attached to the ligand. The isothiocyanate group, which is resistant to reaction 
with water and hydroxyls but reacts readily with amines,5  has been utilized as 
electrophile in this capacity.2,3  
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Figure 5.2 Identifying binding site-proximal amines to target with an 
electrophile The binding region of a discovered ligand on a target protein is 
probed through a disulfide tether strategy using single K to C point mutants of the 
protein in parallel. Identification of a binding region also identifies a proximal 
lysine, which can be targeted with an isothiocyanate-derivatized ligand. 
 
Using FKBP fusions to probe GR function and define targets of extrinsic 
recruitment 
An FKBP fusion to the transcriptional activation domain from VP16 was used to 
demonstrate that functionality can be directly recruited to nuclear receptors. 
Experiments with fusions of FKBP to CyclinT1 or Cdk9 were done in hope of 
demonstrating their limiting and sufficient role in GR transrepression. Although 
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these preliminary efforts were inconclusive with regards to that specific question, 
they are examples of a new conceptual strategy of utilizing FKBP fusion proteins 
to give insight into NR mechanisms. FKBP-fusion cloning vectors and small 
molecule dimerizers of GR and FKBP were made to facilitate such future studies. 
Because of the possible interference of endogenous FKBPs, an orthogonal pair 
of engineered synthetic ligands of FK506 and mutant FKBP has been reported.6 
The “bumped” ligand binds with low-nanomolar affinity to a FKBP (with a single 
point mutation) and with 1500-fold selectivity over wild-type FKBP. I have 
completed part of the synthesis of this reported ligand (Figure 5.3).  
 
 
 
Figure 5.3 Synthesis of a “bumped” ligand of F37V-FKBP1A Structures 1 
and 3 were prepared according to published procedure with minor changes.7 The 
method of chiral reduction to prepare 2 was changed. Reagents and conditions: 
(a) KOH, EtOH, H2O; (b) Lindlar catalyst (5% Pd), 40 psi H2, MeOH; (c) tert-butyl 
bromoacetate, K2CO3, DMF, 0oC; (d) (S)-2-methyl-CBS-oxazaborolidine, BH3, 
THF; (e) (S)-Fmoc-pipecolic acid, DIC, DMAP, DCM. 
 
In addition to probing NR function with FKBP fusion proteins, these can be used 
to validate endogenous recruitment targets. A family of proteins that are 
attractive but likely difficult recruitment targets, are the small ubiquitin-like 
modifier (SUMO) proteins. These proteins are transferred to synergy control (SC) 
motifs present in nuclear receptorsby SUMO ligases, and modulate the activity of 
the receptors.8,9 In breast cancers, associated high intracellular kinase activity 
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has been proposed to block ligand-dependent sumoylation of the progesterone 
receptor (PR) and represent a possible mechanism of how therapeutic hormone 
sensitivity is altered in cancer.10,11 It may be possible to recruit SUMO with a 
conjugate of a PR ligand and a peptidic or synthetic substrate of SUMO ligases. 
It will be an involved effort to develop such structures, and prior studies with 
FKBP-SUMO fusions would be beneficial to decide if the efforts are worth 
pursuing.  
 
Other ligands of coregulatory complex subunits 
The HDAC inhibitor SAHA is pan-specific and may be able to recruit a number of 
target complexes. It will likely be functionally more efficient to have fewer targets. 
Several HDAC inhibitors are either isoform selective12 or their selectivity is 
complex dependent.13 Only one of the four major HDAC containing corepressor 
complexes includes a class II HDAC: HDAC4 resides together with HDAC3 in the 
NCoR/SMRT complex.14 HDAC4 is necessary for HDAC3 activity, but the 
catalytic activity of HDAC4 is not needed for corepressor function.15 This complex 
may be an ideal target of class II selective HDAC inhibitors, which have been 
discovered.16  
 
The CBP/p300 coactivator has a histone acetyltransferase (HAT) domain, which 
is not always required for its coactivator function as the protein also has 
important scaffolding functions,17 and CBP/p300 selective HAT inhibitors have 
been discovered.18,19 I have devised and tested a synthetic strategy for 
incorporation of one of these inhibitors into a bifunctional molecule. The HAT 
inhibitor 5 was synthesized according to published procedure, which occurs 
through the bromoacetate 4.18 To facilitate linking of other ligands to the inhibitor, 
an orthogonally protected lysine is coupled to resin prior to portions common with 
the HAT inhibitor to give structure 6. 6 was coupled to SDex and converted to a 
bromoacetate intermediate, which is related to structure 4. The subsequent steps 
to convert 7 into a bifunctional HAT inhibitor have not yet been attempted, but the 
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same conditions used to prepare 5 from 4, should be compatible with the 
conjugated SDex.  
 
 
Figure 5.4 Synthesis of an intermediate for SDex conjugation with p300 
HAT inhibitor Structure 4 is a bromoacetate intermediate in synthesis of HAT 
inhibitor 5.  Synthesis was done according to published procedure.18 Structure 6 
is a modified intermediate with an added orthogonally protected lysine. It was 
prepared on solid phase. Structure 7 is a bromoacetate intermediate similar to 4 
but with SDex attached.   
 
5.3 Concluding remarks 
Gene regulation occurs through the action of numerous effector proteins 
recruited to genes by transcription factors, but the interaction networks that 
specify recruitment of individual factors in a gene context-dependent fashion are 
poorly understood. These could ideally be probed through the use of an arsenal 
of small molecules that selectively block interaction surfaces. These interfaces 
are shallow and difficult to target with small molecules, and the identification of a 
new potent ligand of a human coactivator protein with an apparently novel 
binding mode, is a significant outcome of this dissertation work. The finding that a 
simple two-component biochemical assay can identify potent interaction 
inhibitors suggests that a multiplexed assay, as described above, can be 
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employed to efficiently expand the chemical genetic toolbox by screening 
multiple targets simultaneously and providing an initial specificity profile for each 
hit. The difficulty of finding inhibitors with high binding affinity should not 
discourage screening efforts, as strategies to modify hits for enhanced potency 
and specificity exist.  
 
Design strategies for artificial transcription factors were defined over a decade 
ago, and the paradigm has been to focus on mimicking the natural counterparts 
by targeting their interaction partners. This involves gene specific recruitment 
through molecules that bind directly to DNA, linked to coregulator recruitment 
through ligands of proteins that are also direct binding targets of natural 
transcription factors. Thus, ligands of two very difficult target surfaces have been 
pursued, and bifunctional molecules made by combining the discovered ligands 
have not resulted in functional conjugates. In this work, the artificial transcription 
factor has been strategically redefined: recruitment of transcriptional regulatory 
proteins to genes should be pursued through any tractable surface. The nuclear 
receptors were identified as a structure that could be targeted with bifunctional 
molecules, and indeed functionality can be recruited to their target genes via 
small molecules. These receptors do not represent a general strategy to target all 
genes, but the genes that can be targeted through this class of proteins are 
validated therapeutic targets. The enzymatic subunits of coregulatory complexes 
were also identified as potential targets of bifunctional recruiters. It was shown 
that an inhibitor of one of these could be incorporated into bifunctional molecules 
with retained binding ability, and the numerous available related ligands holds 
promise that effective recruiters can be constructed from these.  
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